Siqing Fu, M.D., Ph.D.

Peer-Reviewed Articles

1. Torrado C, Andersen CR, Kang L, Brink AL, Adesoye T, Le H, Patterson CJ, Poullard A, Osburn JA, Tan HN, Gouda MA, Charles S, Urschel GE, Tang T-Y, Hong DS, Champiat S, Naing A, Tsimberidou AM, Dumbrava EE, Piha-Paul SA, Rodon J, Yap TA, Pohlmann PR, Meric-Bernstam F, Fu S. Telemedicine as a Gateway to Early-Phase Oncology Trials: Lessons from 14,000 Patients and Future Directions for Global Access and Equity. Oncologist. e-Pub 2026.
2. Nelson BE, Janku F, Fu S, Dumbrava EE, Hong DS, Karp DD, Naing A, Rodon J, Tsimberidou AM, Murthy R, Sheth RA, Amaria RN, Conley AP, Damodaran S, Raghav KPS, Carapanceanu N, Singh MP, Carapanceanu V, Pezeshki A, Leontovich AA, Kreider BL, Tung D, Varterasian M, Khazaie K, Piha-Paul SA. Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi-NT in Patients with Advanced Solid Tumors. Clin Cancer Res 31(18):3864-3875, 2025. e-Pub 2025. PMID: 40643985.
3. Braganca Xavier C, Andersen CR, Lim J, Slade JH, Bean SA, Kang L, Le H, Tsimberidou AM, Naing A, Hong DS, Dumbrava EE, Rodon Ahnert J, Pohlmann PR, Piha-Paul SA, Champiat S, Yap TA, Tang TY, Meric-Bernstam F, Fu S. Modulating Treatment Outcomes of Patients with Solid Tumors in Immunotherapy Trials: A Drug Interaction Analysis from a Phase I Unit. Cancer Res Commun 5(9):1631-1641, 2025. e-Pub 2025. PMID: 40862547.
4. Lin SH, Subbiah V, Neri S, Cohen EN, Li Z, Lu YJ, Son YL, Lyu Y, Braun C, Gao H, Jayachandran G, Sharma A, Ye R, Fang P, Li N, Karp D, Hong D, Rodon J, Yu H, Peng J, Lloyd GK, Tonra JR, Reuben JM, Huang L, Fu S. Plinabulin following radiation enhances dendritic cell maturation and checkpoint inhibitor retreatment of relapsed/refractory cancers. Med:100752, 2025. PMID: 40580957.
5. Ma Y, Yang Y, Huang Y, Fang W, Xue J, Meng X, Fan Y, Fu S, Wu L, Zheng Y, Liu J, Liu Z, Zhuang W, Rosen S, Qu S, Li B, Li M, Zhao Y, Yang S, Ji Y, Sommerhalder D, Luo S, Yang K, Li J, Lv D, Zhang P, Zhao Y, Hong S, Zhang Y, Zhao S, Chin S, Zhang X, Lian W, Cai J, Xue T, Zhang L, Zhao H. A B7H3-targeting antibody-drug conjugate in advanced solid tumors: a phase 1/1b trial. Nat Med 31(6):1949-1957, 2025. e-Pub 2025. PMID: 40082695.
6. Nardo M, Gouda MA, Reilley MJ, Biter AB, Lim J, Bean SA, Nguyen LM, Bhosale PR, Ager CR, Couillault CA, Piha-Paul SA, Fu S, Tsimberidou AM, Yap TA, Naing A, Rodon J, Subbiah V, Karp DD, Curran MA, Hong DS. Lefitolimod in Combination with Ipilimumab in Patients with Advanced Solid Tumors: A Phase I Trial. J Immunother Precis Oncol 8(2):89-98, 2025. e-Pub 2025. PMID: 39959251.
7. Yeku OO, Barve M, Tan WW, Wang J, Patnaik A, LoRusso P, Richardson DL, Naqash AR, Lynam SK, Fu S, Gordon M, Hubbard J, Kummar S, Kyriakopoulos C, Dowlati A, Chamberlain M, Winer I. Myeloid targeting antibodies PY159 and PY314 for platinum-resistant ovarian cancer. J Immunother Cancer 13(3), 2025. e-Pub 2025. PMID: 40081941.
8. Alhalabi O, Gouda MA, Milton DR, Momin HA, Yilmaz B, Stephen B, Ejezie CL, Moyers JT, Gurses SA, How J, Fu S, Rodon J, Hong DS, Piha-Paul SA, Subbiah V, Elena Dumbrava E, Karp DD, Janku F, Meric-Bernstam F, Tannir NM, Naing A. A Phase IB Trial of Selinexor in Combination with Immune Checkpoint Blockade in Patients with Advanced Renal Cell Carcinoma. Cancer Med 14(4):e70280, 2025. e-Pub 2025. PMID: 39945382.
9. Hamilton EP, Falchook GS, Wang JS, Fu S, Oza AM, Imedio ER, Kumar S, Ottesen L, Mugundu GM, de Bruin EC, O'Connor MJ, Jones SF, Spigel DR, Li BT. Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial. Target Oncol 19(6):879-892, 2024. e-Pub 2024. PMID: 39487373.
10. Worden FP, Pisick E, Rothe M, Mangat PK, Garrett-Mayer E, Khalil MF, Carrizosa DR, Bauman JR, Leidner RS, Duvivier HL, Fu S, Park MS, Yost KJ, Calfa CJ, Marr AS, Balmanoukian AS, Behl D, Cannon TL, Nabell L, Powell SF, Thota R, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Palbociclib in Patients With Head and Neck Cancer and Other Tumors With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol 8:e2400477, 2024. e-Pub 2024. PMID: 39413339.
11. Majd NK, Vo HH, Moran CA, Weathers SP, Song IW, Williford GL, Rodon J, Fu S, Tsimberidou AM. Metastatic extraneural glioblastoma diagnosed with molecular testing. Oncologist 29(9):811-816, 2024. e-Pub 2024. PMID: 38837109.
12. Piha-Paul SA, Tseng C, Leung CH, Yuan Y, Karp DD, Subbiah V, Hong D, Fu S, Naing A, Rodon J, Javle M, Ajani JA, Raghav KP, Somaiah N, Mills GB, Tsimberidou AM, Zheng X, Chen K, Meric-Bernstam F. Phase II study of talazoparib in advanced cancers with BRCA1/2, DNA repair, and PTEN alterations. NPJ Precis Oncol 8(1):166, 2024. e-Pub 2024. PMID: 39085400.
13. Gouda, MA, Shunyakova, J, Naing, A, Ileana Dumbrava, EE, Hong, DS, Yuan, Y, Yang, P, Myers, AL, Liang, Y, Peng, J, Karp, DD, Tsimberidou, AM, Rodon Ahnert, J, Yap, TA, Piha-Paul, SA, Meric-Bernstam, F, Fu, S. A phase I study of TAK-659 and paclitaxel in patients with taxane-refractory advanced solid tumors. ESMO Open 9(6):103486, 2024. e-Pub 2024. PMID: 38914452.
14. Coleman N, Stephen B, Fu S, Karp D, Subbiah V, Ahnert JR, Piha-Paul SA, Wright J, Fessahaye SN, Ouyang F, Yilmaz B, Meric-Bernstam F, Naing A. Phase I study of sapanisertib (CB-228/TAK-228/MLN0128) in combination with ziv-aflibercept in patients with advanced solid tumors. Cancer Med 13(3):e6877, 2024. e-Pub 2024. PMID: 38400671.
15. Knisely A, Ahmed J, Stephen B, Piha-Paul SA, Karp D, Zarifa A, Fu S, Hong DS, Rodon Ahnert J, Yap TA, Tsimberidou AM, Alshawa A, Dumbrava EE, Yang Y, Song J, Meric-Bernstam F, Jazaeri AA, Naing A. Phase 1/2 trial of avelumab combined with utomilumab (4-1BB agonist), PF-04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies. Cancer 130(3):400-409, 2024. e-Pub 2024. PMID: 37864520.
16. Subbiah V, Coleman N, Piha-Paul SA, Tsimberidou AM, Janku F, Rodon J, Pant S, Dumbrava EEI, Fu S, Hong DS, Zhang S, Sun M, Jiang Y, Roszik J, Song J, Yuan Y, Meric-Bernstam F, Naing A. Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies. Cancer Res Commun 4(2):378-387, 2024. e-Pub 2024. PMID: 38126764.
17. Tang C, Tang C, Hartley GP, Hartley GP, Couillault C, Couillault C, Yuan Y, Yuan Y, Lin H, Lin H, Nicholas C, Nicholas C, Srinivasamani A, Srinivasamani A, Dai J, Dai J, Dumbrava EEI, Dumbrava EEI, Fu S, Fu S, Karp DD, Karp DD, Naing A, Naing A, Piha-Paul SA, Piha-Paul SA, Rodon Ahnert J, Rodon Ahnert J, Pant S, Pant S, Subbiah V, Subbiah V, Yap TA, Yap TA, Tsimberidou AM, Tsimberidou AM, Guerrero P, Guerrero P, Dhebat S, Dhebat S, Proia T, Proia T, Curran MA, Curran MA, Hong DS, Hong DS. Preclinical study and parallel phase II trial evaluating antisense STAT3 oligonucleotide and checkpoint blockade for advanced pancreatic, non-small cell lung cancer and mismatch repair-deficient colorectal cancer. BMJ Oncol 3(1):e000133, 2024. e-Pub 2024. PMID: 39886125.
18. Nelson BE, Tsimberidou AM, Fu X, Fu S, Subbiah V, Sood AK, Rodon J, Karp DD, Blumenschein G, Kopetz S, Pant S, Piha-Paul SA. A Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid Tumors. Oncologist 28(12):1100-e1292, 2023. e-Pub 2023. PMID: 37311055.
19. DiPeri TP, Evans KW, Raso MG, Zhao M, Rizvi YQ, Zheng X, Wang B, Kirby BP, Kong K, Kahle M, Yap TA, Ileana Dumbrava EE, Ajani JA, Fu S, Keyomarsi K, Meric-Bernstam F. Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers. Clin Cancer Res 29(21):4385-4398, 2023. e-Pub 2023. PMID: 37279095.
20. Stephen B, Hajjar J, Sarda S, Duose DY, Conroy JM, Morrison C, Alshawa A, Xu M, Zarifa A, Patel SP, Yuan Y, Kwiatkowski E, Wang L, Rodon Ahnert J, Fu S, Meric-Bernstam F, Lowman GM, Looney T, Naing A. T-cell receptor beta variable gene polymorphism predicts immune-related adverse events during checkpoint blockade immunotherapy. J Immunother Cancer 11(8), 2023. e-Pub 2023. PMID: 37604642.
21. Piha-Paul SA, Tseng C, Tran HT, Gao M, Karp DD, Subbiah V, Tsimberidou AM, Kawedia JD, Fu S, Pant S, Yap TA, Morris VK, Kee BK, Blum Murphy M, Lim J, Meric-Bernstam F. A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation. Cancer Chemother Pharmacol 92(2):107-118, 2023. e-Pub 2023. PMID: 37314501.
22. Bauer TM, Moore KN, Rader JS, Simpkins F, Mita AC, Beck JT, Hart L, Chu Q, Oza A, Tinker AV, Imedio ER, Kumar S, Mugundu G, Jenkins S, Chmielecki J, Jones S, Spigel D, Fu S. A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors. Target Oncol 18(4):517-530, 2023. e-Pub 2023. PMID: 37278879.
23. Carmagnani Pestana R, Moyers JT, Roszik J, Sen S, Hong DS, Naing A, Herzog CE, Fu S, Piha-Paul SA, Rodon J, Yap TA, Karp DD, Tsimberidou AM, Pant S, Zarzour MA, Ratan R, Ravi V, Benjamin RS, Lazar AJ, Wang WL, Daw N, Gill JB, Harrison DJ, Lewis VO, Roland CL, Patel SR, Livingston JA, Somaiah N, Ludwig JA, Conley AP, Hamerschlak N, Gorlick R, Meric-Bernstam F, Subbiah V. Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101). Clin Cancer Res 29(9):1708-1718, 2023. e-Pub 2023. PMID: 37058010.
24. Fu S, Yao S, Yuan Y, Previs RA, Elias AD, Carvajal RD, George TJ, Yuan Y, Yu L, Westin SN, Xing Y, Dumbrava EE, Karp DD, Piha-Paul SA, Tsimberidou AM, Ahnert JR, Takebe N, Lu K, Keyomarsi K, Meric-Bernstam F. Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification. J Clin Oncol 41(9):1725-1734, 2023. e-Pub 2023. PMID: 36469840.
25. Fu, S. Highlights of the NCCN Oncology Research Program. JNCCN Journal of the National Comprehensive Cancer Network 21(2):X-XI, 2023. e-Pub 2023.
26. Son J, Lin HY, Fu S, Biter AB, Dumbrava EE, Karp DD, Naing A, Pant S, Piha-Paul SA, Rodon J, Subbiah V, Tsimberidou AM, Yap TA, Frumovitz MM, Jazaeri AA, Ramirez PT, Westin SN, Yuan Y, Meric-Bernstam F, Hong DS. Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical Cancer. J Immunother Precis Oncol 6(1):10-18, 2023. e-Pub 2023. PMID: 36751659.
27. Nelson BE, Roszik J, Janku F, Hong DS, Kato S, Naing A, Piha-Paul S, Fu S, Tsimberidou A, Cabanillas M, Busaidy NL, Javle M, Byers LA, Heymach JV, Meric-Bernstam F, Subbiah V. BRAF v600E-mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study. NPJ Precis Oncol 7(1):19, 2023. e-Pub 2023. PMID: 36801912.
28. Moyers JT, Carmagnani Pestana R, Roszik J, Hong DS, Naing A, Fu S, Piha-Paul S, Yap T, Karp D, Rodon J, Livingston JA, Zarzour MA, Ravi V, Patel S, Benjamin RS, Ludwig J, Herzog C, Ratan R, Somaiah N, Conley A, Gorlick R, Meric-Bernstam F, Subbiah V. Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102). Clin Cancer Res 29(2):401-409, 2023. e-Pub 2023. PMID: 36288393.
29. Westin SN, Fu S, Tsimberidou A, Piha-Paul S, Akhmedzhanov F, Yilmaz B, McQuinn L, Brink AL, Gong J, Leung CH, Lin H, Hong DS, Pant S, Carter B, Jazaeri A, Gershenson D, Sood AK, Coleman RL, Shah J, Meric-Bernstam F, Naing A. Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer. Gynecol Oncol 168:76-82, 2023. e-Pub 2023. PMID: 36423446.
30. Yap TA, Daver N, Mahendra M, Zhang J, Kamiya-Matsuoka C, Meric-Bernstam F, Kantarjian HM, Ravandi F, Collins ME, Francesco MED, Dumbrava EE, Fu S, Gao S, Gay JP, Gera S, Han J, Hong DS, Jabbour EJ, Ju Z, Karp DD, Lodi A, Molina JR, Baran N, Naing A, Ohanian M, Pant S, Pemmaraju N, Bose P, Piha-Paul SA, Rodon J, Salguero C, Sasaki K, Singh AK, Subbiah V, Tsimberidou AM, Xu QA, Yilmaz M, Zhang Q, Li Y, Bristow CA, Bhattacharjee MB, Tiziani S, Heffernan TP, Vellano CP, Jones P, Heijnen CJ, Kavelaars A, Marszalek JR, Konopleva M. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. Nat Med 29(1):115-126, 2023. e-Pub 2023. PMID: 36658425.
31. Vo HH, Fu S, Hong DS, Karp DD, Piha-Paul S, Subbiah V, Janku F, Naing A, Yap TA, Rodon J, Ajani JA, Cartwright C, Johnson A, Song IW, Beck J, Kahle M, Nogueras-Gonzalez GM, Miller V, Chao C, Vining DJ, Berry DA, Meric-Bernstam F, Tsimberidou AM. Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology. NPJ Precis Oncol 6(1):78, 2022. e-Pub 2022. PMID: 36302890.
32. Ngoi, NY, Pilie, PG, Piha-Paul, SA, Dumbrava, EE, Fu, S, Hong, DS, Karp, DD, Naing, A, Pant, S, Rodon Ahnert, J, Subbiah, V, Tsimberidou, AM, Salguero, C, Brown, CV, Hoadley, WE, Johnson, A, Yuan, Y, Westin, SN, Meric-Bernstam, F, Yap, TA. DNA Damage Response (DDR) Basket of Baskets (D-BOB) Trial. 34th EORTC-NCI-AACR Symposium 174(Suppl 1):S10, 2022. e-Pub 2022.
33. Mendoza TR, Hong DS, Peterson CB, Stephen B, Dumbrava E, Pant S, Tsimberidou AM, Yap TA, Sheshadri A, Altan M, George G, Castillo L, Rodriguez E, Gong J, Subbiah V, Janku F, Fu S, Piha-Paul SA, Ahnert JR, Karp DD, Cleeland C, Meric-Bernstam F, Naing A. Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial. Sci Rep 12(1):14367, 2022. e-Pub 2022. PMID: 35999229.
34. Fu S, Corr BR, Culm-Merdek K, Mockbee C, Youssoufian H, Stagg R, Naumann RW, Wenham RM, Rosengarten RD, Benjamin L, Hamilton EP, Moore KN. Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. J Clin Oncol 40(23):2568-2577, 2022. e-Pub 2022. PMID: 35439029.
35. How JA, Jazaeri AA, Fu S, Rodon Ahnert J, Gong J, Stephen B, Ferreira Dalla Pria H, Bhosale P, Johnson A, Yuan Y, Meric-Bernstam F, Naing A. Clinical Outcomes of Patients with Recurrent Microsatellite-Stable Endometrial Cancer in Early-Phase Immunotherapy Clinical Trials. Cancers (Basel) 14(15), 2022. e-Pub 2022. PMID: 35954359.
36. Gouda MA, Huang HJ, Piha-Paul SA, Call SG, Karp DD, Fu S, Naing A, Subbiah V, Pant S, Dustin DJ, Tsimberidou AM, Hong DS, Rodon J, Meric-Bernstam F, Janku F. Longitudinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced Cancers. JCO Precis Oncol 6:e2100512, 2022. e-Pub 2022. PMID: 35834760.
37. Nelson BE, Ejezie CL, Stephen BA, Nardo M, Campbell E, Gong J, Hong DS, Fu S, Yap TA, Murphy MB, Piha-Paul S, Daver NG, Rojas-Hernandez CM, Naing A. Spectrum of Immune Checkpoint Inhibitor Anemias: Results From a Single Center, Early-Phase Clinical Trials Case Series Experience. J Hematol 11(3):113-120, 2022. e-Pub 2022. PMID: 35837373.
38. Thein KZ, Karp DD, Tsimberidou A, Gong J, Sulovic S, Shah J, Milton DR, Hong DS, Janku F, McQuinn L, Stephen BA, Colen R, Carter BW, Yap TA, Piha-Paul SA, Fu S, Meric-Bernstam F, Naing A. Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study. Invest New Drugs 40(2):290-299, 2022. e-Pub 2022. PMID: 34562230.
39. Thein KZ, Karp DD, Tsimberidou A, Gong J, Sulovic S, Shah J, Milton DR, Hong DS, Janku F, McQuinn L, Stephen BA, Colen R, Carter BW, Yap TA, Piha-Paul SA, Fu S, Meric-Bernstam F, Naing A. Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single-center, multi-arm phase Ib study. Invest New Drugs 40(2):463, 2022. e-Pub 2022. PMID: 34731355.
40. DiPeri TP, Demirhan M, Karp DD, Fu S, Hong DS, Subbiah V, Lim J, Ballester LY, Tayar JH, Suarez-Almazor ME, Javle M, Meric-Bernstam F. Corticosteroid-Refractory Myositis After Dual BRAF and MEK Inhibition in a Patient with BRAF V600E-Mutant Metastatic Intrahepatic Cholangiocarcinoma. J Immunother Precis Oncol 5(1):26-30, 2022. e-Pub 2022. PMID: 35663835.
41. Alhalabi O, Hahn AW, Msaouel P, Meric-Bernstam F, Wilson N, Naing A, Piha-Paul S, Janku F, Pant S, Yap TA, Hong DS, Fu S, Karp D, Beltran K, Campbell E, Le H, Campbell MT, Shah A, Tannir NM, Siefker-Radtke A, Gao J, Roszik J, Subbiah V. Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials. Clin Genitourin Cancer 20(1):e16-e24, 2022. e-Pub 2022. PMID: 34362693.
42. Kato S, Adashek JJ, Subbiah V, Fu S, Sun M, Nguyen L, Brown EJ, Yap TA, Karp DD, Piha-Paul SA, Hong DS. A phase i study of ixazomib and erlotinib in patients with advanced solid tumors. Invest New Drugs 40(1):99-105, 2022. e-Pub 2022. PMID: 34468905.
43. Dev R, Zhong LL, Zarifa A, Albittar AA, Rubin L, Liu S, Yap TA, Dalal S, Hui D, Karp DD, Tsimberidou AM, Piha-Paul SA, Ahnert JR, Fu S, Meric-Bernstam F, Naing A. Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients: an exploratory study. Invest New Drugs 40(1):124-133, 2022. e-Pub 2022. PMID: 34559346.
44. Thein KZ, Fu S, Janku F, Tsimberidou AM, Piha-Paul SA, Karp DD, Shah J, Milton DR, Gong J, Sulovic S, McQuinn L, Stephen BA, Colen RR, Carter BW, Meric-Bernstam F, Naing A. Selinexor in Combination with Carboplatin and Pemetrexed in Patients with Advanced or Metastatic Solid Tumors: Results of an Open-Label, Single-Center, Multi-Arm Phase 1b Study. J Immunother Precis Oncol 5(1):10-12, 2022. e-Pub 2022. PMID: 35663832.
45. Yao S, Janku F, Koenig K, Tsimberidou AM, Piha-Paul SA, Shi N, Stewart J, Johnston A, Bomalaski J, Meric-Bernstam F, Fu S. Phase 1 trial of ADI-PEG 20 and liposomal doxorubicin in patients with metastatic solid tumors. Cancer Med 11(2):340-347, 2022. e-Pub 2022. PMID: 34841717.
46. Thein KZ, Piha-Paul SA, Tsimberidou A, Karp DD, Janku F, Fu S, Subbiah V, Hong DS, Yap TA, Shah J, Milton DR, McQuinn L, Gong J, Tran Y, Carter BW, Colen R, Meric-Bernstam F, Naing A. Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors. Exp Hematol Oncol 10(1):59, 2021. e-Pub 2021. PMID: 34965890.
47. Fu S, Piccioni DE, Liu H, Lukas RV, Kesari S, Aregawi D, Hong DS, Yamaguchi K, Whicher K, Zhang Y, Chen YL, Poola N, Eddy J, Blum D. A phase I study of the WT2725 dosing emulsion in patients with advanced malignancies. Sci Rep 11(1):22355, 2021. e-Pub 2021. PMID: 34785698.
48. Kim ST, Tayar J, Fu S, Ke D, Norry E, Sun A, Miller J, Hong DS. Newly developed pseudogout arthritis after therapy with MAGE-A4 directed TCR T cells responded to treatment with tocilizumab. J Immunother Cancer 9(7), 2021. e-Pub 2021. PMID: 34233963.
49. Al-Zubidi N, Gombos DS, Hong DS, Subbiah V, Fu S, Ahnert JR, Piha-Paul SA, Tsimberidou AM, Karp DD, Bernstam FM, Naing A. Overview of Ocular Side Effect of Selinexor. Oncologist 26(7):619-623, 2021. e-Pub 2021. PMID: 33728727.
50. Hegde A, Jayaprakash P, Couillault CA, Piha-Paul S, Karp D, Rodon J, Pant S, Fu S, Dumbrava EE, Yap TA, Subbiah V, Bhosale P, Coarfa C, Higgins JP, Williams ET, Wilson TF, Lim J, Meric-Bernstam F, Sumner E, Zain H, Nguyen D, Nguyen LM, Rajapakshe K, Curran MA, Hong DS. A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies. Clin Cancer Res 27(11):3050-3060, 2021. e-Pub 2021. PMID: 33771853.
51. Xu M, Tapia C, Hajjar J, Sabir S, Colen R, Nagarajan P, Aung PP, Gong J, Rodon J, Fu S, Stephen B, Roy-Chowdhuri S, Le H, Yang V, Zarifa A, Abdelsalam ME, Jhingran A, Javle M, Pant S, Carter B, Milton DR, Sun R, Karp DD, Koay EJ, Yang Y, Wistuba II, Hwu P, Meric-Bernstam F, Naing A. Implementation of a Novel Web-Based Lesion Selection Tool to Improve Acquisition of Tumor Biopsy Specimens. J Immunother Precis Oncol 4(2):45-52, 2021. e-Pub 2021. PMID: 35663531.
52. Harding JJ, Moreno V, Bang YJ, Hong MH, Patnaik A, Trigo J, Szpurka AM, Yamamoto N, Doi T, Fu S, Calderon B, Velez de Mendizabal N, Calvo E, Yu D, Gandhi L, Liu ZT, Galvao VR, Leow CC, de Miguel MJ. Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody. Clin Cancer Res 27(8):2168-2178, 2021. e-Pub 2021. PMID: 33514524.
53. Yao S, Janku F, Subbiah V, Stewart J, Patel SP, Kaseb A, Westin SN, Naing A, Tsimberidou AM, Hong D, Piha-Paul SA, Shi N, Johnston A, Bomalaski J, Fu S. Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies. Br J Cancer 124(9):1533-1539, 2021. e-Pub 2021. PMID: 33674736.
54. Huey RW, George GC, Phillips P, White R, Fu S, Janku F, Karp DD, Naing A, Piha-Paul S, Subbiah V, Tsimberidou AM, Pant S, Yap TA, Rodon J, Meric-Bernstam F, Shih YT, Hong DS. Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical Trials. The Oncologist 26(7):588-596, 2021. e-Pub 2021. PMID: 33783054.
55. Hajjar J, Mendoza T, Zhang L, Fu S, Piha-Paul SA, Hong DS, Janku F, Karp DD, Ballhausen A, Gong J, Zarifa A, Peterson CB, Meric-Bernstam F, Jenq R, Naing A. Associations between the gut microbiome and fatigue in cancer patients. Sci Rep 11(1):5847, 2021. e-Pub 2021. PMID: 33712647.
56. Tsimberidou AM, Hong DS, Fu S, Karp DD, Piha-Paul S, Kies MS, Ravi V, Subbiah V, Patel SM, Tu SM, Janku F, Heymach J, Johnson A, Cartwright C, Zhao L, Zhang J, Berry DA, Vining DJ, Futreal A, Miller VA, Meric-Bernstam F. Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study. NPJ Precis Oncol 5(1):21, 2021. e-Pub 2021. PMID: 33742104.
57. Alhalabi O, Hahn AW, Msaouel P, Andreev-Drakhlin AY, Meric-Bernstam F, Naing A, Piha-Paul S, Filip J, Pant S, Yap TA, Hong DS, Fu S, Karp D, Campbell E, Le H, Campbell MT, Shah AY, Tannir NM, Siefker-Radtke AO, Gao J, Roszik J, Subbiah V. Molecular profiling of metastatic bladder cancer early-phase clinical trial participants predicts patient outcomes. Mol Cancer Res 19(3):395-402, 2021. e-Pub 2021. PMID: 33323389.
58. Ballhausen A, Wheler JJ, Karp DD, Piha-Paul SA, Fu S, Pant S, Tsimberidou AM, Hong DS, Subbiah V, Holley VR, Huang H, Brewster AM, Koenig KB, Ibrahim NK, Meric-Bernstam F, Janku F. Phase I study of everolimus, letrozole, and trastuzumab in patients with hormone receptor-positive metastatic breast cancer or other solid tumors. Clin Cancer Res 27(5):1247-1255, 2021. e-Pub 2021. PMID: 33115815.
59. Piha-Paul SA, Dumbrava EE, Nair BC, Xiong W, Xu L, Mostorino R, Subbiah V, Tannir N, Fu S, Naing A, Janku F, Karp DD, Patel S, Daw NC, Hong D, Meric-Bernstam F, Zinner R. A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies. Onco Targets Ther 14:3037-3049, 2021. e-Pub 2021. PMID: 33994796.
60. Majd N, Waguespack SG, Janku F, Fu S, Penas-Prado M, Xu M, Alshawa A, Kamiya-Matsuoka C, Raza SM, McCutcheon IE, Naing A. Efficacy of pembrolizumab in patients with pituitary carcinoma: report of four cases from a phase II study. J Immunother Cancer 8(2), 2020. e-Pub 2020. PMID: 33427689.
61. Saleh M, Cassier PA, Eberst L, Naik G, Morris VK, Pant S, Terret C, Gao L, Long A, Mao H, McNeely S, Wagner EK, Carlesi RM, Fu S. Phase I Study of Ramucirumab Plus Merestinib in Previously Treated Metastatic Colorectal Cancer: Safety, Preliminary Efficacy, and Pharmacokinetic Findings. Oncologist 25(11):e1628-e1639, 2020. e-Pub 2020. PMID: 32537847.
62. Friedman CF, Snyder Charen A, Zhou Q, Carducci MA, Buckley De Meritens A, Corr BR, Fu S, Hollmann TJ, Iasonos A, Konner JA, Konstantinopoulos PA, Modesitt SC, Sharon E, Aghajanian C, Zamarin D. Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer. J Immunother Cancer 8(2), 2020. e-Pub 2020. PMID: 33004542.
63. Mendoza T, Sheshadri A, Altan M, Hess K, George G, Stephen B, Castillo L, Rodriguez E, Gong J, Peterson C, Rodon Ahnert J, Fu S, Piha-Paul SA, Pant S, Dumbrava E, Yap TA, Janku F, Tsimberidou AM, Subbiah V, Karp DD, Zarifa A, McQuinn LM, Cleeland C, Hong DS, Naing A. Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory. J Immunother Cancer 8(2), 2020. e-Pub 2020. PMID: 33097611.
64. Bang YJ, Golan T, Dahan L, Fu S, Moreno V, Park K, Geva R, De Braud F, Wainberg ZA, Reck M, Goff L, Laing N, Mi G, Oliveira JM, Wasserstrom H, Lin CC. Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ). Eur J Cancer 137:272-284, 2020. e-Pub 2020. PMID: 32827847.
65. Jimenez C, Subbiah V, Stephen B, Ma J, Milton D, Xu M, Zarifa A, Akhmedzhanov FO, Tsimberidou A, Habra MA, Rodon Anhert J, Fu S, Naing A. Phase II Clinical Trial of Pembrolizumab in Patients with Progressive Metastatic Pheochromocytomas and Paragangliomas. Cancers (Basel) 12(8), 2020. e-Pub 2020. PMID: 32824391.
66. Konstantinopoulos PA, Cheng SC, Wahner Hendrickson AE, Penson RT, Schumer ST, Doyle LA, Lee EK, Kohn EC, Duska LR, Crispens MA, Olawaiye AB, Winer IS, Barroilhet LM, Fu S, McHale MT, Schilder RJ, Färkkilä A, Chowdhury D, Curtis J, Quinn RS, Bowes B, D'Andrea AD, Shapiro GI, Matulonis UA. Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol 21(7):957-968, 2020. e-Pub 2020. PMID: 32553118.
67. Pairawan S, Hess KR, Janku F, Sánchez NS, Shaw KRM, Eng C, Damodaran S, Javle M, Kaseb AO, Hong DS, Subbiah V, Fu S, Fogelman DR, Raymond VM, Lanman RB, Meric-Bernstam F. Cell-Free circulating tumor DNA variant allele frequency associates with survival in metastatic cancer. Clin Cancer Res 26(8):1924-1931, 2020. e-Pub 2020. PMID: 31852833.
68. Naing A, Meric-Bernstam F, Stephen B, Karp DD, Hajjar J, Rodon Ahnert J, Piha-Paul SA, Colen RR, Jimenez C, Raghav KP, Ferrarotto R, Tu SM, Campbell M, Wang L, Sabir SH, Tapia C, Bernatchez C, Frumovitz M, Tannir N, Ravi V, Khan S, Painter JM, Abonofal A, Gong J, Alshawa A, McQuinn LM, Xu M, Ahmed S, Subbiah V, Hong DS, Pant S, Yap TA, Tsimberidou AM, Dumbrava EEI, Janku F, Fu S, Simon RM, Hess KR, Varadhachary GR, Amir Habra M. Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer 8(1), 2020. e-Pub 2020. PMID: 32188704.
69. Falchook GS, Kurzrock R, Amin HM, Xiong W, Fu S, Piha-Paul SA, Janku F, Eskandari G, Catenacci DVT, Klevesath MB, Bruns R, Stammberger U, Johne A, Bladt F, Friese-Hamim M, Girard P, El Bawab S, Hong DS. First-in-man phase I trial of the selective MET inhibitor tepotinib in patients with advanced solid tumors. Clin Cancer Res 26(6):1237-1246, 2020. e-Pub 2020. PMID: 31822497.
70. Wang Y, Janku F, Piha-Paul S, Hess K, Broaddus R, Liu L, Shi N, Overman M, Kopetz S, Subbiah V, Naing A, Hong D, Tsimberidou AM, Karp D, Yao J, Fu S. Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies. Sci Rep 10(1):3080, 2020. e-Pub 2020. PMID: 32080210.
71. Subbiah V, Dumbrava EI, Jiang Y, Thein KZ, Naing A, Hong DS, Fu S, Piha-Paul SA, Tsimberidou AM, Janku F, Meric-Bernstam F, Kurzrock R, Falchook G. Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial. Exp Hematol Oncol 9:7, 2020. e-Pub 2020. PMID: 32337094.
72. Tsimberidou AM, Hong DS, Wheler JJ, Falchook GS, Janku F, Naing A, Fu S, Piha-Paul S, Cartwright C, Broaddus RR, Nogueras Gonzalez GM, Hwu P, Kurzrock R. Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine. J Hematol Oncol 12(1):145, 2019. e-Pub 2019. PMID: 31888672.
73. Maymani H, Hess K, Groisberg R, Hong DS, Naing A, Piha-Paul S, Janku F, Fu S, Tsimberidou AM, Pant S, Karp D, Liu S, Sun M, Heymach J, Simon G, Meric-Bernstam F, Subbiah V. Corrigendum to "Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials" [Lung Cancer 120 (June) (2018) 137-141]. Lung Cancer 136:158, 2019. e-Pub 2019. PMID: 31445783.
74. Habra MA, Stephen B, Campbell M, Hess K, Tapia C, Xu M, Rodon Ahnert J, Jimenez C, Lee JE, Perrier ND, Boraddus RR, Pant S, Subbiah V, Hong DS, Zarifa A, Fu S, Karp DD, Meric-Bernstam F, Naing A. Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma. J Immunother Cancer 7(1):253, 2019. e-Pub 2019. PMID: 31533818.
75. Zhou X, Lockhart AC, Fu S, Nemunaitis J, Sarantopoulos J, Muehler A, Rangachari L, Bargfrede M, Venkatakrishnan K. Pharmacokinetics of the investigational aurora A kinase inhibitor alisertib in adult patients with advanced solid tumors or relapsed/refractory lymphoma with varying degrees of hepatic dysfunction. J Clin Pharmacol 59(9):1204-1215, 2019. e-Pub 2019. PMID: 30985952.
76. Drilon A, Fu S, Patel MR, Fakih M, Wang D, Olszanski AJ, Morgensztern D, Liu SV, Cho BC, Bazhenova L, Rodriguez CP, Doebele RC, Wozniak A, Reckamp KL, Seery T, Nikolinakos P, Hu Z, Oliver J, Trone D, McArthur K, Patel R, Multani PS, Ahn MJ. A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105. Cancer Discov 9(3):384-395, 2019. e-Pub 2019. PMID: 30487236.
77. George GC, Iwuanyanwu EC, Buford AS, Piha-Paul SA, Subbiah V, Fu S, Karp DD, Pant S, Hinojosa CO, Hess KR, Cleeland CS, Bernstam EV, Meric-Bernstam F, Hong DS. Cancer-related internet use and its association with patient decision making and trust in physicians among patients in an early drug development clinic: a questionnaire-based cross-sectional observational study. J Med Internet Res 21(3):e10348, 2019. e-Pub 2019. PMID: 30869638.
78. Falchook G, Coleman RL, Roszak A, Behbakht K, Matulonis U, Ray-Coquard I, Sawrycki P, Duska LR, Tew W, Ghamande S, Lesoin A, Schwartz PE, Buscema J, Fabbro M, Lortholary A, Goff B, Kurzrock R, Martin LP, Gray HJ, Fu S, Sheldon-Waniga E, Lin HM, Venkatakrishnan K, Zhou X, Leonard EJ, Schilder RJ. Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial. JAMA Oncol 5(1):e183773, 2019. e-Pub 2019. PMID: 30347019.
79. Chen X, Low KH, Alexander A, Jiang Y, Karakas C, Hess KR, Carey JP, Bui T, Vijayaraghavan S, Evans KW, Yi M, Ellis DC, Cheung KL, Ellis IO, Fu S, Meric-Bernstam F, Hunt KK, Keyomarsi K. Cyclin E overexpression sensitizes triple negative breast cancer to Wee1 kinase Inhibition. Clin Cancer Res 24(24):6594-6610, 2018. e-Pub 2018. PMID: 30181387.
80. Fountzilas E, Krishnan E, Janku F, Fu S, Karp DD, Naing A, Subbiah V, Hong DS, Piha-Paul SA, Vining DJ, Tsimberidou AM. A phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without intravenous bevacizumab, in patients with advanced cancer and predominant liver involvement. Cancer Chemother Pharmacol 82(5):877-885, 2018. e-Pub 2018. PMID: 30182147.
81. Fu S, Wang Y, Keyomarsi K, Meric-Bernstein F. Strategic development of AZD1775, a Wee1 kinase inhibitor, for cancer therapy. Expert Opin Investig Drugs 27(9):741-751, 2018. e-Pub 2018. PMID: 30102076.
82. Wang Y, Wang Z, Piha-Paul S, Janku F, Subbiah V, Shi N, Hess K, Broaddus R, Shan B, Naing A, Hong D, Tsimberidou AM, Karp D, Lu C, Papadimitrakopoulou V, Heymach J, Meric-Bernstam F, Fu S. Outcome analysis of Phase I trial patients with metastatic KRAS and/or TP53 mutant non-small cell lung cancer. Oncotarget 9(70):33258-33270, 2018. e-Pub 2018. PMID: 30279957.
83. Dembla V, Somaiah N, Barata P, Hess K, Fu S, Janku F, Karp DD, Naing A, Piha-Paul SA, Subbiah V, Tsimberidou AM, Shaw K, Meric-Bernstam F, Hong DS. Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic. Oncotarget 9(69):33232-33243, 2018. e-Pub 2018. PMID: 30237864.
84. Patnaik A, Gordon M, Tsai F, Papadopoulous K, Rasco D, Beeram SM, Fu S, Janku F, Hynes SM, Gundala SR, Willard MD, Zhang W, Lin AB, Hong D. A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer. Cancer Chemother Pharmacol 82(3):407-418, 2018. e-Pub 2018. PMID: 29926131.
85. Patnaik A, Gordon M, Tsai F, Papadopoulos KP, Rasco D, Beeram M, Fu S, Janku F, Hynes SM, Gundala SR, Willard MD, Zhang W, Lin AB, Hong D. Correction to: A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer. Cancer Chemother Pharmacol 82(3):419, 2018. e-Pub 2018. PMID: 30014222.
86. Colen RR, Fujii T, Bilen MA, Kotrotsou A, Abrol S, Hess KR, Hajjar J, Suarez-Almazor ME, Alshawa A, Hong DS, Giniebra-Camejo D, Stephen B, Subbiah V, Sheshadri A, Mendoza T, Fu S, Sharma P, Meric-Bernstam F, Naing A. Radiomics to predict immunotherapy-induced pneumonitis: proof of concept. Invest New Drugs 36(4):601-607, 2018. e-Pub 2018. PMID: 29075985.
87. Fujii T, Colen RR, Bilen MA, Hess KR, Hajjar J, Suarez-Almazor ME, Alshawa A, Hong DS, Tsimberidou A, Janku F, Gong J, Stephen B, Subbiah V, Piha-Paul SA, Fu S, Sharma P, Mendoza T, Patel A, Thirumurthi S, Sheshadri A, Meric-Bernstam F, Naing A. Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. Invest New Drugs 36(4):638-646, 2018. e-Pub 2018. PMID: 29159766.
88. Kato S, Jardim DL, Johnson FM, Subbiah V, Piha-Paul S, Tsimberidou AM, Falchook GS, Karp D, Zinner R, Wheler J, Janku F, Fu S, Lim J, Bean S, Nguyen L, Urban S, Browne E, Meric-Bernstam F, Hong DS. Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer. Invest New Drugs 36(3):416-423, 2018. e-Pub 2018. PMID: 29047029.
89. Maymani H, Hess K, Groisberg R, Hong DS, Naing A, Piha-Paul S, Janku F, Fu S, Tsimberidou AM, Pant S, Karp D, Liu S, Sun M, Heymach J, Simon G, Meric-Bernstam F, Subbiah V. Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials. Lung Cancer 120:137-141, 2018. e-Pub 2018. PMID: 29748008.
90. Sen S, Kato S, Agarwal R, Piha-Paul S, Hess K, Karp D, Janku F, Fu S, Naing A, Pant S, Falchook G, Tang C, Wu X, Ye Y, Tsimberidou A, Subbiah V, Kurzrock R, Byers L, Westin S, Lim J, Bean S, Bass A, Nguyen L, Meric-Bernstam F, Hong D. Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers. Br J Cancer 118(11):1419-1424, 2018. e-Pub 2018. PMID: 29695765.
91. Sen S, Hess K, Hong DS, Naing A, Piha-Paul S, Janku F, Fu S, Subbiah IM, Liu H, Khanji R, Huang L, Moorthy S, Karp DD, Tsimberidou A, Meric-Bernstam F, Subbiah V. Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase I clinical trials. Br J Cancer 118(6):763-769, 2018. e-Pub 2018. PMID: 29462132.
92. Sakamuri D, Glitza IC, Betancourt Cuellar SL, Subbiah V, Fu S, Tsimberidou AM, Wheler JJ, Hong DS, Naing A, Falchook GS, Fanale MA, Cabanillas ME, Janku F. Phase 1 dose-escalation study of anti CTLA-4 antibody ipilimumab and lenalidomide in patients with advanced cancers. Mol Cancer Ther 17(3):671-676, 2018. e-Pub 2018. PMID: 29237802.
93. Möhrmann L, Huang H, Hong DS, Tsimberidou AM, Fu S, Piha-Paul S, Subbiah V, Karp DD, Naing A, Krug AK, Enderle D, Priewasser T, Noerholm M, Eitan E, Coticchia C, Stoll G, Jordan LM, Eng C, Kopetz S, Skog J, Meric-Bernstam F, Janku F. Liquid biopsies using plasma exosomal nucleic acids and plasma cell-free DNA compared with clinical outcomes of patients with advanced cancers. Clin Cancer Res 24(1):181-188, 2018. e-Pub 2018. PMID: 29051321.
94. Li Y, Liu T, Ivan C, Huang J, Shen DY, Kavanagh JJ, Bast RC, Fu S, Hu W, Sood AK. Corrigendum: enhanced cytotoxic effects of combined valproic acid and the aurora kinase inhibitor VE465 on gynecologic cancer cells. Front Oncol 8:9, 2018. e-Pub 2018. PMID: 29456965.
95. Groisberg R, Hong DS, Behrang A, Hess K, Janku F, Piha-Paul S, Naing A, Fu S, Benjamin R, Patel S, Somaiah N, Conley A, Meric-Bernstam F, Subbiah V. Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials. J Immunother Cancer 5(1):100, 2017. e-Pub 2017. PMID: 29254498.
96. Tanaka N, Patel AA, Tang L, Silver NL, Lindemann A, Takahashi H, Jaksik R, Rao X, Kalu NN, Chen TC, Wang J, Frederick MJ, Johnson FM, Gleber-Netto F, Fu S, Kimmel M, Wang J, Hittelman WN, Pickering CR, Myers JN, Osman AA. Replication stress leading to apoptosis within the S-phase contributes to synergism between vorinostat and AZD1775 in HNSCC harboring high risk TP53 mutation. Clin Cancer Res 23(21):6541-6554, 2017. e-Pub 2017. PMID: 28790110.
97. Dembla V, Groisberg R, Hess K, Fu S, Wheler J, Hong DS, Janku F, Zinner R, Piha-Paul SA, Ravi V, Benjamin RS, Patel S, Somaiah N, Herzog CE, Karp DD, Roszik J, Meric-Bernstam F, Subbiah V. Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors. Sci Rep 7(1):15963, 2017. e-Pub 2017. PMID: 29162825.
98. Mita M, Fu S, Piha-Paul SA, Janku F, Mita A, Natale R, Guo W, Zhao C, Kurzrock R, Naing A. Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors. Invest New Drugs 35(5):616-626, 2017. e-Pub 2017. PMID: 28194539.
99. Goldstein JB, Tang C, Hess KR, Hong D, Subbiah V, Janku F, Fu S, Karp DD, Naing A, Tsimberidou AM, Wheler J, Zinner R, Javle M, Varadhachary GR, Wolff RA, Fogelman DR, Meric-Bernstam F, Piha-Paul SA. Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience. Oncotarget 8(50):87163-87173, 2017. e-Pub 2017. PMID: 29152071.
100. Tsimberidou AM, Hong DS, Ye Y, Cartwright C, Wheler JJ, Falchook GS, Naing A, Fu S, Piha-Paul S, Janku F, Meric-Bernstam F, Hwu P, Kee B, Kies MS, Broaddus R, Mendelsohn J, Hess KR, Kurzrock R. Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study. JCO Precis Oncol 1:PO.17.00002, 2017. e-Pub 2017. PMID: 29082359.
101. Janku F, Zhang S, Waters J, Liu L, Huang HJ, Subbiah V, Hong DS, Karp DD, Fu S, Cai X, Ramzanali NM, Madwani K, Cabrilo G, Andrews DL, Zhao Y, Javle M, Kopetz ES, Luthra R, Kim HJ, Gnerre S, Satya RV, Chuang HY, Kruglyak KM, Toung J, Zhao C, Shen R, Heymach JV, Meric-Bernstam F, Mills GB, Fan JB, Salathia NS. Development and validation of an ultradeep next-generation sequencing assay for testing of plasma cell-free DNA from patients with advanced cancer. Clin Cancer Res 23(18):5648-5656, 2017. e-Pub 2017. PMID: 28536309.
102. Kehl KL, Fullmer CP, Fu S, George GC, Hess KR, Janku F, Karp DD, Kato S, Kizer CK, Kurzrock R, Naing A, Pant S, Piha-Paul SA, Subbiah V, Tsimberidou AM, Hong DS. Insurance clearance for early-phase oncology clinical trials following the affordable care act. Clin Cancer Res 23(15):4155-4162, 2017. e-Pub 2017. PMID: 28729355.
103. Wang Z, Piha-Paul S, Janku F, Subbiah V, Shi N, Gong J, Wathoo C, Shaw K, Hess K, Broaddus R, Naing A, Hong D, Tsimberidou AM, Karp D, Yao J, Meric-Bernstam F, Fu S. Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer. Oncotarget 8(20):33796-33806, 2017. e-Pub 2017. PMID: 28430579.
104. Subbiah V, Khawaja MR, Hong DS, Amini B, Yungfang J, Liu H, Johnson A, Schrock AB, Ali SM, Sun JX, Fabrizio D, Piha-Paul S, Fu S, Tsimberidou AM, Naing A, Janku F, Karp DD, Overman M, Eng C, Kopetz S, Meric-Bernstam F, Falchook GS. First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients. JCI Insight 2(8):e90380, 2017. e-Pub 2017. PMID: 28422758.
105. Piha-Paul SA, Xu B, Dumbrava EE, Fu S, Karp DD, Meric-Bernstam F, Hong DS, Rodon JA, Tsimberidou AM, Raghav K, Ajani JA, Conley AP, Mott F, Fan Y, Fan J, Peng P, Wang H, Ni S, Sun C, Qiang X, Levin WJ, Ngo B, Ru QC, Wu F, Javle MM. First-in-human phase I study of tinengotinib (TT-00420), a multiple kinase inhibitor, as a single agent in patients with advanced solid tumors. Oncologist 29(4):e514-e525, 2017. e-Pub 2017. PMID: 38297981.
106. Tang C, Welsh JW, de Groot P, Massarelli E, Chang JY, Hess KR, Basu S, Curran MA, Cabanillas ME, Subbiah V, Fu S, Tsimberidou AM, Karp D, Gomez DR, Diab A, Komaki R, Sharma P, Naing A, Hong DS. Ipilimumab with stereotactic ablative radiation therapy: Phase I results and immunologic correlates from peripheral T-cells. Clin Cancer Res 23(6):1388-1396, 2017. e-Pub 2017. PMID: 27649551.
107. Bupathi M, Hajjar J, Bean S, Fu S, Hong D, Karp D, Stephen B, Hess K, Meric-Bernstam F, Naing A. Incidence of infusion reactions to anti-neoplastic agents in early phase clinical trials: The MD Anderson Cancer Center experience. Invest New Drugs 35(1):59-67, 2017. e-Pub 2017. PMID: 27687047.
108. Kinahan H, Maiti A, Hess K, Dempsey J, Beatty L, Baldwin S, Hong DS, Naing A, Fu S, Tsimberidou AM, Piha-Paul S, Janku F, Karp D, Reddy S, Yennu S, Epner D, Bruera E, Meric-Bernstam F, Falchook G, Subbiah V. Post-discharge survival outcomes of patients with advanced cancer from The University of Texas MD Anderson Cancer Center Investigational Cancer Therapeutics (phase I trials) inpatient unit. Oncology 92(1):14-20, 2017. e-Pub 2017. PMID: 27802448.
109. Subbiah IM, Wheler JJ, Hess KR, Hong DS, Naing A, Fu S, Kurzrock R, Tsimberidou AM. Outcomes of patients ≥65 years old with advanced cancer treated on phase I trials at MD Anderson Cancer Center. Int J Cancer 140(1):208-215, 2017. e-Pub 2017. PMID: 27599876.
110. Reilley MJ, Bailey A, Subbiah V, Janku F, Naing A, Falchook G, Karp D, Piha-Paul S, Tsimberidou A, Fu S, Lim J, Bean S, Bass A, Montez S, Vence L, Sharma P, Allison J, Meric-Bernstam F, Hong DS. Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies. J Immunother Cancer 5:35, 2017. e-Pub 2017. PMID: 28428884.
111. Wang Z, Shi N, Naing A, Janku F, Subbiah V, Araujo DM, Patel SR, Ludwig JA, Ramondetta LM, Levenback CF, Ramirez PT, Piha-Paul SA, Hong D, Karp DD, Tsimberidou AM, Meric-Bernstam F, Fu S. Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for Targeted Therapy experience. Cancer Med 5(12):3437-3444, 2016. e-Pub 2016. PMID: 27882721.
112. Hong DS, Morris VK, El Osta B, Sorokin AV, Janku F, Fu S, Overman MJ, Piha-Paul S, Subbiah V, Kee B, Tsimberidou A, Fogelman D, Bellido J, Shureiqi I, Huang H, Atkins J, Tarcic G, Sommer N, Lanman R, Meric-Bernstam F, Kopetz S. Phase 1B study of vemurafenib in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with BRAFV600E mutation. Cancer Discov 6(12):1352-1365, 2016. e-Pub 2016. PMID: 27729313.
113. George GC, Iwuanyanwu EC, Anderson KO, Yusuf A, Zinner RG, Piha-Paul SA, Tsimberidou AM, Naing A, Fu S, Janku F, Subbiah V, Cleeland CS, Mendoza TR, Hong DS. Sleep quality and its association with fatigue, symptom burden, and mood in patients with advanced cancer in a clinic for early-phase oncology clinical trials. Cancer 122(21):3401-3409, 2016. e-Pub 2016. PMID: 27412379.
114. Park H, Garrido-Laguna I, Naing A, Fu S, Falchook GS, Piha-Paul SA, Wheler JJ, Hong DS, Tsimberidou AM, Subbiah V, Zinner RG, Kaseb AO, Patel S, Fanale MA, Velez-Bravo VM, Meric-Bernstam F, Kurzrock R, Janku F. Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. Oncotarget 7(41):67521-67531, 2016. e-Pub 2016. PMID: 27589687.
115. Wheler JJ, Janku F, Naing A, Li Y, Stephen B, Zinner R, Subbiah V, Fu S, Karp D, Falchook GS, Tsimberidou AM, Piha-Paul S, Anderson R, Ke D, Miller V, Yelensky R, Lee JJ, Hong D, Kurzrock R. TP53 alterations correlate with response to VEGF/VEGFR inhibitors: implications for targeted therapeutics. Mol Cancer Ther 15(10):2475-2485, 2016. e-Pub 2016. PMID: 27466356.
116. Subbiah V, Hess KR, Khawaja MR, Wagner MJ, Tang C, Naing A, Fu S, Janku F, Piha-Paul S, Tsimberidou AM, Herzog CE, Ludwig JA, Patel S, Ravi V, Benjamin RS, Meric-Bernstam F, Hong DS. Evaluation of novel targeted therapies in aggressive biology sarcoma patients after progression from US FDA approved therapies. Sci Rep 6:35448, 2016. e-Pub 2016. PMID: 27748430.
117. Gupta N, Hanley MJ, Venkatakrishnan K, Perez R, Norris RE, Nemunaitis J, Yang H, Qian MG, Falchook G, Labotka R, Fu S. Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment. Br J Clin Pharmacol 82(3):728-38, 2016. e-Pub 2016. PMID: 27121262.
118. Hou MM, Wang Z, Janku F, Piha-Paul S, Naing A, Hong D, Westin S, Coleman RL, Sood AK, Tsimberidou AM, Subbiah V, Wheler J, Zinner R, Lu K, Meric-Bernstam F, Fu S. Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience. Oncotarget 7(23):35132-43, 2016. e-Pub 2016. PMID: 27147567.
119. Wheler JJ, Janku F, Naing A, Li Y, Stephen B, Zinner RG, Subbiah V, Fu S, Karp DD, Falchook GS, Tsimberidou AM, Piha-Paul SA, Anderson R, Ke D, Miller VA, Yelensky R, Lee JJ, Hong D, Kurzrock R. Cancer therapy directed by comprehensive genomic profiling: a single center study. Cancer Res 76(13):3690-701, 2016. e-Pub 2016. PMID: 27197177.
120. Janku F, Huang HJ, Claes B, Falchook GS, Fu S, Hong D, Ramzanali NM, Nitti G, Cabrilo G, Tsimberidou AM, Naing A, Piha-Paul SA, Wheler JJ, Karp DD, Holley VR, Zinner RG, Subbiah V, Luthra R, Kopetz S, Overman MJ, Kee BK, Patel S, Devogelaere B, Sablon E, Maertens G, Mills GB, Kurzrock R, Meric-Bernstam F. BRAF mutation testing in cell-free DNA from the plasma of patients with advanced cancers using a rapid, automated molecular diagnostics system. Mol Cancer Ther 15(6):1397-404, 2016. e-Pub 2016. PMID: 27207774.
121. Said R, Kakadiaris E, Piha-Paul S, Fu S, Falchook G, Janku F, Wheler JJ, Zinner R, Hong DS, Kurzrock R, Tsimberidou AM. Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer. Cancer Chemother Pharmacol 77(5):1097-102, 2016. e-Pub 2016. PMID: 27085994.
122. Khawaja MR, Nick AM, Madhusudanannair V, Fu S, Hong D, McQuinn LM, Ng CS, Piha-Paul SA, Janku F, Subbiah V, Tsimberidou A, Karp D, Meric-Bernstam F, Lu KH, Naing A. Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers. Cancer Chemother Pharmacol 77(5):973-7, 2016. e-Pub 2016. PMID: 27014780.
123. Fu S, Culotta KS, Falchook GS, Hong DS, Myers AL, Zhang YP, Naing A, Janku F, Hou MM, Kurzrock R. Erratum to: Pharmacokinetic evaluation of nanoparticle albumin-bound paclitaxel delivered via hepatic arterial infusion in patients with predominantly hepatic metastases. Cancer Chemother Pharmacol 77(4):881, 2016. e-Pub 2016. PMID: 26994910.
124. Liu X, Kambrick S, Fu S, Naing A, Subbiah V, Blumenschein GR, Glisson BS, Kies MS, Tsimberidou AM, Wheler JJ, Zinner RG, Hong DS, Kurzrock R, Piha-Paul SA. Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus. Oncotarget 7(17):23227-38, 2016. e-Pub 2016. PMID: 26933802.
125. Said R, Ye Y, Hong DS, Naing A, Falchook G, Fu S, Wheler JJ, Piha-Paul S, Tsimberidou AM. Phase I clinical trial of lenalidomide in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 77(3):575-81, 2016. e-Pub 2016. PMID: 26825327.
126. Fu S, Culotta KS, Falchook GS, Hong DS, Myers AL, Zhang YP, Naing A, Janku F, Hou MM, Kurzrock R. Pharmacokinetic evaluation of nanoparticle albumin-bound paclitaxel delivered via hepatic arterial infusion in patients with predominantly hepatic metastases. Cancer Chemother Pharmacol 77(2):357-64, 2016. e-Pub 2016. PMID: 26698868.
127. Wang Z, Fu S. An overview of tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer. Expert Opin Investig Drugs 25(1):15-30, 2016. e-Pub 2016. PMID: 26560712.
128. Hong DS, Kurzrock R, Wheler JJ, Naing A, Falchook GS, Fu S, Kim KB, Davies MA, Nguyen LM, George GC, Xu L, Shumaker R, Ren M, Mink J, Bedell C, Andresen C, Sachdev P, O'Brien JP, Nemunaitis J. Phase I dose-escalation study of the multikinase inhibitor lenvatinib in patients with advanced solid tumors and in an expanded cohort of patients with melanoma. Clin Cancer Res 21(21):4801-10, 2015. e-Pub 2015. PMID: 26169970.
129. Chen HH, Chen WC, Liang ZD, Tsai WB, Long Y, Aiba I, Fu S, Broaddus R, Liu J, Feun LG, Savaraj N, Kuo MT. Targeting drug transport mechanisms for improving platinum-based cancer chemotherapy. Expert Opin Ther Targets 19(10):1307-17, 2015. e-Pub 2015. PMID: 26004625.
130. Janku F, Angenendt P, Tsimberidou AM, Fu S, Naing A, Falchook GS, Hong DS, Holley VR, Cabrilo G, Wheler JJ, Piha-Paul SA, Zinner RG, Bedikian AY, Overman MJ, Kee BK, Kim KB, Kopetz ES, Luthra R, Diehl F, Meric-Bernstam F, Kurzrock R. Erratum: Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget 6(27):24581, 2015. e-Pub 2015. PMID: 26405159.
131. Naing A, Dalal S, Abdelrahim M, Wheler J, Hess K, Fu S, Hong DS, Janku F, Falchook GS, Ilustre A, Ouyang F, Kurzrock R. Olanzapine for cachexia in patients with advanced cancer: an exploratory study of effects on weight and metabolic cytokines. Support Care Cancer 23(9):2649-54, 2015. e-Pub 2015. PMID: 25680763.
132. Subbiah IM, Falchook GS, Kaseb AO, Hess KR, Tsimberidou AM, Fu S, Subbiah V, Hong DS, Naing A, Piha-Paul SA, Akmal O, Janku F, Kurzrock R. Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials. Oncotarget 6(29):28453-62, 2015. e-Pub 2015. PMID: 26164085.
133. Henary H, George GC, Wheler J, Naing A, Piha-Paul S, Fu S, Mistry R, Zinner R, Kurzrock R, Hong DS. A phase 1 study of intermittently administered pazopanib in combination with continuous daily dosing of lapatinib in patients with solid tumors. Cancer Chemother Pharmacol 76(3):597-603, 2015. e-Pub 2015. PMID: 26210681.
134. Janku F, Claes B, Huang HJ, Falchook GS, Devogelaere B, Kockx M, Bempt IV, Reijans M, Naing A, Fu S, Piha-Paul SA, Hong DS, Holley VR, Tsimberidou AM, Stepanek VM, Patel SP, Kopetz ES, Subbiah V, Wheler JJ, Zinner RG, Karp DD, Luthra R, Roy-Chowdhuri S, Sablon E, Meric-Bernstam F, Maertens G, Kurzrock R. BRAF mutation testing with a rapid, fully integrated molecular diagnostics system. Oncotarget 6(29):26886-94, 2015. e-Pub 2015. PMID: 26330075.
135. Said R, Kurzrock R, Naing A, Hong DS, Fu S, Piha-Paul SA, Wheler JJ, Janku F, Kee BK, Bidyasar S, Lim J, Wallace M, Tsimberidou AM. Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver. Invest New Drugs 33(4):911-20, 2015. e-Pub 2015. PMID: 25990659.
136. Boland GM, Piha-Paul SA, Subbiah V, Routbort M, Herbrich SM, Baggerly K, Patel KP, Brusco L, Horombe C, Naing A, Fu S, Hong DS, Janku F, Johnson A, Broaddus R, Luthra R, Shaw K, Mendelsohn J, Mills GB, Meric-Bernstam F. Clinical next generation sequencing to identify actionable aberrations in a phase I program. Oncotarget 6(24):20099-110, 2015. e-Pub 2015. PMID: 26015395.
137. Hong DS, Rosen P, Lockhart AC, Fu S, Janku F, Kurzrock R, Khan R, Amore B, Caudillo I, Deng H, Hwang YC, Loberg R, Ngarmchamnanrith G, Beaupre DM, Lee P. A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors. Oncotarget 6(21):18693-706, 2015. e-Pub 2015. PMID: 26155941.
138. Falchook GS, Venkatakrishnan K, Sarantopoulos J, Kurzrock R, Mita AC, Fu S, Mita MM, Zhou X, Jung JA, Ullmann CD, Milch C, Rosen LS. Relative bioavailability of a prototype oral solution of the Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors. Int J Clin Pharmacol Ther 53(7):563-72, 2015. e-Pub 2015. PMID: 26073352.
139. Busaidy NL, LoRusso P, Lawhorn K, Hess KR, Habra MA, Fu S, Hong DS, Chen HX, Doyle LA, Kurzrock R, Naing A. The prevalence and impact of hyperglycemia and hyperlipidemia in patients with advanced cancer receiving combination treatment with the mammalian target of rapamycin inhibitor temsirolimus and insulin growth factor-receptor antibody cixutumumab. Oncologist 20(7):737-41, 2015. e-Pub 2015. PMID: 26054632.
140. Hong DS, Janku F, Naing A, Falchook GS, Piha-Paul S, Wheler JJ, Fu S, Tsimberidou AM, Stecher M, Mohanty P, Simard J, Kurzrock R. Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer. Invest New Drugs 33(3):621-31, 2015. e-Pub 2015. PMID: 25822109.
141. Rodrigues HV, Ke D, Lim J, Stephen B, Bellido J, Janku F, Zinner R, Tsimberidou A, Hong D, Piha-Paul S, Fu S, Naing A, Subbiah V, Karp D, Falchook G, Kurzrock R, Wheler J. Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy. Invest New Drugs 33(3):700-9, 2015. e-Pub 2015. PMID: 25902899.
142. Fu S, Hou MM, Naing A, Janku F, Hess K, Zinner R, Subbiah V, Hong D, Wheler J, Piha-Paul S, Tsimberidou A, Karp D, Araujo D, Kee B, Hwu P, Wolff R, Kurzrock R, Meric-Bernstam F. Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation. Ann Oncol 26(5):1012-8, 2015. e-Pub 2015. PMID: 25669829.
143. Janku F, Angenendt P, Tsimberidou AM, Fu S, Naing A, Falchook GS, Hong DS, Holley VR, Cabrilo G, Wheler JJ, Piha-Paul SA, Zinner RG, Bedikian AY, Overman MJ, Kee BK, Kim KB, Kopetz ES, Luthra R, Diehl F, Meric-Bernstam F, Kurzrock R. Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget 6(14):12809-21, 2015. e-Pub 2015. PMID: 25980577.
144. Bilen MA, Fu S, Falchook GS, Ng CS, Wheler JJ, Abdelrahim M, Erguvan-Dogan B, Hong DS, Tsimberidou AM, Kurzrock R, Naing A. Phase I trial of valproic acid and lenalidomide in patients with advanced cancer. Cancer Chemother Pharmacol 75(4):869-74, 2015. e-Pub 2015. PMID: 25666183.
145. Falchook GS, Moulder S, Naing A, Wheler JJ, Hong DS, Piha-Paul SA, Tsimberidou AM, Fu S, Zinner R, Janku F, Jiang Y, Huang M, Parkhurst KL, Kurzrock R. A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer. Invest New Drugs 33(1):177-86, 2015. e-Pub 2015. PMID: 25323060.
146. Falchook GS, Wheler JJ, Naing A, Piha-Paul SA, Fu S, Tsimberidou AM, Hong DS, Janku F, Zinner R, Jiang Y, Huang M, Lin Q, Parkhurst K, Kurzrock R. Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors. Invest New Drugs 33(1):215-24, 2015. e-Pub 2015. PMID: 25363205.
147. Jardim DL, de Melo Gagliato D, Falchook G, Zinner R, Wheler JJ, Janku F, Subbiah V, Piha-Paul SA, Fu S, Tannir N, Corn P, Tang C, Hess K, Roy-Chowdhuri S, Kurzrock R, Meric-Bernstam F, Hong DS. MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors. Clin Genitourin Cancer 13(1):e19-26, 2015. e-Pub 2015. PMID: 25087088.
148. Fu S, Shi N, Wheler J, Naing A, Janku F, Piha-Paul S, Gong J, Hong D, Tsimberidou A, Zinner R, Subbiah V, Hou MM, Ramirez P, Ramondetta L, Lu K, Meric-Bernstam F. Characteristics and outcomes for patients with advanced vaginal or vulvar cancer referred to a phase I clinical trials program: the MD Anderson cancer center experience. Gynecol Oncol Res Pract 2:10, 2015. e-Pub 2015. PMID: 27231570.
149. Tsimberidou AM, Said R, Culotta K, Wistuba I, Jelinek J, Fu S, Falchook G, Naing A, Piha-Paul S, Zinner R, Siddik ZH, He G, Hess K, Stewart DJ, Kurzrock R, Issa JP. Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy. Clin Epigenetics 7(1):29, 2015. e-Pub 2015. PMID: 25806091.
150. Liu X, George GC, Tsimberidou AM, Naing A, Wheler JJ, Kopetz S, Fu S, Piha-Paul SA, Eng C, Falchook GS, Janku F, Garrett C, Karp D, Kurzrock R, Zinner R, Raghav K, Subbiah V, Hess K, Meric-Bernstam F, Hong DS, Overman MJ. Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response. BMC Cancer 15(1):713, 2015. e-Pub 2015. PMID: 26474549.
151. de Melo Gagliato D, Jardim DL, Falchook G, Tang C, Zinner R, Wheler JJ, Janku F, Subbiah V, Piha-Paul SA, Fu S, Hess K, Roy-Chowdhuri S, Moulder S, Gonzalez-Angulo AM, Meric-Bernstam F, Hong DS. Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unit. Clin Breast Cancer 14(6):468-74, 2014. e-Pub 2014. PMID: 25065564.
152. Jardim DL, Tang C, Gagliato Dde M, Falchook GS, Hess K, Janku F, Fu S, Wheler JJ, Zinner RG, Naing A, Tsimberidou AM, Holla V, Li MM, Roy-Chowdhuri S, Luthra R, Salgia R, Kurzrock R, Meric-Bernstam F, Hong DS. Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I clinic. Clin Cancer Res 20(24):6336-45, 2014. e-Pub 2014. PMID: 25326232.
153. Tang C, Hess K, Jardim DL, Gagliato Dde M, Tsimberidou AM, Falchook G, Fu S, Janku F, Naing A, Piha-Paul S, Subbiah V, Wheler J, Zinner RG, Kurzrock R, Ellis LM, Meric-Berstam F, Hong DS. Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinic. Clin Cancer Res 20(23):5956-63, 2014. e-Pub 2014. PMID: 25316815.
154. Ganesan P, Moulder S, Lee JJ, Janku F, Valero V, Zinner RG, Naing A, Fu S, Tsimberidou AM, Hong D, Stephen B, Stephens P, Yelensky R, Meric-Bernstam F, Kurzrock R, Wheler JJ. Triple negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agents. Mol Cancer Ther 13(12):3175-84, 2014. e-Pub 2014. PMID: 25253784.
155. Hong DS, Henary H, Falchook GS, Naing A, Fu S, Moulder S, Wheler JJ, Tsimberidou A, Durand JB, Khan R, Yang P, Johansen M, Newman RA, Kurzrock R. First-in-human study of pbi-05204, an oleander-derived inhibitor of akt, fgf-2, nf-κ? and p70s6k, in patients with advanced solid tumors. Invest New Drugs 32(6):1204-12, 2014. e-Pub 2014. PMID: 24919855.
156. Hou MM, Liu X, Wheler J, Naing A, Hong D, Coleman RL, Tsimberidou A, Janku F, Zinner R, Lu K, Kurzrock R, Fu S. Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience. Oncotarget 5(22):11168-79, 2014. e-Pub 2014. PMID: 25426553.
157. Said R, Ye Y, Falchook GS, Janku F, Naing A, Zinner R, Blumenschein GR, Fu S, Hong DS, Piha-Paul SA, Wheler JJ, Kurzrock R, Palmer GA, Aldape K, Hess KR, Tsimberidou AM. Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials. Oncotarget 5(19):8937-46, 2014. e-Pub 2014. PMID: 25313136.
158. Tsimberidou AM, Wen S, Hong DS, Wheler JJ, Falchook GS, Fu S, Piha-Paul S, Naing A, Janku F, Aldape K, Ye Y, Kurzrock R, Berry D. Personalized medicine for patients with advanced cancer in the Phase I program at MD Anderson: validation and landmark analyses. Clin Cancer Res 20(18):4827-36, 2014. e-Pub 2014. PMID: 24987059.
159. Bilen MA, Durand JB, McQuinn L, Hess KR, Fu S, Falchook GS, Hong DS, Wheler JJ, Said R, Ewer MS, Kurzrock R, Naing A. Evaluation of a novel blood pressure scoring method and its association with clinical response in cancer patients treated with anti-vascular endothelial growth factor therapy. Invest New Drugs 32(4):717-22, 2014. e-Pub 2014. PMID: 24764123.
160. Hong DS, Garrido-Laguna I, Ekmekcioglu S, Falchook GS, Naing A, Wheler JJ, Fu S, Moulder SL, Piha-Paul S, Tsimberidou AM, Wen Y, Culotta KS, Anderes K, Davis DW, Liu W, George GC, Camacho LH, Percy Ivy S, Kurzrock R. Dual inhibition of the vascular endothelial growth factor pathway: A phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors. Cancer 120(14):2164-73, 2014. e-Pub 2014. PMID: 24752867.
161. Said R, Ye Y, Hong DS, Janku F, Fu S, Naing A, Wheler JJ, Kurzrock R, Thomas C, Palmer GA, Hess KR, Aldape K, Tsimberidou AM. Characteristics and survival of patients with advanced cancer and p53 mutations. Oncotarget 5(11):3871-9, 2014. e-Pub 2014. PMID: 25003695.
162. Fu S, Hou MM, Wheler J, Hong D, Naing A, Tsimberidou A, Janku F, Zinner R, Piha-Paul S, Falchook G, Kuo MT, Kurzrock R. Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies. Invest New Drugs 32(3):465-72, 2014. e-Pub 2014. PMID: 24306314.
163. Hong DS, Hui D, Bruera E, Janku F, Naing A, Falchook GS, Piha-Paul S, Wheler JJ, Fu S, Tsimberidou AM, Stecher M, Mohanty P, Simard J, Kurzrock R. MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. Lancet Oncol 15(6):656-66, 2014. e-Pub 2014. PMID: 24746841.
164. Wheler JJ, Parker BA, Lee JJ, Atkins JT, Janku F, Tsimberidou AM, Zinner R, Subbiah V, Fu S, Schwab R, Moulder S, Valero V, Schwaederle M, Yelensky R, Miller VA, Stephens MP, Meric-Bernstam F, Kurzrock R. Unique molecular signatures as a hallmark of patients with metastatic breast cancer: Implications for current treatment paradigms. Oncotarget 5(9):2349-54, 2014. e-Pub 2014. PMID: 24811890.
165. Hou MM, Liu X, Wheler J, Naing A, Hong D, Bodurka D, Schmeler K, Tsimberidou A, Janku F, Zinner R, Piha-Paul S, Hu CY, Lu K, Kurzrock R, Fu S. Outcomes of patients with metastatic cervical cancer in a phase I clinical trials program. Anticancer Res 34(5):2349-55, 2014. e-Pub 2014. PMID: 24778042.
166. Wheler JJ, Moulder SL, Naing A, Janku F, Piha-Paul SA, Falchook GS, Zinner R, Tsimberidou AM, Fu S, Hong DS, Atkins JT, Yelensky R, Stephens PJ, Kurzrock R. Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway. Oncotarget 5(10):3029-38, 2014. e-Pub 2014. PMID: 24912489.
167. Ganesan P, Piha-Paul S, Naing A, Falchook G, Wheler J, Fu S, Hong DS, Kurzrock R, Janku F, Laday S, Bedikian AY, Kies M, Wolff RA, Tsimberidou AM. Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer. Invest New Drugs 32(2):279-86, 2014. e-Pub 2014. PMID: 23756764.
168. Liu X, Lorusso P, Mita M, Piha-Paul S, Hong DS, Fu S, McQuinn L, Asatiani E, Doyle LA, Chen HX, Hess KR, Kurzrock R, Naing A. Incidence of mucositis in patients treated with temsirolimus-based regimens and correlation to treatment response. Oncologist 19(4):426-428, 2014. e-Pub 2014. PMID: 24668327.
169. Jardim DL, de Melo Gagliato D, Falchook GS, Janku F, Zinner R, Wheler JJ, Subbiah V, Piha-Paul SA, Fu S, Murphy MB, Ajani J, Tang C, Hess K, Hamilton SR, Roy-Chowdhuri S, Kurzrock R, Meric-Bernstam F, Hong DS. MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit. Oncotarget 5(7):1837-45, 2014. e-Pub 2014. PMID: 24742823.
170. Piha-Paul SA, Wheler JJ, Fu S, Levenback C, Lu K, Falchook GS, Naing A, Hong DS, Tsimberidou AM, Kurzrock R. Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus. Oncotarget 5(7):1846-55, 2014. e-Pub 2014. PMID: 24742900.
171. Wheler JJ, Janku F, Falchook GS, Jackson TL, Fu S, Naing A, Tsimberidou AM, Moulder SL, Hong DS, Yang H, Piha-Paul SA, Atkins JT, Garcia-Manero G, Kurzrock R. Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers. Cancer Chemother Pharmacol 73(3):495-501, 2014. e-Pub 2014. PMID: 24435060.
172. Tsimberidou AM, Adamopoulos AM, Ye Y, Piha-Paul S, Janku F, Fu S, Hong D, Falchook GS, Naing A, Wheler J, Fortier A, Kurzrock R, Hess KR. Phase I clinical trial of bendamustine and bevacizumab for patients with advanced cancer. J Natl Compr Canc Netw 12(2):194-203, 2014. e-Pub 2014. PMID: 24586081.
173. Naing A, Fu S, Zinner RG, Wheler JJ, Hong DS, Arakawa K, Falchook GS, Kurzrock R. Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid tumors. Invest New Drugs 32(1):154-9, 2014. e-Pub 2014. PMID: 23609829.
174. Janku F, Hong DS, Fu S, Piha-Paul SA, Naing A, Falchook GS, Tsimberidou AM, Stepanek VM, Moulder SL, Lee JJ, Luthra R, Zinner RG, Broaddus RR, Wheler JJ, Kurzrock R. Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. Cell Rep 6(2):377-87, 2014. e-Pub 2014. PMID: 24440717.
175. Tang C, Jardim DL, Falchook GS, Hess K, Fu S, Wheler JJ, Zinner RG, Naing A, Tsimberidou AM, De Melo Galgiato D, Westin SN, Meric-Bernstam F, Kurzrock R, Hong DS. MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors. Oncoscience 1(1):5-13, 2014. e-Pub 2014. PMID: 25593979.
176. Falchook GS, Naing A, Wheler JJ, Tsimberidou AM, Zinner R, Hong DS, Fu S, Piha-Paul SA, Janku F, Hess KR, Bastida C, Kurzrock R. Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer. Oncoscience 1(8):540-9, 2014. e-Pub 2014. PMID: 25594061.
177. Naing A, Agarwal R, Falchook G, Hong DS, Janku F, Wheler J, Fu S, Kurzrock R. Retreatment after secondary resistance or mixed response: a pilot study. Oncology 85(6):350-355, 2013. e-Pub 2013. PMID: 24335388.
178. Ganesan P, Janku F, Naing A, Hong DS, Tsimberidou AM, Falchook GS, Wheler JJ, Piha-Paul SA, Fu S, Stepanek VM, Lee JJ, Luthra R, Overman MJ, Kopetz ES, Wolff RA, Kurzrock R. Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations. Mol Cancer Ther 12(12):2857-63, 2013. e-Pub 2013. PMID: 24092809.
179. Tsimberidou AM, Vaklavas C, Fu S, Wen S, Lim JA, Hong D, Wheler J, Naing A, Uehara C, Wallace M, Kurzrock R. Hepatic arterial infusion therapy in advanced cancer and liver-predominant disease: the MD Anderson Experience. Hepatogastroenterology 60(127):1611-23, 2013. e-Pub 2013. PMID: 24634931.
180. Falchook GS, Fu S, Naing A, Hong DS, Hu W, Moulder S, Wheler JJ, Sood AK, Bustinza-Linares E, Parkhurst KL, Kurzrock R. Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies. Invest New Drugs 31(5):1192-200, 2013. e-Pub 2013. PMID: 23907406.
181. Veasey Rodrigues H, Baracos VE, Wheler JJ, Parsons HA, Hong DS, Naing A, Fu S, Falchoock G, Tsimberidou AM, Piha-Paul S, Chisholm G, Kurzrock R. Body composition and survival in the early clinical trials setting. Eur J Cancer 49(15):3068-75, 2013. e-Pub 2013. PMID: 23867127.
182. Wheler JJ, Tsimberidou AM, Falchook GS, Zinner RG, Hong DS, Fok JY, Fu S, Piha-Paul SA, Naing A, Kurzrock R. Combining erlotinib and cetuximab is associated with activity in patients with non small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or resistant mutations. Mol Cancer Ther 12(10):2167-75, 2013. e-Pub 2013. PMID: 23963360.
183. Gonzalez-Angulo AM, Meric-Bernstam F, Chawla S, Falchook G, Hong D, Akcakanat A, Chen H, Naing A, Fu S, Wheler J, Moulder S, Helgason T, Li S, Elias I, Desai N, Kurzrock R. Weekly nab-rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trial. Clin Cancer Res 19(19):5474-5484, 2013. e-Pub 2013. PMID: 24089446.
184. Kurzrock R, Atkins J, Wheler J, Fu S, Naing A, Busaidy N, Hong D, Sherman S. Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy. Ann Oncol 24(9):2256-61, 2013. e-Pub 2013. PMID: 23676418.
185. Henary H, Hong DS, Falchook GS, Tsimberidou A, George GC, Wen S, Wheler J, Fu S, Naing A, Piha-Paul S, Janku F, Kim KB, Hwu P, Kurzrock R. Melanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes. Ann Oncol 24(8):2158-65, 2013. e-Pub 2013. PMID: 23576709.
186. Jiang Y, Janku F, Subbiah V, Angelo LS, Naing A, Anderson PM, Herzog CE, Fu S, Benjamin RS, Kurzrock R. Germline PTPRD mutations in Ewing Sarcoma: biologic and clinical implications. Oncotarget 4(6):884-9, 2013. e-Pub 2013. PMID: 23800680.
187. Said R, Hong DS, Warneke CL, Lee JJ, Wheler JJ, Janku F, Naing A, Falchook GS, Fu S, Piha-Paul S, Tsimberidou AM, Kurzrock R. P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy. Oncotarget 4(5):705-14, 2013. e-Pub 2013. PMID: 23670029.
188. Wheler J, Falchook G, Tsimberidou AM, Hong D, Naing A, Piha-Paul S, Chen SS, Heymach J, Fu S, Stephen B, Fok JY, Janku F, Kurzrock R. Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population. Oncotarget 4(5):772-784, 2013. e-Pub 2013. PMID: 23800712.
189. Li Y, Liu T, Ivan C, Huang J, Shen DY, Kavanagh JJ, Bast RC, Fu S, Hu W, Sood AK. Enhanced cytotoxic effects of combined valproic acid and the aurora kinase inhibitor VE465 on gynecologic cancer cells. Front Oncol 3:58, 2013. e-Pub 2013. PMID: 23519775.
190. Naing A, Lorusso P, Fu S, Hong D, Chen HX, Doyle LA, Phan AT, Habra MA, Kurzrock R. Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma. Br J Cancer 108(4):826-30, 2013. e-Pub 2013. PMID: 23412108.
191. Wheler JJ, Falchook GS, Tsimberidou AM, Hong DS, Naing A, Piha-Paul SA, Chen SS, Fu S, Stephen B, Fok JY, Janku F, Kurzrock R. Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced tumors: implications for therapy. Ann Oncol 24(3):838-42, 2013. e-Pub 2013. PMID: 23139256.
192. Tsimberidou AM, Leick MB, Lim J, Fu S, Wheler J, Piha-Paul SA, Hong D, Falchook GS, Naing A, Subbiah IM, Fortier A, Avritscher R, Kurzrock R. Dose-finding study of hepatic arterial infusion of oxaliplatin-based treatment in patients with advanced solid tumors metastatic to the liver. Cancer Chemother Pharmacol 71(2):389-97, 2013. e-Pub 2013. PMID: 23143207.
193. Janku F, Wheler JJ, Naing A, Falchook GS, Hong DS, Stepanek VM, Fu S, Piha-Paul SA, Lee JJ, Luthra R, Tsimberidou AM, Kurzrock R. PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early phase clinical trials. Cancer Res 73(1):276-84, 2013. e-Pub 2013. PMID: 23066039.
194. Falchook GS, Naing A, Hong DS, Zinner R, Fu S, Piha-Paul SA, Tsimberidou AM, Morgan-Linnell SK, Jiang Y, Bastida C, Wheler JJ, Kurzrock R. Dual EGFR inhibition in combination with anti-VEGF treatment: A phase I clinical trial in non-small cell lung cancer. Oncotarget 4(1):118-27, 2013. e-Pub 2013. PMID: 23435217.
195. Subbiah IM, Subbiah V, Tsimberidou AM, Naing A, Kaseb AO, Javle M, Fu S, Hong DS, Piha-Paul S, Wheler JJ, Hess KR, Janku F, Falchook GS, Wolff RA, Kurzrock R. Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials. Oncotarget 4(1):153-162, 2013. e-Pub 2013. PMID: 23847722.
196. Subbiah IM, Subbiah V, Tsimberidou AM, Naing A, Kaseb AO, Javle M, Fu S, Hong DS, Piha-Paul S, Wheler JJ, Hess KR, Janku F, Falchook GS, Wolff RA, Kurzrock R. Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials. Oncotarget 4(1):156-65, 2013. e-Pub 2013. PMID: 23391555.
197. Fu S, McQuinn L, Naing A, Wheler JJ, Janku F, Falchook GS, Piha-Paul SA, Tu D, Howard A, Tsimberidou A, Zinner R, Hong DS, Kurzrock R. Barriers to study enrollment in patients with advanced cancer referred to a phase I clinical trials unit. Oncologist 18(12):1315-20, 2013. e-Pub 2013. PMID: 24153239.
198. Kurzrock R, Goel S, Wheler J, Hong D, Fu S, Rezai K, Morgan-Linnell SK, Urien S, Mani S, Chaudhary I, Ghalib MH, Buchbinder A, Lokiec F, Mulcahy M. Safety, pharmacokinetics, and activity of EZN-2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies. Cancer 118(24):6144-51, 2012. e-Pub 2012. PMID: 22674635.
199. Hong DS, Patel JC, Wheler J, Naing A, Garrido-Laguna I, Falchook G, Fu S, Tsimberidou AM, Kopetz S, Win S, Kurzrock R. Outcomes in 144 patients with colorectal cancer treated in a phase I clinic: the MD Anderson Cancer Center experience. Clin Colorectal Cancer 11(4):297-303, 2012. e-Pub 2012. PMID: 22537607.
200. Janku F, Wheler JJ, Naing A, Stepanek VM, Falchook GS, Fu S, Garrido-Laguna I, Tsimberidou AM, Piha-Paul SA, Moulder SL, Lee JJ, Luthra R, Hong DS, Kurzrock R. PIK3CA mutations in advanced cancers: characteristics and outcomes. Oncotarget 3(12):1566-75, 2012. e-Pub 2012. PMID: 23248156.
201. Liang ZD, Long Y, Tsai WB, Fu S, Kurzrock R, Gagea-Iurascu M, Zhang F, Chen HH, Hennessy BT, Mills GB, Savaraj N, Kuo MT. Mechanistic basis for overcoming platinum resistance using copper chelating agents. Mol Cancer Ther 11(11):2483-94, 2012. e-Pub 2012. PMID: 22914438.
202. Tsimberidou AM, Iskander NG, Hong DS, Wheler JJ, Falchook GS, Fu S, Piha-Paul S, Naing A, Janku F, Luthra R, Ye Y, Wen S, Berry D, Kurzrock R. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res 18(22):6373-83, 2012. e-Pub 2012. PMID: 22966018.
203. Naing A, Veasey-Rodrigues H, Hong DS, Fu S, Falchook GS, Wheler JJ, Tsimberidou AM, Wen S, Fessahaye SN, Golden EC, Aaron J, Ewer MS, Kurzrock R. Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs. Ann Oncol 23(11):2960-3, 2012. e-Pub 2012. PMID: 22745218.
204. Moroney J, Fu S, Moulder S, Falchook G, Helgason T, Levenback C, Hong D, Naing A, Wheler J, Kurzrock R. Phase I study of the anti-angiogenic antibody bevacizumab and the mTOR / hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin. Clin Cancer Res 18(20):5796-805, 2012. e-Pub 2012. PMID: 22927482.
205. Kuo MT, Fu S, Savaraj N, Chen HH. Role of the human high-affinity copper transporter in copper homeostasis regulation and cisplatin sensitivity in cancer chemotherapy. Cancer Res 72(18):4616-21, 2012. e-Pub 2012. PMID: 22962276.
206. Fu S, Li Y, Huang J, Liu T, Hong Z, Chen A, Bast RC, Kavanagh JJ, Gershenson DM, Sood AK, Hu W. Aurora kinase inhibitor VE 465 synergistically enhances cytotoxicity of carboplatin in ovarian cancer cells through induction of apoptosis and downregulation of histone 3. Cancer Biol Ther 13(11):1034-41, 2012. e-Pub 2012. PMID: 22895067.
207. Fu S, Barber FD, Naing A, Wheler J, Hong D, Falchook G, Piha-Paul S, Tsimberidou A, Howard A, Kurzrock R. Advance care planning in patients with cancer referred to a phase I clinical trials program: the MD Anderson Cancer Center experience. J Clin Oncol 30(23):2891-6, 2012. e-Pub 2012. PMID: 22778314.
208. Wheler JJ, Tsimberidou AM, Hong DS, Naing A, Falchook GS, Fu S, Moulder S, Stephen B, Wen S, Kurzrock R. Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experience. Ann Oncol 23(8):1963-7, 2012. e-Pub 2012. PMID: 22377564.
209. Fu S, Hennessy BT, Ng CS, Ju Z, Coombes KR, Wolf JK, Sood AK, Levenback CF, Coleman RL, Kavanagh JJ, Gershenson DM, Markman M, Dice K, Howard A, Li J, Li Y, Stemke-Hale K, Dyer M, Atkinson E, Jackson E, Kundra V, Kurzrock R, Bast RC, Mills GB. Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. Gynecol Oncol 126(1):47-53, 2012. e-Pub 2012. PMID: 22487539.
210. Tsimberidou AM, Fu S, Subbiah IM, Naing A, Hong DS, Wen S, Fortier AH, Lim J, Kurzrock R. Intraperitoneal and intravenous chemotherapy in peritoneal carcinomatosis. Hepatogastroenterology 59(116):960-4, 2012. e-Pub 2012. PMID: 22580643.
211. Fu S, Naing A, Fu C, Kuo MT, Kurzrock R. Overcoming platinum resistance through the use of a copper-lowering agent. Mol Cancer Ther 11(6):1221-5, 2012. e-Pub 2012. PMID: 22491798.
212. Naing A, LoRusso P, Fu S, Hong DS, Anderson P, Benjamin RS, Ludwig J, Chen HX, Doyle LA, Kurzrock R. Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors. Clin Cancer Res 18(9):2625-31, 2012. e-Pub 2012. PMID: 22465830.
213. Wheler J, Tsimberidou AM, Hong D, Naing A, Falchook G, Piha-Paul S, Fu S, Moulder S, Stephen B, Wen S, Kurzrock R. Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience. Clin Cancer Res 18(10):2922-9, 2012. e-Pub 2012. PMID: 22452943.
214. Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, Tsimberidou AM, Fu S, Falchook GS, Hong DS, Garrido-Laguna I, Luthra R, Lee JJ, Lu KH, Kurzrock R. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol 30(8):777-82, 2012. e-Pub 2012. PMID: 22271473.
215. Garrido-Laguna I, Janku F, Vaklavas C, Falchook GS, Fu S, Hong DS, Naing A, Tsimberidou AM, Wen S, Kurzrock R. Validation of the Royal Marsden Hospital prognostic score in patients treated in the phase I clinical trials program at the MD Anderson Cancer Center. Cancer 118(5):1422-8, 2012. e-Pub 2012. PMID: 21823111.
216. Parsons HA, Tsimberidou AM, Pontikos M, Fu S, Hong D, Wen S, Baracos VE, Kurzrock R. Evaluation of the clinical relevance of body composition parameters in patients with cancer metastatic to the liver treated with hepatic arterial infusion chemotherapy. Nutr Cancer 64(2):206-17, 2012. e-Pub 2012. PMID: 22229660.
217. Garrido-Laguna I, Hong DS, Janku F, Nguyen LM, Falchook GS, Fu S, Wheler JJ, Luthra R, Naing A, Wang X, Kurzrock R. KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors. PLoS One 7(5):e38033, 2012. e-Pub 2012. PMID: 22675430.
218. Naing A, Stephen SK, Frenkel M, Chandhasin C, Hong DS, Lei X, Falchook G, Wheler JJ, Fu S, Kurzrock R. Prevalence of complementary medicine use in a phase 1 clinical trials program: The MD Anderson Cancer Center Experience. Cancer 117(22):5142-50, 2011. e-Pub 2011. PMID: 21538342.
219. Fu S, Hong DS, Naing A, Wheler J, Falchook G, Wen S, Howard A, Barber D, Nates J, Price K, Kurzrock R. Outcome analyses after the first admission to an intensive care unit in patients with advanced cancer referred to a phase I clinical trials program. J Clin Oncol 29(26):3547-52, 2011. e-Pub 2011. PMID: 21844494.
220. Fu S, Naing A, Moulder SL, Culotta KS, Madoff DC, Ng CS, Madden TL, Falchook GS, Hong DS, Kurzrock R. Phase I trial of hepatic arterial infusion of nanoparticle albumin-bound Paclitaxel: toxicity, pharmacokinetics, and activity. Mol Cancer Ther 10(7):1300-7, 2011. e-Pub 2011. PMID: 21571911.
221. Tsimberidou AM, Letourneau K, Fu S, Hong D, Naing A, Wheler J, Uehara C, McRae SE, Wen S, Kurzrock R. Phase I clinical trial of hepatic arterial infusion of paclitaxel in patients with advanced cancer and dominant liver involvement. Cancer Chemother Pharmacol 68(1):247-53, 2011. e-Pub 2011. PMID: 20941597.
222. Fu S, Hu W, Iyer R, Kavanagh JJ, Coleman RL, Levenback CF, Sood AK, Wolf JK, Gershenson DM, Markman M, Hennessy BT, Kurzrock R, Bast RC. Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Cancer 117(8):1661-9, 2011. e-Pub 2011. PMID: 21472713.
223. Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS, Naing A, Falchook GS, Moroney JW, Piha-Paul SA, Wheler JJ, Moulder SL, Fu S, Kurzrock R. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther 10(3):558-65, 2011. e-Pub 2011. PMID: 21216929.
224. Janku F, Lee JJ, Tsimberidou AM, Hong DS, Naing A, Falchook GS, Fu S, Luthra R, Garrido-Laguna I, Kurzrock R. PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS One 6(7):e22769, 2011. e-Pub 2011. PMID: 21829508.
225. El-Osta H, Hong D, Wheler J, Fu S, Naing A, Falchook G, Hicks M, Wen S, Tsimberidou AM, Kurzrock R. Outcomes of research biopsies in phase I clinical trials: the MD Anderson Cancer Center experience. Oncologist 16(9):1292-8, 2011. e-Pub 2011. PMID: 21859821.
226. Wang X, Fan J, Liu D, Fu S, Ingvarsson S, Chen H. Spreading of Alu methylation to the promoter of the MLH1 gene in gastrointestinal cancer. PLoS One 6(10):e25913, 2011. e-Pub 2011. PMID: 22022465.
227. Camacho LH, Garcia S, Panchal AM, Lim J, Hong DS, Ng C, Madoff DC, Fu S, Gayed I, Kurzrock R. Exploratory study of hepatic arterial infusion oxaliplatin with systemic 5-fluorouracil/bevacizumab in patients with refractory solid tumor and extensive liver metastases. Clin Colorectal Cancer 9(5):311-4, 2010. e-Pub 2010. PMID: 21208846.
228. Tsimberidou AM, Moulder S, Fu S, Wen S, Naing A, Bedikian AY, Daring S, Uehara C, Ng C, Wallace M, Camacho L, Kurzrock R. Phase I clinical trial of hepatic arterial infusion of cisplatin in combination with intravenous liposomal doxorubicin in patients with advanced cancer and dominant liver involvement. Cancer Chemother Pharmacol 66(6):1087-93, 2010. e-Pub 2010. PMID: 20204368.
229. Tsimberidou AM, Fu S, Ng C, Lim JA, Wen S, Hong D, Wheler J, Bedikian AY, Eng C, Wallace M, Camacho LH, Kurzrock R. A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver. Cancer 116(17):4086-94, 2010. e-Pub 2010. PMID: 20564148.
230. Garrido-Laguna I, Janku F, Falchook GS, Fu S, Hong DS, Naing A, Aaron J, Wang X, Kies M, Kurzrock R. Patients with advanced head and neck cancers have similar progression-free survival on phase I trials and their last FDA-approved treatment. Clin Cancer Res 16(15):4031-7, 2010. e-Pub 2010. PMID: 20525754.
231. Zheng H, Hu W, Deavers MT, Shen DY, Fu S, Li YF, Kavanagh JJ. Nuclear cyclin B1 is overexpressed in low-malignant-potential ovarian tumors but not in epithelial ovarian cancer. Am J Obstet Gynecol 201(4):367. e1-6, 2009. e-Pub 2009.
232. Cheng X, Maroney JW, Levenback CF, Fu S, Jaishuen A, Kvanagh JJ. What is the benefit of bevacizumab combined with chemotherapy in patients with recurrent ovarian, fallopian tube or primary peritoneal malignancies?. J Chemotherapy 21(5):556-72, 2009. e-Pub 2009.
233. Craft BS, Kurzrock R, Lei X, Herbst R, Lippman S, Fu S, Karp DD. The changing face of phase 1 cancer clinical trials: new challenges in study requirements. Cancer 115(8):1592-7, 2009. e-Pub 2009.
234. Li Y, Hu W, Shen DY, Kavanagh JJ, Fu S. Azacitidine enhances sensitivity of platinum-resistant ovarian cancer cells to carboplatin through induction of apoptosis. Am J Ob Gyn 200(2):177, 2008. e-Pub 2008. PMID: 19110234.
235. Tao X, Chon HS, Fu S, Kavanagh JJ, Hu W. Update on aurora kinase inhibitors in gynecological malignancies. Recent Pat Anticancer Drug Discov 3(3):162-77, 2008. e-Pub 2008. PMID: 18991785.
236. Zheng H, Hu W, Yu D, Shen DY, Fu S, Kavanagh JJ, Wei IC, Yang DJ. Diammine dicarboxylic acid platinum enhances cytotoxiciy in platinum-resistant ovarian cancer cells through induction of apoptosis and S-phase cell arrest. Pharm Res 25(10):2272-82, 2008. e-Pub 2008.
237. Li YF, Hu W, Fu SQ, Chon HS, Kavananagh JJ. Aromatase inhibitors in ovarian cancer: is there a role?. Int J Gynecol Cancer 18(4):600-14, 2008. e-Pub 2008. PMID: 17894799.
238. Zheng H, Kavanagh JJ, Hu W, Liao Q, Fu S. Hormonal therapy in ovarian cancer. Int J Gynecol Cancer 17(2):325-38, 2007. e-Pub 2007. PMID: 17362310.
239. Li YF, Fu S, Hu W, Liu JH, Finkel KW, Gershenson DM, Kavanagh JJ. Systemic anticancer therapy in gynecological cancer patients with renal dysfunction. Int J Gynecol Cancer 17(4):739-63, 2007. e-Pub 2007. PMID: 17309673.
240. Li Y, Finkel KW, Hu W, Fu S, Liu J, Coleman R, Kavanagh JJ. Pegylated liposomal doxorubicin treatment in recurrent gynec patients with renal dysfunction. Gynecologic Oncololgy 106(2):375-80, 2007. e-Pub 2007. PMID: 17512575.
241. Wang X, Fu S, Freedman RS, Kavanagh JJ. Venous thromboembolism syndrome in gynecological cancer. Int J Gynecol Cancer 16(Suppl 1):458-71, 2006. e-Pub 2006. PMID: 16515646.
242. Fu S, Hu W, Kavanagh JJ, Jr BR. Targeting aurora kinases in ovarian cancer. Expert Opin Ther Targets 10(1):77-85, 2006. e-Pub 2006.
243. Wang HY, Sun JM, Lu HF, Shi DR, Ou ZL, Ren YL, Fu S. Micrometastases detected by cytokeratin 19 expression in sentinel lymph nodes of patients with early-stage cervical cancer. Int J Gynecol Cancer 16(2):643-8, 2006. e-Pub 2006. PMID: 16681740.
244. Li YF, Hu W, Fu S, Kobayashi R, Kavanagh JJ. Proteomics in gynecologic malignancies: advances to date. AM J Cancer 5(5):299-317, 2006. e-Pub 2006.
245. Fu S, Abboud CN, Brennan JK, Ifthikharuddin JJ, Nichols D, Liesveld JL. Impact of mobilized blood progenitor cell quality determined by the CFU-GM/CD34+ ratio on rapid engraftment after blood stem cell transplantation. Blood Cells Mol Dis 28(3):315-21, 2002. e-Pub 2002. PMID: 12367578.
246. Yin L, Fu S, Wang X, Nanakorn T, Won J, Deisseroth A. Sensitization of prostate cancer cell lines to 5-fluorocytosine induced by adenoviral vector carrying a CD transcription unit. Chin Med J (Engl) 114(9):972-5, 2001. e-Pub 2001. PMID: 11780394.
247. Fu S, Liesveld J. Mobilization of hematopoietic stem cells. Blood Rev 14(1):2717-21, 2000. e-Pub 2000.
248. Yin L, Fu S, Zhao X, Garcia-Sanchez F, Deisseroth AB. Correlation of cell proliferation inhibition and apoptosis induction with expression of human beta 5 integrin on hematopoietic cells. Chin Med (Eng) 112(7):659-64, 1999. e-Pub 1999. PMID: 11601265.
249. Rahman Z, Kavanagh J, Champlin R, Giles R, Hanania E, Fu S, Zu Z, Mehra R, Holmes F, Kudelka A, Claxton D, Verschraegen C, Gajewski J, Andreeff M, Heimfeld S, Berenson R, Ellerson D, Calvert L, Mechetner E, Holzmayer T, Dayne A, Hamer J, Bachier C, Ostrove J, Deisseroth A, et al. Chemotherapy immediately following autologous stem-cell transplantation in patients with advanced breast cancer. Clin Cancer Res 4(11):2717-21, 1998. e-Pub 1998. PMID: 9829734.
250. Garcia-Sanchez F, Pizzorno G, Fu S, Nanakorn T, Krause DS, Liang J, Adams E, Leffert JJ, Yin LH, Cooperberg MR, Hanania E, Wang WL, Won JH, Peng XY, Cote R, Brown R, Burtness B, Giles R, Crystal R, Deisseroth AB. Cytosine deaminase adenoviral vector and 5-fluorocytosine selectively reduce breast cancer cells 1 million-fold when they contaminate hematopoietic cells: a potential purging method for autologous transplantation. Blood 92(2):672-82, 1998. e-Pub 1998. PMID: 9657770.
251. Deisseroth A, Guo D, Wang T, Fujii T, Fu S, Cote R, Savinov S, Liu F, Loewe R, Pizzorno G, Austin D, Crystal R, Chung I. Molecular therapy for cancer. Cancer J Sci Am 4(Suppl 1):S5-7, 1998. e-Pub 1998. PMID: 9619264.
252. Yin LH, Fu S, Nanakorn T, Garcia-Sanchez F, Chung I, Cote R, Pizzorno G, Hanania E, Heimfeld S, Crystal R, Deisseroth A. Results of retroviral and adenoviral approaches to cancer gene therapy. Stem Cells 16(Suppl 1):247-50, 1998. e-Pub 1998. PMID: 11012168.
253. Fu S, Deisseroth AB. Use of the cosmid adenoviral vector cloning system for the in vitro construction of recombinant adenoviral vectors. Hum Gene Ther 8(11):1321-30, 1997. e-Pub 1997. PMID: 9295127.
254. Fu S, Garcia Sanchez F, Chung I, Deisseroth A. Adenoviral vectors and hematopoietic cells. Blood 89(4):1460-2, 1997. e-Pub 1997. PMID: 9028971.
255. Fujii T, Fu S, Yin LH, Nanakorn T, Sanchez FG, Cooperberg M, Guo D, Wang T, D L, Pizzorno G, Deisseroth A. Multidrug resistance and prodrug activation for cancer gene therapy of breast cancer. Breast Cancer 4(4):210-12, 1997. e-Pub 1997.
256. Hanania EG, Giles RE, Kavanagh J, Fu S, Ellerson D, Zu Z, Wang T, Su Y, Kudelka A, Rahman Z, Holmes F, Hortobagyi G, Claxton D, Bachier C, Thall P, Cheng S, Hester J, Ostrove JM, Bird RE, Chang A, Korbling M, Seong D, Cote R, Holzmayer T, Deisseroth AB, et al. Results of MDR-1 vector modification trial indicate that granulocyte/macrophage colony-forming unit cells do not contribute to posttransplant hematopoietic recovery following intensive systemic therapy. Proc Natl Acad Sci U S A 93(26):15346-51, 1996. e-Pub 1996. PMID: 8986814.
257. Hegewisch-Becker S, Hanania EG, Fu S, Korbling M, Deisseroth AB, Andreeff M. Transduction of MDR1 into human and mouse haemopoietic progenitor cells: use of rhodamine (Rh123) to determine transduction frequency and in vivo selection. Br J Haematol 90(4):876-83, 1995. e-Pub 1995. PMID: 7669666.
258. Hanania EG, Fu S, Roninson I, Su Z, Deisseroth AB. Resistance to taxol chemotherapy produced in mouse marrow cells by safety-modified retroviruses containing a human MDR-1 transcription unit. Gene Ther 2(4):279-84, 1995. e-Pub 1995. PMID: 7552988.
259. Fu S, Consoli U, Hanania EG, Zu Z, Claxton DF, Andreeff M, Deisseroth AB. PML/RARalpha, a fusion protein in acute promyelocytic leukemia, prevents growth factor withdrawal-induced apoptosis in TF-1 cells. Clin Cancer Res 1(6):583-90, 1995. e-Pub 1995. PMID: 9816019.
260. Hanania EG, Fu S, Zu ZF, Hegewisch-Becker S, Korbling M, Hester J, Durett, Andreeff M, Mechetner E, Holzmayer T, Roninson IB, Giles RE, Berenson R, Heimfeld, Deisseroth AB. Chemotherapy resistance to taxol in clonogenic progenitor cells following transduction of CD34 selected marrow and peripheral blood cells with a retrovirus that contains the MDR-1 chemotherapy resistance gene. Gene Therapy 2(4):285-294, 1995. e-Pub 1995. PMID: 7552989.
261. Hanania EG, Fu S, Zu Z, Hegewisch-Becker S, Korbling M, Hester J, Durett A, Andreeff M, Mechetner E, Holzmayer T. Chemotherapy resistance to taxol in clonogenic progenitor cells following transduction of CD34 selected marrow and peripheral blood cells with a retrovirus that contains the MDR-1 chemotherapy resistance gene. Gene Ther 2(4):285-94, 1995. e-Pub 1995. PMID: 7552989.
262. Hu G, Liu W, Hanania EG, Fu S, Wang T, Deisseroth AB. Suppression of tumorigenesis by transcription units expressing the antisense E6 and E7 messenger RNA (mRNA) for the transforming proteins of the human papilloma virus and the sense mRNA for the retinoblastoma gene in cervical carcinoma cells. Cancer Gene Ther 2(1):19-32, 1995. e-Pub 1995. PMID: 7621252.
263. Giles RE, Hanania EG, Fu S, Deisseroth. Genetic therapy using bone marrow transplantation. Cancer Treat Res 76:271-80, 1995. e-Pub 1995. PMID: 7577339.
264. Deisseroth AB, Zu Z, Claxton D, Hanania EG, Fu S, Ellerson D, Goldberg L, Thomas M, Janicek K, Anderson WF, et al. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 83(10):3068-76, 1994. e-Pub 1994. PMID: 7514051.
265. Deisseroth AB, Kantarjian H, Talpaz M, Champlin R, Reading C, Hanania EG, Fu S, Randhawa GS, Cha Y, Fang X. Molecular approaches to the diagnosis and treatment of cancer. Stem Cells 11(Suppl 3):129-30, 1993. e-Pub 1993. PMID: 7905320.
266. Deisseroth AB, Fu S, Hanania E, Randhawa G, Claxton D, Reading C, Champlin R, Andreeff M, Logothetis C, Hong WK, Holmes F, Hortobagyi G, Benedict W. Evolution of gene therapy: the M. D. Anderson experience. Contemporary Oncology 3:10-25, 1993. e-Pub 1993.
267. Deisseroth AB, Hanania EG, Fu S, Claxton D, Andreeff M, Champlin R, Kavanagh J, Hortobagyi G, Holmes F, Reading C. Genetic therapy of human neoplastic disease. J Hematother 2(3):373-5, 1993. e-Pub 1993. PMID: 7921999.
268. Fu S, Ji WQ, Cheng L, Song HY. Construction of SRS-MuLV cDNA library. Acta Academiae Medicinae Shanghai 12(5):236-239, 1990. e-Pub 1990.
269. Fu S, Song HY, Cheng L. Polymerase chain reaction (PCR) and its application. Prog Biophys Biochem 9(6):434-437, 1990. e-Pub 1990.
270. Fu S, Ji WQ. Progress in regulation of eukaryotic gene expression. Prog Biophys Biochem 9(2):129-132, 1990. e-Pub 1990.
271. Fu S, Yan J, Song HY. Detection of single-copy gene with polymerase chain reaction (PCR). Acta Academiae Medicinae Shanghai 12(7):362-365, 1990. e-Pub 1990.
272. Fu S, Ji WQ. The role of small nuclear ribonucleoprotein particles in pre-mRNA splicing. Foreign Med: Rev Mol Biol 10(1):1-5, 1988. e-Pub 1988.
273. Fu S, Cheng L. Structure and biological properties of retroviruse. Foreign Med: Rev Microbiol 11(2):49-52, 1988. e-Pub 1988.
274. Fu S, Cheng L. Platelet-derived growth factors. Foreign Med: Rev Physiol Pathol Clin 7(3):139-141, 1987. e-Pub 1987.
275. Fu S, Cheng L. Structure and function of human immunodeficiency virus. Foreign Med: Rev Mol Biol 9(5):218-221, 1987. e-Pub 1987.

Invited Articles

1. Fu S, Kavanagh J. First-line Chemotherapy Trial in Advanced Endometrial Carcinoma. Curr Oncol Rep 6(6):455, 2004. e-Pub 2004.

Review Articles

1. Nelson, BE, Naing, A, Fu, S, Sheth, RA, Murthy, R, Piha-Paul, SA. Potentiating intratumoral therapy with immune checkpoint inhibitors. Immuno-Oncology and Technology 25, 2025. e-Pub 2025. PMID: 39981134.
2. Hein KZ, Stephen B, Fu S. Therapeutic Role of Synthetic Lethality in ARID1A-Deficient Malignancies. J Immunother Precis Oncol 7(1):41-52, 2024. e-Pub 2024. PMID: 38327752.
3. Alhalabi O, Groisberg R, Zinner R, Hahn AW, Naing A, Zhang S, Tsimberidou AM, Rodon J, Fu S, Yap TA, Hong DS, Sun M, Jiang Y, Pant S, Shah AY, Zurita A, Tannir NM, Vikram R, Roszik J, Meric-Bernstam F, Subbiah V. Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies. NPJ Precis Oncol 7(1):37, 2023. e-Pub 2023. PMID: 37072571.
4. Yao S, Meric-Bernstam F, Hong D, Janku F, Naing A, Piha-Paul SA, Tsimberidou AM, Karp D, Subbiah V, Yap TA, Ahnert JR, Pant S, Dumbrava EEI, Wathoo C, Campbell E, Yu L, Yamamura Y, Fu S. Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences. Sci Rep 12(1):8701, 2022. e-Pub 2022. PMID: 35610322.
5. Hein KZ, Yao S, Fu S. Wilms' Tumor 1 (WT1): The Vaccine for Cancer. J Immunother Precis Oncol 3(4):165-171, 2020. e-Pub 2020. PMID: 35665371.
6. Fu S, Kurzrock R. Development of curcumin as an epigenetic agent. Cancer 116(20):4670-6, 2010. e-Pub 2010. PMID: 20597137.
7. Fu S, Kavanagh JJ, Hu W, Bast RC, Jr. Clinical application of oxaliplatin in epithelial ovarian cancer. Int J Gynecol Cancer 16(5):1717-32, 2006. e-Pub 2006. PMID: 17009963.
8. Wang X, Fu S, Freedman RS, Liu J, Kavanagh JJ. Immunobiology of gestational trophoblastic diseases. Int J Gynecol Cancer 16:1500-15, 2006. e-Pub 2006. PMID: 16884358.

Other Articles

1. Thein KZ, Karp DD, Tsimberidou A, Gong J, Sulovic S, Shah J, Milton DR, Hong DS, Janku F, McQuinn L, Stephen BA, Colen R, Carter BW, Yap TA, Piha-Paul SA, Fu S, Meric-Bernstam F, Naing A Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single-center, multi-arm phase Ib study. Invest New Drugs 43(2):446-447, 2025. PMID: 39976873.
2. Fu S Gene Transfer by Viral Vectors,. Ph. D. Dissertation, 1996.

Abstracts

1. Li J, Fu S, Spira A, Lu S, Liu T, Sommerhalder D, Yuan Y, Lou H, Shi J, Yu Y, Li W, Xu T, Song B, Dong C, Ma S, Li J, Zhong B, Zhang T, Shen L. Updated results of the phase 1/2 study of TSN1611, a highly selective KRAS G12D inhibitor, in patients with advanced solid tumors. 2026 ASCO Gastrointestinal Cancers Symposium 44(Suppl 2), 2026. e-Pub 2026.
2. Li J, Fu S, Spira A, Lu S, Liu T, Sommerhalder D, Yuan Y, Lou H, Shi J, Yu Y, Li W, Xu T, Song B, Dong C, Ma S, Li J, Zhong B, Zhang T, Shen L. Updated results of the phase 1/2 study of TSN1611, a highly selective KRAS G12D inhibitor, in patients with advanced solid tumors. 2026 ASCO Gastrointestinal Cancers Symposium 44(suppl 2), 2026. e-Pub 2026.
3. Wu T, Teymur A, Derbala MH, Stephen B, Castillo L, Yang Y, Gurses SA, Tan HN, Dumbrava EE, Tsimberidou AM, Champiat S, Hajjar J, Tang T-Y, Yap TA, Rodon Ahnert J, Piha-Paul SA, Fu S, Hong DS, Meric-Bernstam F, Naing A. Immune Complex Profiling Identifies Biomarkers of Response to Immune Checkpoint Inhibitors Across Cancers. ESMO Immuno-Oncology Congress 28(Suppl), 2025. e-Pub 2025.
4. Fu S, Shen L, Lu S, Sommerhalder D, Liu T, Spira A, Li J, Yu Y, Li W, Li J, Song B, Dong C, Lai L, Ma S, Shang E, Zhong B, Zhang T. The first-in-human phase 1/2 study of TSN1611, a highly selective KRAS G12D inhibitor, in patients with advanced solid tumors. 2025 ASCO Annual Meeting 43(16_Suppl), 2025. e-Pub 2025.
5. Spira AI, Frankel SR, Fu S, Kazmi SM, Naqash AR, Zhu X, Tripathi A, Hsu A, Ahn J, Orr DW, Mumm JB. Phase 1 study of DK210 (EGFR), a tumor-targeted IL2 x IL10 dual immunocytokine, in advanced cancer patients: Dose escalation, immune activation, and safety results. 2025 ASCO Annual Meeting 43(16_Suppl), 2025. e-Pub 2025.
6. Venturini J, Baysal MA, Chakraborty A, Yap TA, Fu S, Hong DS, Piha-Paul SA, Naing A, Rodon Ahnert J, Dumbrava EE, Beck J, Andersen C, Kahle M, Vining DJ, Meric-Bernstam F, Tsimberidou AM. Clinical outcomes of patients with or without DNA repair pathway alterations by treatment type: The MD Anderson Cancer Center IMPACT 2 study. 2025 ASCO Annual Meeting 43(16_Suppl), 2025. e-Pub 2025.
7. Srour SA, Tannier NM, Jazaeri AA, Campbell MT, Nieto Y, Haymaker CL, Yuan Y, Salih I, Yang Y, Doppler V, Garibal J, Escande M, Yang QM, Kushner J, Koo J, Gurses SA, Hong DS, Fu S, Meric-Bernstam F, Naing A. Safety and efficacy of HLA-G–targeted CAR T cells (IVS-3001) in patients with advanced HLA-G–positive solid tumors: Clinical trial in progress. 2025 ASCO Annual Meeting 43(16_Suppl), 2025. e-Pub 2025.
8. Su F, Uzunparmak B, Johnson A, Shaw KR, Fowler NH, Kontselidze L, Bagaev A, Butusova A, Dumbrava EE, Rodon Ahnert J, Fu S, Hong DS, Yap TA, Naing A, Piha-Paul SA, Ferrarotto R, Iorgulescu B, Kulkarni S, Patel K, Meric-Bernstam F. Clinical utility of comprehensive transcriptome testing in advanced solid tumors. 2025 ASCO Annual Meeting 43(16_Suppl), 2025. e-Pub 2025.
9. Reddy RA, Naing A, Lopez-Berestein G, Rodriguez-Aguayo C, Momin HA, Madhyannapu A, Yuan Y, Pasyar S, Karp DD, Pant S, Piha-Paul SA, Fu S, Tsimberidou AM, Coleman RL, Sood AK, Westin SN. EphA2 siRNA in DOPC nanoliposomes (EPHARNA): A phase I clinical trial in patients with solid tumors. 2025 ASCO Annual Meeting 43(16_Suppl), 2025. e-Pub 2025.
10. Song MM, Tolcher AW, Gutierrez ME, Zsiros E, Fu S, Liu JF, Morgensztern D, Kordahi S, Nietubicz C, Barbu EA, Morawski A, Kahan S, Kothari P, Flies D, Panneer Selvam S, Slocum S, Ruiz-Soto R, Langermann S, Guha U, Mahadevan D. A phase 1 dose escalation and dose expansion study for LNCB74, a B7-H4 targeted antibody drug conjugate, as monotherapy in participants with advanced solid tumors. 2025 ASCO Annual Meeting 43(16_Suppl), 2025. e-Pub 2025.
11. Ochsenreither S, Anguera G, Dieter S, Trikalinos N, Fu S, Castelo Fernandez B, Ferrandiz AC, Kim SY, Medina Rodriguez L, Graue Berg KC, Bin Hassan HI, Rosholm A, Fredricksen AB, Investigators N. Induction of neoantigen-specific immune responses by VB10.NEO in combination with atezolizumab in heavily pretreated patients with advanced solid tumors: Final analysis of the phase 1b VB N-02 trial. 2025 ASCO Annual Meeting 43(16_Suppl), 2025. e-Pub 2025.
12. Uk Lim J, Kang L, Le H, Tang T-Y, Champiat S, Dumbrava EE, Le X, Naing A, Piha-Paul A, Rodon Ahnert J, Tsimberidou AM, Yap TA, Fu S, Meric-Bernstam F, Hong DS. Therapeutic responses in 555 advanced NSCLC patients enrolled in phase I studies at MD Anderson Cancer Center. 2025 ASCO Annual Meeting 43(16_Suppl), 2025. e-Pub 2025.
13. Fox DA, Bhamidipati D, Lin HY, Hinkle LE, Pham CT, Rodon Ahnert J, Champiat S, Dumbrava EE, Fu S, Kang L, Le H, Meric-Bernstam F, Naing A, Piha-Paul SA, Pohlmann PR, Tang T-Y, Tsimberidou AM, Yap TA, Huey RW, Hong DS. Outcomes of young-onset colorectal cancer vs late-onset colorectal cancer patients on phase 1 matched and non-matched therapies. 2025 ASCO Annual Meeting 43(16_Suppl), 2025. e-Pub 2025.
14. Braganca Xavier C, Lei K, Le Hung Kahle M, Tsimberidou AM, Naing A, Dumbrava EE, Rodon Ahnert J, Pohlmann PR, Piha-Paul SA, Fu S, Champiat S, Yap TA, Tang T-Y, Kopetz S, Meric-Bernstam F, Hong DS. Colorectal cancer with gene fusions: Navigating the genomic landscape and treatment selection in a phase I unit. 2025 ASCO Annual Meeting 43(16_Suppl), 2025. e-Pub 2025.
15. Srour SA, Tannir N, Jazaeri A, Campbell MT, Nieto Y, Haymaker C, Yuan Y, Salih I, Yang Y, Doppler V, Garibal J, Escande M, Yang M, Kushner J, Koo J, Gurses SA, Hong DS, Fu S, Meric-Bernstam F, Naing A. Safety and efficacy of HLA-G-targeted CAR T cells (IVS-3001) in patients with advanced HLA-G-positive solid tumors: Clinical trial in progress. AACR Annual Meeting 2025 85(8_Suppl_2), 2025. e-Pub 2025.
16. Torrado C, Tomczak K, Dumbrava EE, Sun B, Ngoi N, Arrechedera C, Para ER, Rodon Anhert J, Piha-Paul SA, Tsimberidou AM, Fu S, Naing A, Pohlmann PR, Hong DS, Meric-Bernstam F, Msaouel P, Haymaker CL, Yap TA. Clinical and translational study of the TGF-β monoclonal antibody SAR439459 in combination with the PD-1 inhibitor cemiplimab for patients (pts) with advanced solid tumors: Results from the phase 1b TACTIC trial. AACR Annual Meeting 2025 85(8_Suppl_2), 2025. e-Pub 2025.
17. George GC, Lee H, Piha-Paul SA, Dumbrava E, Tsimberidou A, Fu S, Appleton G, Noor L, Rodon J, Yap TA, Meric-Bernstam F, Hong DS. Food choices of patients with advanced cancer at start of early-phase combination trials with immune checkpoint blockade. AACR Annual Meeting 2025 85(8_Suppl_1), 2025. e-Pub 2025.
18. Braganca Xavier C, Andersen C, Lim JT, Slade JH, Bean SA, Kang L, Le H, Tsimberidou A, Naing A, Hong D, Dumbrava E, Rodon J, Pohlmann P, Piha-Paul S, Champiat S, Yap TA, Tang T-Y, Meric-Bernstam F, Fu S. Modulating treatment outcomes of patients with solid tumors in immunotherapy trials: a drug interaction analysis from a phase I unit. AACR Annual Meeting 2025 85(8_Suppl_1), 2025. e-Pub 2025.
19. Ngoi NYL, Rodon J, Dumbrava EE, Garmezy B, Hong DS, Piha-Paul S, Tsimberidou AM, Fu S, Naing A, Pohlmann PR, Tang T-Y, Clemente H, Rhudy J, Valladolid C, Salguero C, Velez NA, Tran HT, Meric-Bernstam F, Yap TAA. TalaCom: Phase Ib investigator-initiated trial combining talazoparib and axitinib in patients with DNA damage response mutated cancers or BRCA1/2 wildtype ovarian cancer incorporating prospective intrapatient dose titration. ESMO Targeted Anticancer Therapies (TAT) Congress 2025 10(Suppl 2), 2025. e-Pub 2025.
20. Stephen B, Kwiatkowski E, Anderson MR, Derbala MH, Salih I, Castillo L, Yang Y, Gurses SA, Lim JT, Klekers AR, Le H, Kang L, Xu M, Ahmed J, Tan HN, Champiat S, TANG T-Y, Dumbrava EE, Fu S, Piha-Paul SA, Rodon Ahnert J, Tsimberidou AM, Yap T, Yuan Y, Hong DS, Meric-Bernstam F, Bhosale P, Naing A. Impact of liver metastases and systemic biomarkers on immunotherapy response and survival outcomes in patients with solid tumors. AACR IO 2025 13(2_Suppl), 2025. e-Pub 2025.
21. Fu S, McKean M, Falchook G, Barve M, Chee C-E, Lemech C, Tan T, Meniawy T, Hernandez-Guerrero T, Wang W, Baakili A, Marina N, Abbadessa G, Gastine S, Wang R, Calvo E. Utilizing pharmacokinetic (PK) and pharmacodynamic (PD) biomarkers to support recommended Phase 2 dose (RP2D) selection for Phase 1 study of SAR444245 (SAR’245) in patients with advanced solid tumors. SITC 2044 12(Suppl 3), 2024. e-Pub 2024.
22. Stephen B, Anderson M, Kwiatkowski E, Derbala M, Yang Y, Lim J, Klekers A, Dumbrava E, Fu S, Piha-Paul S, Rodon J, Tsimberidou A, Yap T, Yuan Y, Hong D, Meric-Bernstam F, Bhosale P, Naing A. Impact of liver metastasis on immunotherapy in patients with solid tumors. SITC 2024 12(Suppl 3), 2024. e-Pub 2024.
23. Naqash AR, Ayanambakkam A, Spira A, Kazmi S, Orr D, Zhu X, Fu S, Tripathi A, Marabelle A, Langan D, Hsu A, McCright J, Dudics S, Hamdan F, George B, Kuri P, Long A, Kientop D, Frankel S, Mumm J. Immune Biomarkers from Phase 1 First-in-Human Trial Treating Advanced Cancer Patients with DK210(EGFR) compared to ex vivo DiakineTM Response Assay. SITC 2024 12(Suppl 3), 2024. e-Pub 2024.
24. Kim DW, Uboha N, Alese O, Saenger Y, Zheng L, Fu S, Gong J, Chaves J, Chen C, Powderly J, Zhaohui J, Bekaii-Saab T, Alistar A, Gabrail N, Agensky L, Goel A, Margossian S, Levisetti M, Quayle S, Selfridge JE. A phase 1 trial of CUE-102, a novel WT1-pHLA-IL2-Fc T cell engager in HLA-A*0201 positive patients with WT1-positive recurrent/metastatic cancers. SITC 2024 12(Suppl 3), 2024. e-Pub 2024.
25. Coleman N, Ngoi NYL, Nguyen D, Nelson B, Dumbrava E, Fu S, Hong DS, Karp D, Naing A, Piha-Paul SA, Rodon J, Tsimberidou A, Lim B, Pohlman P, Meric-Bernstam F, Litton JK, Arun B, Yap TA. Poly(ADP-Ribose) Polymerase (PARP) inhibition in metastatic breast cancer: comparison of therapeutic outcomes between patients with BRCA1/2 mutations and other alterations. 36th EORTC-NCI-AACR 211(Suppl 1), 2024. e-Pub 2024.
26. Tsimberidou AM, Fu S, Hong DS, Piha-Paul SA, Naing A, Rodon J, Yap TA, Karp DD, Dumbrava EE, Heymach J, Ajani JA, Cartwright C, Beck J, Andersen CR, Kahle M, Vining DJ, Ross JS, Chao CY, Berry DA, Meric-Bernstam F. Final Results of IMPACT 2, a Randomized Study Evaluating Molecular Profiling and Targeted Agents in Metastatic Cancer at MD Anderson Cancer Center. ESMO Congress 2024 35(Suppl 2), 2024. e-Pub 2024.
27. Christenson ES, Kazmi S, Mahadevan D, Sohal D, Manda S, Martz A, Kordahi S, Zika M, Barbu EA, Morawski A, Flies D, Langermann SA, Chisamore M, Fu S, Wadlow R, Guha U, Myint H, Le D. Results of the phase Ib study of NC410 combined with pembrolizumab in MSS/MSI-L colorectal cancer patients. ESMO Congress 2024 35(Suppl 2), 2024. e-Pub 2024.
28. Fu S, Tsimberidou AM, Dumbrava EE, Yuan Y, McLeod S, Karp D, Rodon J, Yu H, Peng J, Daniel LM, Piha-Paul SA, Naing A, Meric-Bernstam F. Phase I Study of Pamiparib and Cabozantinib in Patients with Metastatic Solid Tumors Harboring Homologous Recombination Deficiency (HRD). ESMO Congress 2024 35(Suppl 2), 2024. e-Pub 2024.
29. Zsiros E, Christenson ES, Sohal D, Manda S, Fu S, Martz A, Zika M, Kordahi S, Kothari P, Kahan S, Barbu EA, Morawski A, Flies D, Langermann SA, Chisamore M, Guha U, Myint H, Mahadevan D. Results of the phase Ib study of NC410 combined with pembrolizumab in ovarian cancer patients. ESMO Congress 2024 35(Suppl 2), 2024. e-Pub 2024.
30. Zhao H, Ma Y, Meng X, Wu L, Fan Y, Aheng Y, Liu Z, Ji Y, Lv D, Luo S, Sommerhalder D, Fu S, Huang Y, Yang Y, Fang W, Zhao Y, Wang Y, Chin S, Xue T, Zhang L. YL201, a novel B7H3-targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors: Results from a first-in-human phase 1 study. ESMO Congress 2024 35(Suppl 2), 2024. e-Pub 2024.
31. George G, Piha-Paul S, Dumbrava E, Subbiah V, Fu S, Tsimberidou A, Pant S, Appleton G, Noor L, Yap T, Rodon Ahnert J, Meric-Bernstam F, Cleeland C, Mendoza T, Hong D. Patient-reported symptom interference with activity- and mood-related functioning prior to start of an early-phase oncology combination trial including immune checkpoint blockade. 2024 ASCO Annual Meeting 42(suppl 16), 2024. e-Pub 2024.
32. Tsimberidou A, Fu S, Hong D, Piha-Paul S, Naing A, Rodon Ahnert J, Yap T, Karp D, Dumbrava E, Heymach J, Ajani J, Cartwright C, Beck J, Andersen C, Kahle M, Vining D, Ross J, Chao C, Berry D, Meric-Bernstam F. Results of IMPACT 2, a randomized study evaluating molecular profiling and targeted agents in metastatic cancer at MD Anderson Cancer Center. 2024 ASCO Annual Meeting 42(suppl 16), 2024. e-Pub 2024.
33. Torrado Martin C, Rai K, Moawad M, Dumbrava E, Fu S, Hong D, Karp D, Meric-Bernstam F, Naing A, Pohlmann P, Rodon Ahnert J, Tsimberidou A, Yap T, Said R, Pelosof L, Piha-Paul S. A phase 1 study of the BET inhibitor ZEN003694 in combination with the MEK1/2 inhibitor binimetinib in solid tumors with RAS pathway alterations and triple-negative breast cancer (NCI number 10449). 2024 ASCO Annual Meeting 42(suppl 16), 2024. e-Pub 2024.
34. Christenson E, Mahadevan D, Kazmi S, Manda S, Sohal D, Hutson T, Fu S, Martz A, Kordahi S, Barbu EA, Flies D, Langermann S, Chisamore M, Gutierrez M, Matrana M, Spira A, Wadlow R, Guha U, Myint H, Le D. A phase 1b study of NC410 in combination with pembrolizumab in immune checkpoint inhibitor (ICI) naïve, and refractory microsatellite stable (MSS)/microsatellite instability-low (MSI-L) colorectal cancer (CRC) and ovarian cancer. 2024 ASCO Annual Meeting 42(suppl 16), 2024. e-Pub 2024.
35. Fu S, Piha-Paul S, Singh S, Peng J, Keenan B, Mei J, Lynch K, Li L, Song M, Zhang X. A first-in-human phase I study of ATG-031, anti-CD24 antibody, in patients with advanced solid tumors or B-cell non-Hodgkin lymphomas (PERFORM). 2024 ASCO Annual Conference 42(suppl 16), 2024. e-Pub 2024.
36. Torrado Martin C, Brink A, Gouda M, Kang L, Osburn J, Patterson C, Charles S, Poullard A, Urschel G, Dumbrava E, Karp D, Naing A, Piha-Paul S, Pohlmann P, Rodon Ahnert J, Tsimberidou A, Yap T, Hong D, Meric-Bernstam F, Fu S. Telehealth consultations and recruitment trends in clinical trials: A retrospective analysis at investigational cancer therapeutics, a dedicated phase I department at The University of Texas MD Anderson Cancer Center. 2024 ASCO Annual Meeting 42(suppl 16), 2024. e-Pub 2024.
37. Gouda M, Shunyakova J, Naing A, Dumbrava E, Hong D, Yuan Y, Yang P, Myers A, Liang Y, Ping J, Karp D, Tsimberidou A, Rodon Ahnert J, Yap T, Piha-Paul S, Meric-Bernstam F, Fu S. A phase I study of TAK-659 and paclitaxel in patients with taxane-refractory advanced solid tumors. 2024 ASCO Annual Meeting 42(suppl 16), 2024. e-Pub 2024.
38. Uboha N, Saenger Y, Alese O, Kim D, Zheng L, Chaves J, Fu S, Gong J, Jin Z, Powderly J, Gabrail N, Bekaii-Saab T, Alistar A, Chen C, Agensky L, Goel A, Margossian S, Quayle S, Levisetti M, Selfridge E. A phase 1, open-label, dose escalation, and expansion study of CUE-102, a novel WT1-pHLA-IL2-Fc fusion protein, in patients with HLA-A*0201-positive disease and WT1-positive recurrent/metastatic cancers. 2024 ASCO Annual Meeting 42(suppl 16), 2024. e-Pub 2024.
39. Gouda M, Lin H, Kang L, Le H, Dumbrava E, Fu S, Karp D, Tsimberidou A, Naing A, Piha-Paul S, Pohlmann P, Rodon Ahnert J, Yap T, Meric-Bernstam F, Hong D. Response to RAF/MEK/ERK inhibitors in patients with RAS altered and wild-type tumors. 2024 ASCO Annual Meeting 42(suppl 16), 2024. e-Pub 2024.
40. Daud A, Velcheti V, Bever K, Chow W, Albany C, Hauke R, Tsai K, Chisamore M, Wang J, Chan CH, Fu S. Efficacy, safety, and PK/PD of LVGN6051, 4-1BB agonistic antibody, with pembrolizumab in a phase Ib dose expansion in resistant NSCLC, melanoma, and GI malignancy. 2024 ASCO Annual Meeting 42(suppl 16), 2024. e-Pub 2024.
41. Spira A, Fu S, Naqash AR, Ayanambakkam A, Kazmi S, Tripathi A, Marabelle A, Long A, Kientop D, Frankel S, Mumm J, Orr D. Safety and activity of Diakine DK210 (EGFR), a next generation tumor-targeted IL2 x IL10 dual immunocytokine, in patients with advanced cancer: Initial results of the phase 1 first-in-human trial. 2024 ASCO Annual Meeting 42(suppl 16), 2024. e-Pub 2024.
42. Yap T, Dumbrava E, Rodon Ahnert J, Tsimberidou A, Hong D, Piha-Paul S, Karp D, Fu S, Naing A, Pohlmann P, Rhudy J, Berenji-Jalaei S, Cole A, Valladolid C, Dufner D, Bockorny B, Bullock A, Fein D, Buchbinder E, Choudhury A, Haddox C, Lee E, Wulf G, Ivy P, Said R, Shapiro G, Meric-Bernstam F. NCI10217: Phase Ib biomarker-driven tumor-agnostic combination (Combo) trial of copanlisib (Copa) and olaparib (Ola) in molecularly-selected patients (pts) with advanced cancers with PIK3CA hotspot, PTEN and DNA damage response (DDR) mutations. AACR Annual Meeting 2024 84(7_Suppl), 2024. e-Pub 2024.
43. Fu S, Sanborn RE, Cai M, Zhang L, Xu Y, Lin K. Preclinical antitumor activity and first-in-human phase I study of NB004/GDC-0570, a novel pan-PIM kinase inhibitor, in patients with advanced solid tumors. AACR Annual Meeting 2024 84(7_Suppl), 2024. e-Pub 2024.
44. Uzunparmak B, Su F, Johnson AM, Nomie K, Fowler N, Kontselidze L, Bagaev A, Butusova A, Dumbrava EE, Rodon-Ahnert J, Fu S, Hong DS, Yap TA, Naing A, Piha-Paul SA, Karp DD, Pohlmann PR, Tsimberidou AM, Patel KP, Meric-Bernstam F. Comprehensive genomic and transcriptomic analysis to guide therapy for patients with metastatic solid tumors. AACR Annual Meeting 2024 84(7_Suppl), 2024. e-Pub 2024.
45. Bhamidipati D, Haro-Silerio J, Dumbrava E, Fu S, Hong D, Karp D, Naing A, Pant S, Piha-Paul S, Rodon Ahnert J, Tsimberidou A, Johnson A, Lee M, Raghav K, Morris V, Overman M, Kopetz S, Meric-Bernstam F, Yap T, Dasari A. Clinical characterization and therapeutic outcomes of patients (pts) with colorectal cancer (CRC) harboring somatic BRCA1/2 mutations. ASCO Gastrointestinal Cancers Symposium 42(suppl 3), 2024. e-Pub 2024.
46. George GC, Piha-Paul SA, Fu S, Dumbrava E, Subbiah V, Tsimberidou A, Blumenschein G, Pant S, Appleton G, Noor L, Rodon Ahnert J, Yap T, Meric-Bernstam F, Cleeland C, Mendoza T, Hong DS. Patient-reported baseline symptomatic adverse events in early-phase trials of combination treatments with immune checkpoint blockade, and their association with concurrent global health status, health utilities and clinical factors. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 22(12_Suppl), 2023. e-Pub 2023.
47. Geurts M, Gramatzki D, Merler S, Duca M, Girardi F, Sener U, Roberti D, Saturno G, Crivori P, Montagnoli A, Mahnke L, Fu S, Gaviani P, Jaeckle K, Zhang J, Shi Y, Guarneri V, Weller M, Kizilbash SH, van den Bent MJ, Milella M, Damian S. Initial Results from 2 Phase I Studies of NMS 03305293, a Selective PARP 1 Inhibitor. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 22(12_Suppl), 2023. e-Pub 2023.
48. Lin S, Lin S, Cohen E, Cohen E, Li Z, Li Z, Reuben J, Reuben J, Gao H, Gao H, Sun H, Sun H, Lu J, Lu J, Lloyd K, Lloyd K, Tonra J, Tonra J, Huang L, Huang L, Fu S, Fu S, Subbiah V, Subbiah V. Immune activation with plinabulin enhances anti-tumor response combining radiation with immune checkpoint blockade. SITC Annual Meeting 2023 11(Suppl 1), 2023. e-Pub 2023.
49. Selfridge JE, Uboha N, Saenger Y, Chaves J, Zheng L, Powderly J, Kim DW, Alese O, Fu S, Gong j, Gabrail N, Zhaohui J, Bekaii-Saab T, Alistar A, Agensky L, Goel A, Margossian S, Quayle S, Levisetti M. A phase 1 trial of CUE-102, a novel WT1-pHLA-IL2-Fc fusion protein in HLA-A*0201 positive patients with WT1-positive recurrent/metastatic cancers. SITC Annual Meeting 2023 11(Suppl 1), 2023. e-Pub 2023.
50. Papadopoulos K, Laurie S, Spira A, Fu S, Hamilton E, Ma B, Wang J, Sharma M, Chu Q, Spreafico. TWT-101: A first-in-clinic study of CFI-402411, a hematopoietic progenitor kinase-1 (HPK1) inhibitor, as single agent or combined with pembrolizumab in subjects with advanced solid malignancies. SITC Annual Meeting 2023 11(Suppl 1), 2023. e-Pub 2023.
51. Ho A, Pearson A, Fu S, Posner M, Adkins D, Nabell L, Niu J, Richardson D, Leidner R, Chung K, Laux D, Nieva J, Wong S, Rojas K, Rosenberg A, Phan M, Kaufmann T, Plescia C, Qing X, Iacobucci C, Tchakov I, Katchar K, Orlinger K, Schlienger K. Characterization of tumor specific CD8+ T cell responses in patients with recurrent/metastatic HPV16 positive head and neck cancer receiving HB-200 monotherapy as second or later line treatment in a Phase 1 study. SITC Annual Meeting 2023 11(Suppl 1), 2023. e-Pub 2023.
52. Yap TA, Piha-Paul SA, Karp D, Dumbrava EE, Hong DS, Fu S, Subbiah V, Tsimberidou AM, Rodon J, Rhudy J, Valladolid C, Yuan Y, Jana B, Spiliopoulou P, Randall L, Poklepovic A, Sehgal K, Shapiro GI, Said R, Meric-Bernstam F. NCI10221: Phase II Multicenter Biomarker Driven Combination Trial of Copanlisib and Nivolumab in Patients with Molecularly-selected Advanced Solid Tumors (BaCoN). ESMO Congress 2023 34(Suppl 2):S487-S488, 2023. e-Pub 2023.
53. Stephen B, Hajjar J, Sarda S, Duose DY, Conroy JM, Morrison C, Alshawa A, Xu M, Zarifa A, Patel SP, Yuan Y, Kwiatkowaki E, Wang L, Rodon Ahnert J, Fu S, Meric-Bernstam F, Lowman GM, Looney T, Naing A. T-cell receptor beta variable gene polymorphism predicts immune-related adverse events during checkpoint blockade immunotherapy. SITC 2024 11(8):e007236, 2023. e-Pub 2023.
54. George GC, Piha-Paul SA, Fu S, Rodon Ahnert J, Yap TA, Subbiah V, Dumbrava E, Tsimberidou A, Pant S, Appleton G, Noor L, Meric-Bernstam F, Cleeland CS, Mendoza TR, Hong DS. Baseline symptom, health status, and health utilities in patients in early-phase clinical trials combining immune checkpoint blockade with other anticancer therapies. 2023 ASCO Annual meeting 41(Suppl 16), 2023. e-Pub 2023.
55. Johnson B, Willis J, Williams C, Wang X, Smith G, You YN, Dumbrava E, Fu S, Karp D, Naing A, Piha-Paul S, Rodon Ahnert J, Tsimberidou A, Yap T, Overman M, Pant S, Hong D, Kopetz S, Meric-Bernstam F, Subbiah V. Molecular landscape and survival outcomes on early phase clinical trials in sporadic young onset colorectal cancer. 2023 ASCO Annual Meeting 41(Suppl 16), 2023. e-Pub 2023.
56. Liu J, Fu S, Richardson G, Vranjes Z, Meniawy T, Shannon C, Hamilton E, Blank S, Mathews C, Alidzanovic j, Ruseva R, Shi Q, Harismendy O, Ptaszynski A, Westin S, Meric-Bernstam F, Thaker P. Correlation of cyclin E1 expression and clinical outcomes in a phase 1b dose-escalation study of azenosertib (ZN-c3), a WEE1 inhibitor, in combination with chemotherapy (CT) in patients (pts) with platinum-resistant or refractory (R/R) epithelial ovarian, peritoneal, or fallopian tube cancer (EOC). 2023 ASCO Annual meeting 41(Suppl 16), 2023. e-Pub 2023.
57. Daud A, Daud A, Albany C, Albany C, Velcheti V, Velcheti V, Hauke R, Hauke R, Rodon Ahnert J, Rodon Ahnert J, Karp D, Karp D, Tsimberidou A, Tsimberidou A, Cohen J, Cohen J, Schmidt E, Schmidt E, Wang J, Wang J, Chan CH, Chan CH, Fu S, Fu S. First-in-human, phase 1a dose finding of LVGN6051 CD137/4-1BB agonistic antibody with or without pembrolizumab in patients with advanced solid tumors. 2023 ASCO Annual meeting 41(Suppl 16), 2023. e-Pub 2023.
58. Fu S, Kundranda M, Rahimian S, Shen Y, Tan Q, Zhao R, Esmaeili N, Singh M, Ding J, Murad Y, Liang T. The initial report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads, in patients with advanced solid tumors. 2023 ASCO Annual meeting 41(Suppl 16), 2023. e-Pub 2023.
59. Winer I, Patnaik A, Barve M, Kummar S, Schenk E, LoRusso P, Yeku O, Fu S, Jahchan N, Myers M, Liang L, Deegan D, Jackson L, Li Y, Reyno L, Chamberlain M. A phase 1a dose-escalation study of PY159, a monoclonal antibody targeting TREM1 (triggering receptor expressed on myeloid cells 1). 2023 ASCO Annual meeting 41(Suppl 16), 2023. e-Pub 2023.
60. Nardo M, Reilley M, Biter A, Lim JA, Bean S, Nguyen L, Bhosale P, Ager C, Couillault C, Piha-Paul S, Fu S, Tsimberidou A, Yap T, Naing A, Rodon Ahnert J, Subbiah V, Karp D, Curran M, Hong D. Lefitolimod (TLR agonist) and ipilimumab in patients with advanced solid tumors: A phase I trial. 2023 ASCO Annual Meeting 41(Suppl 16), 2023. e-Pub 2023.
61. Davidson T, Le H, Campbell E, Ozenne C, Dumbrava E, Fu S, Hong D, Karp D, Naing A, Piha-Paul S, Rodon Ahnert J, Tsimberidou A, Yap T, Meric-Bernstam F, Subbiah V. Clinical trial deserts: US urban vs rural patient enrollment among patients with advanced cancer in phase 1 clinical trials at a major cancer center. 2023 ASCO Annual meeting 41(Suppl 16), 2023. e-Pub 2023.
62. Falchook G, Liang Y, Harvey D, Fu S, Weitao Y, Qin Y, Zhang X, Henry J, Zou Q, Shan B, Liang P, Wang C, Li W, Pamuklar Z, Pei Y, Chang Z, Wang J, Piha-Paul S, Bhave M, Yin Y. First-in-human phase 1 study of pimicotinib (ABSK021), a CSF-1R inhibitor, in patients with advanced solid tumors. 2023 ASCO Annual Meeting 41(Suppl 16), 2023. e-Pub 2023.
63. Ngoi NY, Lin HY, Dumbrava E, Fu S, Karp DD, Naing A, Pant S, Piha-Paul SA, Rodon J, Subbiah V, Tsimberidou AM, Campbell E, Urrutia S, Hong DS, Meric-Bernstam F, Yuan Y, Yap TA. Dynamic changes in monocyte and reticulocyte counts predict mechanism-based anemia development and recovery during ATR inhibitor treatment in phase I/II trials. AACR Annual Meeting 2023 83(7_Suppl), 2023. e-Pub 2023.
64. Nelson BE, Janku F, Fu S, Dumbrava EI, Hong DS, Karp D, Naing A, Rodon J, Tsimberidou A, Amaria RN, Conley A, Damodaran S, Raghav KPS, Kreider BL, Tung D, Varterasian M, Khazaie K, Piha-Paul S. Phase Ib study of pembrolizumab in combination with intratumoral injection of clostridium novyi-NT in patients with advanced solid tumors. AACR Annual Meeting 2023 83(8_Suppl), 2023. e-Pub 2023.
65. Fu S, Falchook GS, Barve M, McKean M, Tan TJ, Lemech C, Chee CE, Marina N, Abbadessa G, Meng R, Rotolo F, Wang H, Deng J, Wang W, Wang R, Meniawy T. Joint modeling of safety and peripheral mode-of-action (MoA) biomarkers to support RP2D identification in Phase 1 study of SAR444245 (SAR’245) as monotherapy (mono) or combined with pembrolizumab (pembro) in patients with advanced solid tumors. AACR Annual Meeting 2023 83(7_Suppl), 2023. e-Pub 2023.
66. Thaker P, Pasic A, Richardson G, Vranjes Z, Prather S, Makris L, Misir S, Pultar P, Voliotis D, Fu S. Phase 1B dose-escalation study of ZN-C3 (wee1 inhibitor) with chemotherapy in patients with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: ZN-C3 plus gemcitabine arm. IGCS 2022 Annual Meeting 32(Suppl 3), 2022. e-Pub 2022.
67. Papadopoulos KP, Fu S, Hamilton EP, Spira AI, Laurie S, Wang JS, Ma B, Spreafico A, Sharma MR, Chu Q, Bray MR, Michelson G, Chen D-Y, Nguyen L, Roberts-Thomson E, Hamid O. TWT-101: A first-in-clinic, phase 1/2 study of CFI-402411, a hematopoietic progenitor kinase-1 (HPK1) inhibitor, as a single agent and in combination with pembrolizumab in subjects with advanced solid malignancies. SITC Annual Meeting 2022 10(Suppl. 2):A782, 2022. e-Pub 2022.
68. Myint H, Chirstenson E, Fu S, Gutierrez M, Martz A, Zeidan S, Nelson MM, Barbu A, Morawski A, Zhou C, Cusumano Z, O'Neill R, Copoland R, Flies DB, Langermann S, Cohen JW, Le DT. A phase 1b/2, open-label, safety, tolerability and efficacy study of NC410 plus pembrolizumab for participants with immune checkpoint inhibitor (ICI) refractory, or MSS/MSI-low ICI naïve advanced or metastatic solid tumors. SITC Annual Meeting 2022 10(Suppl. 2), 2022. e-Pub 2022.
69. Yap TA, Ngoi N, Dumbrava EE, Karp DD, Rodon Ahnert J, Fu S, Hong DS, Naing A, Pant S, Piha-Paul SA, Subbiah V, Tsimberidou AM, Dufner D, Rhudy J, Gore S, Ivy SP, Yuan Y, Westin SN, Mills GB, Meric-Bernstam F. NCI10329: Phase Ib Sequential Trial of Agents against DNA Repair (STAR) Study to investigate the sequential combination of the Poly(ADP-Ribose) Polymerase inhibitor (PARPi) olaparib (ola) and WEE1 inhibitor (WEE1i) adavosertib (ada) in patients (pts) with DNA Damage Response (DDR)-aberrant advanced tumors, enriched for BRCA1/2 mutated and CCNE1 amplified cancers. 34th EORTC-NCI-AACR Symposium 174(Suppl 1):S7, 2022. e-Pub 2022.
70. Falchook GS, Fu S, Lemech C, McKean MA, Azad AA, Gan HK, Sommerhalder D, Wang JS, Tan TJY, Chee CE, Barve M, Moser J, Mooney J, Acuff N, Wang R, Marina N, Abbadessa G, Streit M, Ramusovic S, Meniawy T. Phase I study of SAR444245 (SAR’245) as monotherapy (mono) and combined with pembrolizumab (pembro) or cetuximab (cetux) in patients (pts) with advanced solid tumors. ESMO Congress 2022 33(S7), 2022. e-Pub 2022.
71. Ngoi NY, Lin H, Dumbrava EE, Fu S, Karp D, Naing A, Pant S, Rodon J, Piha-Paul SA, Subbiah V, Tsimberidou AM, Campbell E, Urrutia S, Hong DS, Meric-Bernstam F, Yuan Y, Yap TA. Correlation of clinical, genomic and hematological parameters with ATR inhibitor (ATRi) outcomes in phase I/II clinical trials. ESMO Congress 2022 33(Suppl 7):S761-S762, 2022. e-Pub 2022.
72. Fu S, Vandross AL, Hsin HY, Shi N, Jiang L, Su F, Wang J, Chan CH. Early safety and efficacy from a phase I open-label clinical study of LVGN7409 (CD40 agonist antibody) in patients with advanced or metastatic malignancies. 2022 ASCO Annual Meeting 40(Suppl 16), 2022. e-Pub 2022.
73. Pasic A, Richardson G, Vranjes Z, Meniawy T, Rodriquez J, Makris L, Misir S, Pultar P, Voliotis D, Fu S. A phase 1b dose-escalation study of ZN-c3, a WEE1 inhibitor, in combination with chemotherapy (CT) in subjects with platinum-resistant or refractory ovarian, peritoneal, or fallopian tube cancer. 113th Annual Meeting of the American Association for Cancer Research (AACR) 82(12_Suppl), 2022. e-Pub 2022.
74. Nelson BE, Roszik J, Janku F, Hong D, Kato S, Naing A, Piha-Paul SA, Fu S, Tsimberidou A, Cabanillas M, Busaidy N, Javle M, Byers L, Heymach J, Meric-Bernstam F. B-Raf V600E harboring non-melanoma cancers treated with Vemurafenib monotherapy and in combination with Everolimus/Sorafenib/Crizotinib/Paclitaxel+ Carboplatin: A pooled analysis of five phase 1/2 studies. 113th Annual Meeting of the American Association for Cancer Research (AACR) 82(12_Suppl), 2022. e-Pub 2022.
75. Fu S, Banerji U, Bedard PL, Ferrandiz AC, Chiappori A, Desai J, Jamal R, Perez DR, Yamamoto N, Vieira E, Wong G, Subramanian KK, Wang S, Mueller B, Otero JA, Koo S-L. A phase I/Ib study of the safety and preliminary efficacy of NZV930 alone and in combination with spartalizumab and/or taminadenant in patients (pts) with advanced malignancies. 113th Annual Meeting of the American Association for Cancer Research (AACR) 82(12_Suppl), 2022. e-Pub 2022.
76. Ngoi N, Lin HY, Dumbrava EE, Fu S, Karp DD, Naing A, Pant S, Piha-Paul SA, Rodon Ahnert J, Subbiah V, Tsimberidou AM, Campbell E, Hong DS, Meric-Bernstam F, Yuan Y, Yap TA. Baseline predictors of hematological toxicity in patients with advanced cancer treated with ATR inhibitors in phase I/II clinical trials. 2022 ASCO Annual Meeting 40(Suppl 16), 2022. e-Pub 2022.
77. Fu S, Nabell L, Pearson AT, Leidner R, Adkins D, Posner MR, Nieva JJ, Richardson DL, Pimentel A, Goel S, Wong SJ, Ho AL, Rosenberg A, Taylor MH, Abdul-Karim R, Iacobucci C, Qing X, Katchar K, Schlienger K, Pfister DG. Recommended phase 2 dose (RP2D) of HB-200 arenavirus-based cancer immunotherapies in patients with HPV16+ cancers. 2022 ASCO Annual Meeting 40(Suppl 16), 2022. e-Pub 2022.
78. Matulonis UA, Janku F, Moser JC, Fu S, Wages DS, Wheeler CA, Mori M, Shimoyama S, Yamada N, Subach RA, Cheung K, Madden T, Maier G, Johansen M, Falchook GS. A first-in-human phase 1 dose escalation study of FF-10850 (liposomal topotecan) in patients with advanced solid tumors. 2022 ASCO Annual Meeting 40(Suppl 16), 2022. e-Pub 2022.
79. Borazanci EH, Janku F, Hamilton EP, Thomas JS, Sen S, Fu S, Wheeler CA, Wages DS, Matsumoto T, Shimoyama S, Yamada N, Subach RA, Madden T, Johansen M, Maier G, Cheung K, Korn R, Falchook GS. A phase 1, first-in-human, dose-escalation and biomarker trial of liposomal gemcitabine (FF-10832) in patients with advanced solid tumors. 2022 ASCO Annual Meeting 40(Suppl 16), 2022. e-Pub 2022.
80. Piha-Paul SA, Xu B, Singh Raghav KP, Meric-Bernstam F, Janku F, Dumbrava EE, Fu S, Karp DD, Rodon Ahnert J, Conley AP, Mott F, Ajani JA, Hong DS, Fan Y, Peng P, Levin WJ, Ngo B, Ru QC, Wu F, Javle MM. First-in-human, phase I study of TT-00420, a multiple kinase inhibitor, as a single agent in advanced solid tumors. 2022 ASCO Annual Meeting 40(Suppl 16), 2022. e-Pub 2022.
81. Coleman N, DiPeri TP, Nguyen D, Naing A, Piha-Paul SA, Tsimberidou AM, Zheng X, Johnson A, Wang W, Shaw KR, Dumbrava EE, Fu S, Rodon J, Rodon Ahnert J, Hong DS, Subbiah V, Yap TA, Luthra R, Patel KP, Meric-Bernstam F. Repeat large panel genomic sequencing identifies actionable alterations and characterizes the genomic landscape in patients with metastatic solid tumors. 2022 ASCO Annual Meeting 40(Suppl 16), 2022. e-Pub 2022.
82. Nelson BE, Andersen C, Yuan Y, Hong DS, Naing A, Karp DD, Yap TA, Rodon Ahnert J, Campbell E, Tsimberidou AM, Dumbrava EE, Fu S, Piha-Paul SA, Pant S, Blumenschein GR, Altan M, Tawbi HA, Tannir NM, Meric-Bernstam F, Subbiah V. Effect of immunotherapy and time-of-day infusion chronomodulation on survival in advanced cancers. 2022 ASCO Annual Meeting 40(Suppl 16), 2022. e-Pub 2022.
83. Fu S, Jazaeri AA, Lu Z, Peter M, Morris SW, Bast RC. GRN300–001: Phase 1/1B evaluation of the safety, pharmacokinetics, and efficacy of GRN-300, a salt-inducible kinase inhibitor, alone and in combination with paclitaxel, in recurrent ovarian, primary peritoneal, and fallopian tube cancers. 2022 ASCO Annual Meeting 40(Suppl 16), 2022. e-Pub 2022.
84. Alhalabi O, Tannir NM, Momin HA, Yilmaz B, Stephen B, Ejezie CL, Moyers JT, Gurses SA, How J, Fu S, Rodon Ahnert J, Hong DS, Piha-Paul SA, Subbiah V, Dumbrava EE, Karp DD, Janku F, Meric-Bernstam F, Naing A. Phase Ib trial of selinexor (SEL) in combination with nivolumab (NIVO) alone or nivolumab plus ipilimumab (NIVO+IPI) in patients (pts) with advanced malignancies: The renal cell carcinoma (RCC) experience. 2022 ASCO Annual Meeting 40(Suppl 16), 2022. e-Pub 2022.
85. Hamid O, Bendell J, Fu S, Papadopoulos K, Wang J, Ma B, Spreafico A, Spira A, Bray M, Fletcher G, Michelson G, Roberts-Thomson E. TWT-101: a phase 1 study of the novel Hpk1 inhibitor CFI-402411 in patients with advanced cancer. SITC 36th Annual Meeting 2021 9(Suppl 3), 2021. e-Pub 2021.
86. Falchook F, Gan H, Fu S, McKean M, Azad A, Sommerhalder D, Wang J, Tan T, Chee C, Barve M, Lemeque C, Acuff N, Pham H, Mooney J, Wang R, Marina N, Abbadessa G, Meniawy T. Phase 1/2 study of THOR-707 (SAR444245), a pegylated recombinant NON-ALPHA IL-2, as monotherapy and in combination with pembrolizumab or cetuximab in patients (PTS) with advanced solid tumors. SITC 36th Annual Meeting 2021 9(Suppl 3), 2021. e-Pub 2021.
87. Myint H, Myint H, Tian L, Tian L, Shaik J, Shaik J, Barbu E, Barbu E, Zhou Q, Zhou Q, Morawski A, Morawski A, Abukharma H, Abukharma H, Liu L, Liu L, Shin J, Shin J, Flies D, Flies D, Copeland R, Copeland R, Nelson M, Nelson M, Zeidan S, Zeidan S, Bilusic M, Bilusic M, Pastor D, Pastor D, Madan R, Madan R, Fu S, Fu S, Gutierrez M, Gutierrez M, Langermann S, Langermann S. NC410, a fusion protein of LAIR-2 (leukocyte associated immunoglobulin-like receptor) with human IGG1 FC, is safe & tolerable with evidence of immune modulation in subjects with advanced solid tumors. SITC 36th Annual Meeting 2021 9(Suppl 3), 2021. e-Pub 2021.
88. Fu S, Pasic A, Richardson G, Vranjes ZJ, Meniawy T, de Jong PR, Donate F, Samatar AA, Rodriguez J, Pultar P, Voliotis D. A phase Ib dose-escalation study of ZN-c3, a WEE1 inhibitor, in combination with chemotherapy in patients with platinum-resistant or -refractory ovarian, peritoneal, or fallopian tube cancer. ESMO Congress 2021 32(Suppl_5), 2021. e-Pub 2021.
89. Moyers J, Nguyen D, Hong DS, Ileana Dumbrava E, Fu S, Karp D, Naing A, Pant S, Janku F, Piha-Paul S, Rodon J, Subbiah V, Tsimberidou AM, Meric-Bernstam F, Yap T. Adherence to the Food and Drug Administration (FDA) Guidance for the Co-Development of Two or More Investigational New Drugs in Phase 1/2 Cancer Trials. ESMO Congress 2021 32(Suppl_5), 2021. e-Pub 2021.
90. Fu S, Yao S, Yuan Y, Previs RA, Elias AD, Carvajal R, George TJ, Yuan Y, Yamamura Y, Westin S, Xing Y, Ileana Dumbrava EE, Karp DD, Piha-Paul S, Tsimberidou AM, Rodon J, Takebe N, Kunos C, Lu K, Keyomarsi K, Meric-Bernstam F. Phase II trial of the Wee1 inhibitor adavosertib in advanced refractory solid tumors with CCNE1 amplification. AACR Annual Meeting 2021 81(13 Suppl), 2021. e-Pub 2021.
91. Coleman N, Naing A, Zhang S, Piha-Paul SA, Tsimberidou AM, Janku F, Rodon J, Pant S, Dumbrava EI, Fu S, Hong DS, Meric-Bernstam M, Subbiah V. Phase I study of mTORC1/2 inhibitor sapanisertib (TAK-228) in combination with metformin in patients (pts) with mTOR/AKT/PI3K pathway alterations and advanced solid malignancies. 2021 ASCO Annual Meeting 39(Suppl 15), 2021. e-Pub 2021.
92. Janku F, Hanna GJ, Carvajal RD, Paik PK, Hernando-Calvo A, Gillison ML, Fu S, Wheler JJ, Bohr D, Reiners R, Tan S-L, Bilic S, Bedard PL. First-in-human phase I study of the bifunctional EGFR/TGFβ fusion protein BCA101 in patients with EGFR-driven advanced solid cancers. 2021 ASCO Annual Meeting 39(Suppl 15), 2021. e-Pub 2021.
93. Ho AL, Posner MR, Niu J, Fu S, Leidner RS, Pearson AT, Chung KY, Richardson DL, Wang D, Pimentel A, Nieva JJ, Rosenberg A, Burman B, Iacobucci C, Qing X, Hwang A, Katchar K, Schlienger K, Matushansky I, Pfister DG. First report of the safety/tolerability and preliminary antitumor activity of HB-201 and HB-202, an arenavirus-based cancer immunotherapy, in patients with HPV16+ cancers. 2021 ASCO Annual Meeting 39(Suppl 15), 2021. e-Pub 2021.
94. Piha-Paul SA, Xu B, Janku F, Dumbrava EI, Fu S, Karp DD, Meric-Bernstam F, Hong DS, Rodon Ahnert J, Tsimberidou AM, Javle MM, Fan Y, Peng P, Levin WJ, Ngo B, Wang H, Sun C, Ru QC, Wu F. Phase I study of TT-00420, a multiple kinase inhibitor, as a single agent in advanced solid tumors. 2021 ASCO Annual Meeting 39(Suppl 15), 2021. e-Pub 2021.
95. Pisick EP, Rothe M, Mangat PK, Garrett-Mayer L, Worden FP, Bauman JR, Fu S, Leidner RS, Balmanoukian AS, Calfa C, Carrizosa DR, D'Andre SD, Nabell L, Park MS, Powell SF, Thota R, Schilsky RL. Palbociclib (P) in patients (pts) with head and neck cancer (HNC) with CDKN2A loss or mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. 2021 ASCO Annual Meeting 39(Suppl 15), 2021. e-Pub 2021.
96. Abo-Zahrah R, Karp DD, Adat A, Yap TA, Fu S, Rodon Ahnert J, Piha-Paul SA, Tsimberidou AM, Naing A, Subbiah V, Dumbrava EI, Overman MJ, Patel SP, Amaria RN, Westin SN, Meric-Bernstam F, Janku F. Patients with advanced solid cancers treated with ERK inhibitors exhibit pseudo-progression in lymphatic nodes. 2021 ASCO Annual Meeting 39(Suppl 15), 2021. e-Pub 2021.
97. Yap TA, Dumbrava EI, Jodon Ahnert J, Hong DS, Pant S, Karp DD, Piha-Paul SA, Subbiah V, Tsimberidou AM, Fu S, Janku F, Montez S, Ahmad-Taha MT, Guerrero D, Nazarenko NN, Moore Y, Soth M, Kovacs J, Heffernan TP, Jones P. First-in-human biomarker-driven phase I trial of the potent and selective glutaminase-1 (GLS1) inhibitor IACS-6274 (IPN60090) in patients (pts) with molecularly selected advanced solid tumors. 2021 ASCO Annual Meeting 39(Suppl 15), 2021. e-Pub 2021.
98. Fu S, Harb WA, Patel SP, Lu C, Halperin DM, Hsu YH, Shi N, Yamamura Y, Tang T, Jiang L, Su F, Cohen JW, Schmidt EV, Wang J. Early safety and efficacy from a phase I open-label clinical trial of CD137(4-1BB) agonistic antibody LVGN6051 as monotherapy and in combination with pembrolizumab. 2021 ASCO Annual Meeting 39(Suppl 15), 2021. e-Pub 2021.
99. Vo HH, Fu S, Hong DS, Karp DD, Piha-Paul SA, Subbiah V, Janku F, Naing A, Yap TA, Rodon Ahnert J, Ajani JA, Cartwright C, Naqvi MF, Nogueras-Gonzalez GM, Miller VA, Palmer GA, Vining DJ, Berry DA, Meric-Bernstam F, Tsimberidou AM. Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT2): Challenges and Opportunities in Conducting an MD Anderson Randomized Study in Precision Oncology. 2021 ASCO Annual Meeting 39(Suppl 15), 2021. e-Pub 2021.
100. Westin SN, Fu S, Tsimberidou AM, Piha-Paul SA, Akhmedzhanov F, Yilmaz B, McQuinn L, Brink AL, Gong J, Hong Leung C, Lin HY, Hong DS, Pant S, Jazaeri AA, Gershenson DM, Sood AK, Coleman RL, Shah JJ, Meric-Bernstam F, Naing A. Selinexor in combination with weekly paclitaxel in patients with advanced or metastatic solid tumors: Results of an open label, single-center, multiarm phase 1b study. 2021 ASCO Annual Meeting 39(Suppl 15), 2021. e-Pub 2021.
101. Kim JW, Radke MR, Hafez N, Hussein Soliman H, Fu S, Kato S, Lara LN, Vaishampayan UN, Razak ARA, Baklund Cardin D, Munster PN, Eder JP, Shyr Y, Ivy P, LoRusso P, Swisher EM. Analysis of homologous recombination DNA repair gene mutation status in patients with metastatic small cell lung cancer treated with cediranib and olaparib on NCI 9881 study. 2021 ASCO Annual Meeting 39(Suppl 15), 2021. e-Pub 2021.
102. Naing A, Karp D, Piha-Paul S, Haymaker C, Parra E, Yang F, Pant S, Hong D, Fu S, Yap T, Stephen B, Yang Y, Lin H, Leung CH, Daver N, Choi Y, Hajjar J, Wistuba I, Hwu P, Meric-Bernstam F, Rodon J. Immune correlates associated with clinical outcomes in patients with advanced malignancies treated with avelumab and OX40 agonist. SITC Annual Meeting 2020 8(Suppl 3), 2020. e-Pub 2020.
103. Janku F, Fu S, Murthy R, Karp DD, Hong DS, Tsimberidou AM, Gillison ML, Adat A, Raina A, Call G, Kreider BL, Tung D, Varterasian M, Khazaie K. First-in-man clinical trial of intratumoral injection of Clostridium novyi-NT spores in combination with pembrolizumab in patients with treatment-refractory advanced solid tumors. J Immunother Cancer 8(3), 2020. e-Pub 2020.
104. Thein KZ, Tsimberidou AM, Piha-Paul SA, Janku F, Karp DD, Fu S, Zarifa A, Gong J, Yap TA, Hong DS, Subbiah V, Pant S, Meric-Bernstam F, Naing A. Selinexor in combination with carboplatin and pemetrexed (CP) in patients with advanced or metastatic solid tumors: Results of an open label, single-center, multi-arm phase Ib study. ESMO Asia Virtual Congress 2020 31(Suppl_6), 2020. e-Pub 2020.
105. Thein KZ, Thein KZ, Tsimberidou AM, Tsimberidou AM, Piha-Paul SA, Piha-Paul SA, Janku F, Janku F, Karp DD, Karp DD, Fu S, Fu S, Zarifa A, Zarifa A, Gong J, Gong J, Hong DS, Hong DS, Yap TA, Yap TA, Subbiah V, Subbiah V, Pant S, Pant S, Meric-Bernstam F, Meric-Bernstam F, Naing A, Naing A. Selinexor in combination with standard chemotherapy in patients with advanced solid tumours: Results of an open label, single-center, multi-arm phase Ib study. ESMO Asia Virtual Congress 2020 31(Suppl_6):S1270-S1272, 2020. e-Pub 2020.
106. Lakhani N, Orloff M, Fu S, Liu Y, Wang Y, Zhou H, Lin K, Liu F, Yan S, Patnaik A. First-in-human Phase I trial of IBI188, an anti-CD47 targeting monoclonal antibody, in patients with advanced solid tumors and lymphomas. SITC Annual Meeting 2020 8(Suppl 3), 2020. e-Pub 2020.
107. Lakhani N, Orloff M, Fu S, Liu Y, Wang Y, Zhou H, Lin K, Liu F, Yan S, Patnaik A. First-in-human Phase I trial of IBI188, an anti-CD47 targeting monoclonal antibody, in patients with advanced solid tumors and lymphomas. SITC Annual Meeting 2020 8(Suppl 3), 2020. e-Pub 2020.
108. Hong DS, Hong DS, Fogelman D, Fogelman D, Shaikh F, Shaikh F, Dupont-Roettger D, Dupont-Roettger D, Bisdas S, Bisdas S, Ileana Dumbrava EE, Ileana Dumbrava EE, Piha-Paul SA, Piha-Paul SA, Liu L, Liu L, Dugourd D, Dugourd D, Yamamura Y, Yamamura Y, Fu S, Fu S. A phase Ib study on a TRPV6-inhibitor, SORC13 in patients with advanced solid tumours. ESMO Virtual Congress 2020 31(Suppl_4), 2020. e-Pub 2020.
109. Alhalabi O, Hahn AW, Msaouel P, Meric-Bernstam F, Naing A, Piha-Paul S, Janku F, Pant S, Yap TA, Hong DS, Fu S, Karp DD, Campbell E, Campbell MT, Shah AY, Tannir N, Siefker-Radtke AO, Gao J, Roszik J, Subbiah V. Validation of prognostic scores in patients with metastatic bladder carcinoma (mBC) enrolled in early phase clinical trials. ESMO Virtual Congress 2020 31(Suppl_4), 2020. e-Pub 2020.
110. Glitza IC, Patel S, Zarifa A, Leung CH, Lin H, McQuinn L, Gong J, Yilmaz B, Chambers J, Sulovic S, John I, Hennegan T, Fu S, Tsimberidou AM, Janku F, Karp DD, Meric-Bernstam F, Naing A. Phase Ib study to evaluate the safety of selinexor (SEL) in combination with pembrolizumab (PEM) in patients with advanced malignancies- the: The melanoma experience. ESMO Virtual Congress 2020 31(Suppl_4), 2020. e-Pub 2020.
111. Thein KZ, Tsimberidou AM, Piha-Paul SA, Janku F, Karp DD, Fu S, Zarifa A, Gong J, Hong DS, Yap TA, Subbiah V, Pant S, Meric-Bernstam F, Naing A. Selinexor in combination with topotecan in patients with advanced or metastatic solid tumours: Results of an open label, single-center, multi-arm phase Ib study. ESMO Virtual Congress 2020 31(Suppl_4), 2020. e-Pub 2020.
112. Thein KZ, Thein KZ, Tsimberidou AM, Tsimberidou AM, Piha-Paul SA, Piha-Paul SA, Janku F, Janku F, Karp DD, Karp DD, Fu S, Fu S, Zarifa A, Zarifa A, Gong J, Gong J, Yap TA, Yap TA, Hong DS, Hong DS, Subbiah V, Subbiah V, Pant S, Pant S, Meric-Bernstam F, Meric-Bernstam F, Naing A, Naing A. Selinexor in combination with carboplatin and paclitaxel in patients with advanced or metastatic solid tumours: Results of an open label, single-center, multi-arm phase Ib study. ESMO Virtual Congress 2020 31(Suppl_4), 2020. e-Pub 2020.
113. Wang X, Zheng K, Cao G, Xu L, Zhu X, Chen H, Fu S, Wu D, Yang R, Wang K, Liu W, Bao Q, Hao C, Shen L, Xing B. Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib alone for advanced hepatocellular carcinoma with major portal vein tumor thrombosis (Vp3/4): A randomized phase II trial. ESMO Virtual Congress 2020 31(Suppl_4), 2020. e-Pub 2020.
114. Naing A, Karp DD, Piha-Paul SS, Pant S, Subbiah V, Bodurka DC, Fu S, Jaz. Temsirolimus in combinaton with metformin in patients with advanced or refractory endometrial cancers. AACR Annual Meeting 2020 80(16 Suppl), 2020. e-Pub 2020.
115. Huey R, George G, Phillips P, White R, Fu S, Janku F, Karp DD, Naing A, Piha-Paul SA, Subbiah V, Tsimberidou AM, Pant S, Yap TA, Rodon Ahnert J, Meric-Bernstam F, Shih Y-CT, Hong DS. Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical Trials. ASCO Annual Meeting 2020 38(15_Suppl), 2020. e-Pub 2020.
116. Garrido-Laguna I, Dillon PM, Anthony SP, Janat-Amsbury M, Ashenbramer N, Warner SL, Mouritsen L, Wade ML, Whatcott C, Bearss D, Fu S. A phase I, first-in-human, open-label, dose‑escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP‑3654 administered daily for 28 days to patients with advanced solid tumors. ASCO Annual Meeting 2020 38(15_Suppl), 2020. e-Pub 2020.
117. Subbiah IM, Buzdar A, Dumbrava EEI, Fu S, Janku F, Karp DD, Naing A, Pant S, Rodon J, Tsimberidou AM, Yap TA, Subbiah V, Meric-Bernstam F, Hong DS. Investigating the disparate enrollment of older adults on phase I clinical trials: evolving participation patterns of patients 65 years and older w advanced cancer on phase I trials. ASCO Annual Meeting 2020 38(15_Suppl), 2020. e-Pub 2020.
118. Kim JW, Hafez N, Soliman HH, Fu S, Kato S, Lara P, Vaishampayann UN, Razak ARA, Backlund Cardin D, Munster PN, Eder JP, Swisher EM, Nixon AB, Patel A, Shyr Y, Ivy SP, LoRusso P. Preliminary efficacy data of platinum-pretreated small cell lung cancer (SCLC) cohort of NCI 9881 study: A phase II study of cediranib in combination with olaparib in advanced solid tumors. ASCO Annual Meeting 2020 38(15_Suppl), 2020. e-Pub 2020.
119. Hafez N, Soliman HH, Fu S, Gelmon KA, Razak ARA, Munster PN, Vaishampayan UN, Kato S, Lara P, Swisher EM, Nixon AB, Patel A, Shyr Y, Ivy SP, LoRusso P, Kim JW. Preliminary efficacy data of triple-negative breast cancer cohort of NCI 9881 study: A phase II study of cediranib in combination with olaparib in advanced solid tumors. ASCO Annual Meeting 2020 38(15_Suppl), 2020. e-Pub 2020.
120. Gouda MA, Huang HJ, Piha-Paul SA, Call G, Karp DD, Fu S, Naing A, Subbiah V, Pant S, Tsimberidou AM, Hong DS, Ahnert JR, Meric-Bernstam F, Janku F. Genomically Informed Longitudinal Monitoring of Circulating Tumor DNA (ctDNA) Predicts Outcomes of Cancer Therapy. ASCO Annual Meeting 2020 38(15_Suppl), 2020. e-Pub 2020.
121. Alhalabi O, Hahn AW, Meric-Bernstam F, Naing A, Piha-Paul SA, Janku F, Pant S, Yap TA, Hong DS, Fu S, Campbell E, Le H, Shah AY, Campbell MT, Tannir NM, Siefker-Radtke AO, Gao J, Roszik J, Subbiah V. Outcomes and the impact of genomic characteristics on patients with metastatic urothelial carcinoma enrolled in early phase trials. ASCO Annual Meeting 2020 38(15_Suppl), 2020. e-Pub 2020.
122. Colen RR, Ahmed S, Elshafeey N, Karp DD, Pant S, Subbiah V, Piha-Paul SA, Hong DS, Yap TA, Fu S, Tsimberidou AM, Stephen B, Gong J, Rodon Ahnert J, Naing A. Radiomics to predict response to pembrolizumab in patients with advanced rare cancers. 2020 ASCO-SITC Clinical Immuno-Oncology Symposium 38(suppl 5), 2020. e-Pub 2020.
123. Ballhausen A, Wheler JJ, Karp DD, Piha-Paul SA, Fu S, Pant S, Tsimberidou AM, Hong DS, Subbiah V, Holley VR, Huang HJ, Brewster AM, Koenig KH, Ibrahim NK, Meric-Bernstam F, Janku F. Everolimus, letrozole and trastuzumab in hormone receptor-positive, HER2-positive/amplified or mutant metastatic cancer: Evaluating synergy and overcoming resistance. SABCS 2019 80(4_Suppl), 2020. e-Pub 2020.
124. Hegde A, Jayaprakash P, Sumner E, Nguyen D, Zain H, Piha-Paul S, Karp D, Jordi, Rodon, Pant S, Fu S, Dumbrava E, Yap T, Subbiah V, Bhosale P, Higgins J, Williams ET, Wilson TF, Meric-Bernstam F, Curran M, Hong D. A Phase 1 Dose Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies. SITC Annual Meeting 2019 7(Supp 1), 2019. e-Pub 2019.
125. Huey R, George G, Phillips P, White R, Fu S, Janku F, Karp DD, Naing A, Piha-Paul SA, Subbiah V, Tsimberidou AM, Pant S, Yap TA, Rodon Ahnert J, Meric-Bernstam F, Shih Y-CT, Hong DS. Out-of-pocket costs and financial toxicity experienced by patients in early phase clinical trials. 2019 ASCO Quality Care Symposium 37(Suppl 27), 2019. e-Pub 2019.
126. Naing A, Meric-Bernstam F, Karp D, Rodon JA, Piha-Paul SA, Subbiah V, Hong DS, Pant S, Fu S, Janku F, Yap TA, Tsimberidou AM, Ileana Dumbrava EE, Colen RR, Hess KR, Campbell MT, Tu S, Jimenez C, Habra MA, Varadhachary GR. Pembrolizumab in Advanced Rare Cancers. ESMO Congress 2019 30(Suppl 5), 2019. e-Pub 2019.
127. Tsimberidou AM, Hong DS, Fu S, Karp D, Piha-Paul SA, Kies M, Ravi V, Subbiah V, Patel S, Tu S, Janku F, Heymach J, Johnson A, Zhao L, Zhang J, Berry DA, Vining D, Futreal A, Miller VA, Meric-Bernstam F. Precision medicine: Preliminary results from the initiative for molecular profiling and advanced cancer therapy 2 (IMPACT 2) study. ESMO Congress 2019 30(Suppl 5), 2019. e-Pub 2019.
128. Konstantinopoulos PA, Wahner Hendrickson AE, Penson RT, Doyle A, Kohn EC, Duska LR, Crispens MA, Olawaiye AB, Winer IS, Barroilhet LM, Fu S, McHale MT, Schilder RJ, Farkkila A, Curtis J, Quinn R, Whalen C, Shapiro GI, Matulonis UA. Randomized phase II (RP2) study of ATR inhibitor M6620 in combination with gemcitabine versus gemcitabine alone in platinum-resistant high grade serous ovarian cancer (HGSOC). ESMO Congress 2019 30(Suppl 5), 2019. e-Pub 2019.
129. Hamilton E, Falchook GS, Wang JS, Fu S, Oza A, Karen S, Imedio ER, Kumar S, Ottesen L, Mugundu GM, Chmielecki J, Jones S, Spigel DR, Li BT. Phase Ib study of adavosertib in combination with olaparib in patients with refractory solid tumors: Dose escalation. AACR Annual Meeting 2019 79(13 Suppl), 2019. e-Pub 2019.
130. Bauer TM, Moore K, Rader JS, Simpkins F, Mita A, Beck JT, Hart L, Chu Q, Oza A, Tinker AV, So K, Imedio ER, Kumar S, Mugundu GM, Jenkins S, Chmielecki J, Jones S, Spigel DR, Fu S. Open-label, multicenter, Phase Ib study to assess safety, tolerability and efficacy of adavosertib monotherapy in patients with advanced solid tumors: Expansion cohorts. AACR Annual Meeting 2019 79(13 Suppl), 2019. e-Pub 2019.
131. Schilder RJ, Albertella M, Strauss JF, Sydvander M, Le DT, Norin S, Mita MM, Bostrom E, Fu S, Basse L, Bethell R. Determination of the recommended phase II dose of birinapant in combination with pembrolizumab: Results from the dose-escalation phase of BPT-201. ASCO Annual Meeting 2019 37(15_Suppl), 2019. e-Pub 2019.
132. Y-J B, Bang Y-J, Golan T, Golan T, C-C L, Lin C-C, Dahan L, Dahan L, Fu S, Fu S, Moreno V, Moreno V, Geva R, Geva R, Reck M, Reck M, Wasserstrom HA, Wasserstrom HA, Mi G, Mi G, Laing N, Laing N, Williams Goff L, Williams Goff L. Ramucirumab (Ram) and durvalumab (Durva) treatment of metastatic non-small cell lung cancer (NSCLC), gastric/gastroesophageal junction (G/GEJ) adenocarcinoma, and hepatocellular carcinoma (HCC) following progression on systemic treatment(s). ASCO Annual Meeting 2019 37(15_Suppl), 2019. e-Pub 2019.
133. Reilley M, Tsimberidou AM, Piha-Paul SA, Yap TA, Fu S, Naing A, Rodon J, Nguyen LM, AgerC, Meng M, Jayaprakash P, Schmidt M, Baumann M, Meric-Bernstam F, Curran MA, Hong DS. Phase 1 trial of TLR9 agonist lefitolimod in combination with CTLA-4 checkpoint inhibitor ipilimumab in advanced tumors. ASCO Annual Meeting 2019 37(15_Suppl), 2019. e-Pub 2019.
134. Yap TA, Rodon Ahnert J, Piha-Paul SA, Fu S, Janku F, Karp DD, Naing A, Ileana Dumbrava EE, Pant S, Subbiah V, Tsimberidou AM, Hong DS, rose KM, Xu Q, Vellano CP, Mahendra M, Jones P, Di Francesco ME, Marszalek JR, Meric-Bernstam F. Phase I trial of IACS-010759 (IACS), a potent, selective inhibitor of complex I of the mitochondrial electron transport chain, in patients (pts) with advanced solid tumors. ASCO Annual Meeting 2019 37(15_Suppl), 2019. e-Pub 2019.
135. Huey R, George G, Phillips P, White R, Fu S, Janku F, Karp DD, Naing A, Piha-Paul SA, Subbiah V, Tsimberidou AM, Pant S, Yap TA, Ahnert JR, Meric-Bernstam F, Shih Y-CT, Hong DS. Out of pocket costs and financial toxicity experienced by patients in early phase clinical trials. ASCO Annual Meeting 2019 37(Suppl 15), 2019. e-Pub 2019.
136. Pant S, Pant S, Subbiah V, Subbiah V, Rodon J, Rodon J, Janku F, Janku F, Hong D, Hong D, Karp D, Karp D, Piha-Paul S, Piha-Paul S, Tsimberiodu AM, Tsimberiodu AM, Naing A, Naing A, Fu S, Fu S, Savage RE, Savage RE, Chai F, Chai F, Yu Y, Yu Y, Tith K, Tith K, Alfattal R, Alfattal R, Schwartz B, Schwartz B, Meric-Bernstam F, Meric-Bernstam F, Yap T, Yap T. A phase 1 dose escalation study of ARQ 751 in adult patients with advanced solid tumors with AKT1, 2, 3 genetic alterations, activating PI3K mutations, PTEN-null, or other known actionable PTEN mutations. 30th EORTC-NCI-AACR Symposium 103(S1), 2018. e-Pub 2018.
137. Ahmed S, Elshafeey N, Huang HJ, Madwani K, Fu S, Tsimberidou AM, Piha-Paul SA, Naing A, Hong D, Karp DD, Cabrilo G, Kopetz S, Subbiah V, Kee BK, Eng C, Morris VK, Meric-Bernstam F, Colen R, Janku F. Circulating tumor cell-free DNA correlates with the total tumor volume and survival in patients with advanced cancers. 30th EORTC-NCI-AACR Symposium 103(S1):e57, 2018. e-Pub 2018.
138. Swilling A, de Groot J, Javle M, Penas-Prado M, Shroff R, Luthra R, Banks K, Lanman R, Conley A, Broaddus R, Davies M, Kopetz S, Yung WA, Heymach J, Fu S, Shaw K, Meric-Bernstam F, Janku F. Simultaneous molecular alterations and clinical outcomes in solid tumors with IDH1 orIDH2 mutations. 30th EORTC-NCI-AACR Symposium 103(S1):e53, 2018. e-Pub 2018.
139. Reilley M, Reilley M, Ager C, Ager C, Meng M, Meng M, Tsimberiodu AM, Tsimberiodu AM, Piha-Paul S, Piha-Paul S, yap T, yap T, Fu S, Fu S, Naing A, Naing A, Rodon J, Rodon J, Nguyen L, Nguyen L, Bhosale P, Bhosale P, Schmidt M, Schmidt M, Baumann M, Baumann M, Meric-Bernstam F, Meric-Bernstam F, Curran M, Curran M, Hong DS, Hong DS. Combination of subcutaneously administered TLR9 agonist lefitolimod with CTLA-4 checkpoint inhibitor ipilimumab - A phase I trial in patients with advanced solid tumors. SITC 2018 6(1), 2018. e-Pub 2018.
140. Fu S, Corr B, Hamilton E, Burger RA, Wenham R, Naumann RW, Stagg R, Moore KN. A phase Ib study of navicixizumab & weekly paclitaxel in heavily pretreated platinum resistant ovarian, primary peritoneal or fallopian tube cancer. 43rd ESMO Cancer Congress 2018 29(Suppl 8), 2018. e-Pub 2018.
141. Pant S, Subbiah V, Rodon J, Janku F, Hong DS, Karp D, Piha-Paul SA, Tsimberidou AM, Naing A, Fu S, Savage RE, Chai F, Yu Y, Schwartz B, Meric-Bernstam F, Yap T. Results of a phase I dose escalation study of ARQ 751 in adult subjects with advanced solid tumors with AKT1, 2, 3 genetic alterations, activating PI3K mutations, PTEN-null, or other known actionable PTEN mutations. AACR Annual Meeting 2018 78(13 Suppl), 2018. e-Pub 2018.
142. Piha-Paul SA, Fu S, Hong DS, Janku F, Karp DD, Naing A, Pant S, Rodon Ahnert J, Subbiah V, Tsimberidou AM, Yap TA, Meric-Bernstam F. Phase I study of the pan-HER inhibitor neratinib given in combination with everolimus, palbociclib or trametinib in advanced cancer subjects with EGFR mutation/amplification, HER2 mutation/amplification or HER3/4 mutation. ASCO Annual Meeting 2018 36(15_Suppl), 2018. e-Pub 2018.
143. Kheder E, Hess KR, Xing Y, Cortez MA, Subbiah V, Janku F, Fu S, Naing A, Karp DD, Piha-Paul SA, Yap TA, Pant S, Rodon Ahnert J, Tawbi HA, Welsh JW, Meric-Bernstam F, Hong DS. TP53 mutations and programmed cell death ligand-1 expression in solid tumors: Associations with clinical factors and outcomes. ASCO Annual Meeting 2018 36(15_Suppl), 2018. e-Pub 2018.
144. Tsimberidou AM, Hong DS, Wheler JJ, Falchook GS, Naing A, Fu S, Piha-Paul SA, Janku F, Cartwright C, Broaddus R, Nogueras-Gonzalez GM, Hwu P, Kurzrock R. Precision medicine: Clinical outcomes including long-term survival according to the pathway targeted and treatment period—The IMPACT study. ASCO Annual Meeting 2018 36(15_Suppl), 2018. e-Pub 2018.
145. Fountzilas E, Krishnan E, Janku F, Fu S, Karp DD, Naing A, Subbiah V, Hong DS, Piha-Paul SA, Vining DJ, Tsimberidou AM. A phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without systemic bevacizumab, for patients with advanced cancer and liver involvement. ASCO Annual Meeting 2018 36(15_Suppl), 2018. e-Pub 2018.
146. Pairawan SS, Hess KR, Janku F, Sanchez NS, Eng C, Damodaran S, Javle MM, Kaseb AO, Hong DS, Subbiah V, Fu S, Fogelman DR, Raymond VM, Lanman RB, Meric-Bernstam F. Cell-free circulating tumor DNA somatic alteration burden and its impact on survival in metastatic cancer. ASCO Annual Meeting 2018 36(15_Suppl), 2018. e-Pub 2018.
147. Alshawa A, Fujii T, Abu Sbeih H, Blechacz B, Bilen MA, Hess KR, Suarez-Almazor ME, Hong DS, Tsimberidou AM, Gong J, Stephen B, Subbiah V, Piha-Paul SA, Fu S, Mendoza TR, Thirumurthi S, Meric-Bernstam F, Naing A, Miller E. Hepatotoxicity in advanced cancer patients receiving immune-based cancer treatment. ASCO-SITC Clinical Immuno-Oncology Symposium 36(5S), 2018. e-Pub 2018.
148. Piha-Paul SA, Xiong WW, Moss T, Mostorino RM, Sedelmeier S, Hess K, Fu S, Hong DS, Janku F, Karp D, Naing A, Pant S, Rodon J, Subbiah V, Tsimberidou AM, Yap T, Javle M, Tapia C, Shaw KR, Eterovic K, Mills GB, Meric-Bernstam F. Phase II study of the PARP inhibitor talazoparib in advanced cancer patients with somatic alterations in BRCA1/2, mutations/deletions in PTEN or PTEN loss, aberrations in other BRCA pathway genes, and germline mutations in BRCA1/2 (not breast or ovarian cancer). AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 17(1 Suppl), 2018. e-Pub 2018.
149. Jassowicz A, Liu L, Huang H, Hong DS, Naing A, Subbiah V, Piha-Paul SA, Toung J, Vijayaraghavan R, Zhang R, Kang H, Fu S, Tsimberidou AM, Lu C, Eng C, Moulder S, Kopetz S, Amaria R, Meric-Bernstam F, Janku F. Targeted methylation sequencing of plasma cell-free DNA identifies patients with advanced breast, colorectal, non-small cell lung cancer, melanoma with poor outcomes. ESMO 2017 Congress 28(Suppl 5), 2017. e-Pub 2017.
150. Sen S, Hess K, Hong D, Naing A, Piha-Paul S, Janku F, Fu S, Liu H, Jiang Y, Khanji R, Karp D, Tsimberidou A, Tannier N, Meric-Bernstam F, Subbiah V. Development of a novel prognostic scoring system for patient selection in immune checkpoint inhibitor phase I clinical trials. AACR Annual Meeting 2017 77(13 Suppl), 2017. e-Pub 2017.
151. Kheder E, Huang HJ, Wu A, Hong DS, Piha-Paul SA, Karp DD, Fu S, Subbiah V, Tsimberidou AM, Naing A, Diab A, Javle M, Kopetz S, Sood AK, Kurie JM, Meric-Bernstam F, Gleeson M, Janku F. Detection of circulating antibodies against KRAS in patients with advanced cancers. AACR Annual Meeting 2017 77(13_Suppl), 2017. e-Pub 2017.
152. Fu S, Piccioni DE, Liu H, Lukas RV, Aregawi D, Yamaguchi K, Whicher K, Chen Y-L, Poola N, Eddy J, Zhang I, Blum D. Initial phase 1 study of WT2725 dosing emulsion in patients with advanced malignancies. 2017 ASCO Annual Meeting 35(15_suppl), 2017. e-Pub 2017.
153. Papadopoulos KP, Tsai FY-C, Bauer TM, Muigai L, Liang Y, Bennett MK, Orford KW, Fu S. CX-1158-101: A first-in-human phase 1 study of CB-1158, a small molecule inhibitor of arginase, as monotherapy and in combination with an anti-PD-1 checkpoint inhibitor in patients (pts) with solid tumors. 2017 ASCO Annual Meeting 35(15_suppl), 2017. e-Pub 2017.
154. Naing A, Lopez-Berestein G, Fu S, Tsimberidou AM, Pant S, Piha-Paul SA, Janku F, Hong DS, Sulovic S, Meng X, Jazaeri AA, Ng CS, Karp DD, Subbiah V, Meric-Bernstam F, Mitra R, Wu S, Sood A, Coleman RL. EphA2 gene targeting using neutral liposomal small interfering RNA (EPHARNA) delivery: A phase I clinical trial. 2017 ASCO Annual Meeting 35(15_suppl), 2017. e-Pub 2017.
155. Sen S, Piha-Paul SA, Kato S, Karp DD, Janku F, Fu S, Pant S, Tsimberidou AM, Subbiah V, Kurzrock R, Meric-Bernstam F, Hong DS. Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in advanced cancers. 2017 ASCO Annual Meeting 35(15_suppl), 2017. e-Pub 2017.
156. Tsimberidou AM, Hong DS, Cartwright C, Wheler JJ, Falchook GS, Naing A, Fu S, Piha-Paul SA, Janku F, Hwu P, Kee BK, Kies MS, Broaddus R, Mendelsohn J, Hess KR, Kurzrock R. Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson precision medicine study. 2017 ASCO Annual Meeting 35(15_suppl), 2017. e-Pub 2017.
157. Varadhachary GR, Singh Raghav KP, Pant S, Janku F, Fu S, Hong DS, Piha-Paul SA, Colen RR, Subbiah V, Painter J, Tsimberidou AM, Stephen B, Karp DD, McQuinn L, Mendoza TR, Hess KR, Meric-Bernstam F, Naing A. Phase II study for the evaluation of efficacy of pembrolizumab (MK-3475) in patients with cancer of unknown primary. 2017 ASCO Annual Meeting 35(15_suppl), 2017. e-Pub 2017.
158. Pant S, Wheler JJ, Fu S, Hong DS, Karp DD, Subbiah V, Tsimberidou AM, Holley VR, Brewster AM, Koenig KH, Ibrahim NK, Murthy RK, Meric-Bernstam F, Janku F. Proof-of concept phase I study of everolimus, letrozole and trastuzumab in hormone receptor-positive, HER2-positive/amplified or mutant metastatic breast cancer or other solid tumors: Evaluating synergy and overcoming resistance. 2017 ASCO Annual Meeting 35(15 Suppl), 2017. e-Pub 2017.
159. Naing A, Fu S, Tsimberidou AM, Pant S, Piha-Paul SA, Janku F, Hong DS, Colen RR, Carter BW, Evans E, Tawbi HAH, Karp DD, Subbiah V, Dev R, Hess KR, Ueno NT, Simon GR, Overman MJ, Coleman RL, Meric-Bernstam F. Phase IB study to evaluate the safety of selinexor in combination with multiple standard chemotherapy agents in patients with advanced malignancies. 2017 ASCO Annual Meeting 35(15_suppl), 2017. e-Pub 2017.
160. Moehrmann L, Huang HJ, Hong DS, Tsimberidou AM, Fu S, Piha-Paul SA, Subbiah V, Karp DD, Naing A, Krug A, Enderle D, Priewasser T, Noerholm M, Eng C, Kopetz S, Skog J, Meric-Bernstam F, Janku F. Liquid biopsies of plasma exosomal nucleic acids, plasma cell-free DNA, and survival of patients with advanced cancers. 2017 ASCO Annual Meeting 35(15_suppl), 2017. e-Pub 2017.
161. Janku F, De Groot JF, Javle MM, Penas-Prado M, Shroff RT, Luthra R, Banks K, Lanman RB, Conley AP, Braoddus R, Davies MA, Kopetz S, Yung WKA, Heymach J, Fu S, Shaw KR, Meric-Bernstam F. Simultaneous molecular alterations in solid tumors with IDH1 or IDH2 mutations. 2017 ASCO Annual Meeting 35(15_suppl), 2017. e-Pub 2017.
162. Pant S, Wheler JJ, Fu S, Hong DS, Karp DD, Subbiah V, Tsimberidou AM, Holley VR, Brewster AM, Koenig KH, Ibrahim NK, Murthy RK, Meric-Bernstam F, Janku F. Proof-of concept phase I study of everolimus, letrozole and trastuzumab in hormone receptor-positive, HER2-positive/amplified or mutant metastatic breast cancer or other solid tumors: Evaluating synergy and overcoming resistance. 2017 ASCO Annual Meeting 35(15 Suppl), 2017. e-Pub 2017.
163. Drilon A, Marwan F, Fu S, Patel MR, Olszanski AJ, Lochkart AC, Liu SV, Bazhenova L, Seery T, Nikolinakos P, Patel R, Oliver JW, Multani PS, Wang D. A phase 1/1b study of RXDX-105, an oral RET and BRAF inhibitor, in patients with advanced solid tumors. 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 68(Suppl 1), 2016. e-Pub 2016.
164. Fu S, Bauer T, Molineaux C, Bennett MK, Orford KW, Papadopoulos KP. CX-1158-101: a first-in-human phase I study of a small molecule inhibitor of arginase (CB-1158) as monotherapy and in combination with an anti-PD-1 checkpoint inhibitor in patients with solid tumors. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016) 4(Suppl 1):86, 2016. e-Pub 2016.
165. Fu S, Hirte HH, Welch S, Ilenchuck TT, Dugourd D, Lutes T, Rice C, Stewart JM. A phase I open-label, dose escalation study of a novel peptide (SOR-C13) antagonistic to the TRPV6 ion channel in patients with advanced solid tumor cancers. AACR Annual Meeting 2016 76(14 Suppl), 2016. e-Pub 2016.
166. Fujii T, Vibat CR, Karp DD, Piha-Paul SA, Subbiah V, Tsimberidou AM, Fu S, Hong DS, Huang HJ, Madwani K, Andrews DL, Hancock S, Naing A, Luthra R, Kee BK, Kopetz S, Erlander MG, Melnikova V, Meric-Bernstam F, Janku F. Circulating tumor DNA assay performance for detection and monitoring of KRAS mutations in urine from patients with advanced cancers. AACR Annual Meeting 2016 76(14 Suppl), 2016. e-Pub 2016.
167. Madwani K, Huang HJ, Shelton DN, Fu S, Tsimberidou AM, Piha-Paul SA, Naing A, Hong DS, Karp DD, Andrews DL, Cabrillo G, Kopetz ES, Luthra R, Kee BK, Eng C, Morris VK, Karlin-Neumann GA, Meric-Bernstam F, Janku F. Quantity of KRAS mutations in cell-free DNA is associated with survival of patients with advanced cancers. AACR Annual Meeting 2016 76(14 Suppl), 2016. e-Pub 2016.
168. Cascone T, Hess KR, Piha-Paul SA, Hong DS, Subbiah IM, Bhatt T, Fu S, Naing A, Janku F, Karp DD, Meric-Bernstam F, Heymach J, Subbiah V. Safety, toxicity and activity of multi-kinase inhibitor vandetanib in combination with everolimus in advanced solid tumors. J Clin Oncol, 2016 ASCO Annual Meeting 34(15s), 2016. e-Pub 2016.
169. Reilley M, Biley AM, Subbiah V, Janku F, Naing A, Falchook GS, Karp DD, Piha-Paul SA, Tsimberidou AM, Fu S, Zinner R, Lim JA, Bean SA, Bass A, Montez S, Vence LM, Sharma P, Allison JP, Meric-Bernstam F, Hong DS. Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies. J Clin Oncol, 2016 ASCO Annual Meeting 34(15s), 2016. e-Pub 2016.
170. Westin SN, Stashi E, Pal N, Urbauer DL, Janku F, Piha-Paul SA, Naing A, Tsimiberidou AM, Fu S, Hong DS, Subbiah V, Karp DD, Coleman RL, Meric-Bernstam F, Kurzrock R. Phase I trial of paclitaxel, bevacizumab, and temsirolimus in advanced solid malignancies. J Clin Oncol, 2016 ASCO Annual Meeting 34(15s), 2016. e-Pub 2016.
171. Janku F, Madwani K, Zhang S, Huang HJ, Andrews DL, Hong DS, Karp DD, Fu S, Cai Z, Zhao Y, J-B F, Waters J, Toung J, Liu L, M-JR S, Mills GB, Salathia N. Ultra-deep next-generation sequencing of plasma cell-free (cf) DNA from patients with advanced cancers. J Clin Oncol, 2016 ASCO Annual Meeting 34(15s), 2016. e-Pub 2016.
172. Tang C, Welsh JW, de Groot P, Massarelli E, Chang JY, Hess KR, Curan MA, Cabanillas ME, Subbiah V, Fu S, Tsimberidou AM, Karp DD, Gomez DR, Komaki R, Sharma P, Naing A, Hong DS. Phase I trial combining ipilimumab + high dose stereotactic radiation: Results and serum immune correlates. J Clin Oncol, 2016 ASCO Annual Meeting 34(15s), 2016. e-Pub 2016.
173. Patel MR, Fakih M, Olszanski AJ, Lockhart AC, Drilon AE, Fu S, Bazhenova L, Patel R, Oliver JW, Multani PS, Wang D. A phase 1 dose escalation study of RXDX-105, an oral RET and BRAF inhibitor, in patients with advanced solid tumors. J Clin Oncol, 2016 ASCO Annual Meeting 34(15s), 2016. e-Pub 2016.
174. Dembla V, Fu S, Wheler J, Hong DS, Janku F, Zinner R, Piha-Paul SA, Ravi V, Benjamin RS, Patel S, Somaiah N, Herzgog CE, Karp DD, Meric-Bernstam F, Subbiah V. Outcomes of patients with advanced sarcoma enrolled in clinical trials of pazopanib in combination with histone deacetylase, mTOR, Her2, or MEK inhibitors. 2016 ASCO Annual Meeting 34(15 suppl), 2016. e-Pub 2016.
175. Janku F, Hong DS, Atkins JT, Karp DD, Tsiimberidou AM, Piha-Paul SA, Subbiah V, Naing A, Fu S, Moulder SL, Tripathy D, Meric-Bernstam F, Wheler JJ. Everolimus, Letrozole and Trastuzumab in estrogen receptor and HER2-positive patients with metastatic breast cancer and other solid tumors: Evaluating synergy and overcoming resistance. Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium 76(4 Suppl), 2016. e-Pub 2016.
176. Khawaja MR, Madhusudanannair V, Ng C, Nick A, Janku F, Piha-Paul S, Coleman R, Soliman P, Fu S, Hong D, Karp D, Subbiah V, Tsimberidou A, Meric-Bernstam F, Lu K, Naing A. Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced cancers. AACR-NCI-EORTC - 27th International Symposium 14(12_Suppl_2), 2015. e-Pub 2015.
177. Subbiah V, Hong DS, Amini B, Piha-Paul S, Fernandez JG, Fu S, Tsimberidou AM, Naing A, Janku F, Karp DD, Overman M, Eng C, Kopetz S, Meric-Bernstam F, Falchook GS. Phase I dose escalation study of the oral multi-kinase VEGF inhibitor regorafenib and the anti-EGFR monoclonal antibody cetuximab in patients with advanced solid tumors including colorectal cancer. AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics 14(12_Suppl_2), 2015. e-Pub 2015.
178. Morris V, Janku F, Huang H, Fu S, Overman M, Piha-Paul S, Subbiah V, Kee B, Tsimberidou AM, Fogelman D, Shurieqi I, Manuel S, Scamardo A, Lanman R, Sommer N, Hong D, Kopetz S. Circulating cell-free DNA as a marker for response and resistance to BRAF and EGFR inhibition in BRAF-mutated metastatic colorectal cancer. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics 14(12_Suppl_2), 2015. e-Pub 2015.
179. Cascone T, Hess KR, Piha-Paul S, Hong DS, Roxas M, Subbiah IM, Fu S, Naing A, Janku F, Karp D, Sherman SI, Meric-Bernstam F, Heymach JV, Subbiah V. A phase I study of everolimus (mTOR inhibitor) in combination with vandetanib (multikinase inhibitor of VEGFR, EGFR, and RET) in advanced solid tumors including molecularly matched aberrations. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics 14(12_Suppl_2), 2015. e-Pub 2015.
180. Tang C, Naing A, de Groot P, Chang JY, Massarelli E, Parkhurst K, Erdman D, Barrientes S, Fok J, Subbiah V, Fu S, Tsimberidou A, Karp D, Gomez DR, Heymach J, Hahn SM, Komaki RU, Hong DS, Welsh JW. Phase 1 study of ipilimumab and stereotactic radiation targeting liver or lung lesions in patients with advanced malignancies. American Society for Radiation Oncology 57th Annual Meeting 93(3_Suppl), 2015. e-Pub 2015.
181. Janku F, Huang HJ, Claes B, Falchook GS, Fu S, Tsimberidou AM, Hong DS, Naing A, Wheler JJ, Piha-Paul SA, Karp DD, Subbiah V, Zinner RG, Ramzanali N, Luthra R, Patel SP, Kopetz ES, Sablon E, Maertens G, Kurzrock R, Meric-Bernstam F. Rapid, automated BRAF mutation testing of cell-free DNA from plasma of patients with advanced cancers using the novel Idylla platform. 106th Annual Meeting of the AACR 75(15 Suppl), 2015. e-Pub 2015.
182. Huang HJ, Shelton DN, Fu S, Piha-Paul SA, Tsimberidou AM, Zinner RG, Wheler JJ, Naing A, Hong DS, Falchook GS, Kopetz S, Luthra R, Kee BK, Karlin-Neumann GA, Meric-Bernstam F, Janku F. Multiplex KRAS G12/G13 mutation testing of 16ng of unamplified cell-free DNA from plasma of patients with advanced cancers using Droplet Digital PCR. 106th Annual Meeting of the AACR 2015 75(15 Suppl), 2015. e-Pub 2015.
183. Subbiah V, Murthy R, Hong DS, Brown RE, Prins R, Hosing C, McGuire M, Naing A, Fu S, Chou T, Lin Q, Guevarra RP, Conley A, Kaur I, Meric-Bernstam F, Bosch M. Clinical and immunopathological effects following image-guided intratumoral injection of activated autologous dendritic cells in patients with advanced solid cancers. 106th Annual Meeting of the AACR 75(15 Suppl), 2015. e-Pub 2015.
184. Sakamuri D, Betancourt Cuellar SL, Glitza IC, Fu S, Wheler JJ, Falchook GS, Tsimberidou AM, Hong DS, Subbiah V, Fanale MA, Cabanillas ME, Meric-Bernstam F, Janku F. Phase 1 study: Ipilimumab (anti CTLA-4) in combination with Lenalidomide in patients with advanced cancers. 106 Annual Meeting of the AACR 2015 75(15 Suppl), 2015. e-Pub 2015.
185. Piha-Paul S, Goldstein J, Hess K, Fu S, Hong DS, Janku F, Karp D, Naing A, Subbiah V, Tsimberidou AM, Wheler JJ, Zinner R, Mills GB, Meric-Bernstam F. Phase II Study of the PARP Inhibitor Talazoparib (BMN-673) in advanced cancer patients with somatic alterations in BRCA1/2, mutations/deletions in PTEN or PTEN loss, a homologous recombination defect, mutations/deletions in other BRCA pathway genes and germline mutation S in BRCA1/2 (not breast or ovarian cancer). J Clin Oncol, 2015 ASCO Annual Meeting 33(15s), 2015. e-Pub 2015.
186. Janku F, Huang HJ, Ramzanali NM, Hong DS, Karp DD, Fu S, Cai Z, Zhao Y, Salathia N, Waters J, Liu L, Meric-Bernstam F, Mills GB, J-B F. Ultra-deep next-generation sequencing of plasma cell-free (cf) DNA from patients with advanced cancers. J Clin Oncol, 2015 ASCO Annual Meeting 33(15s), 2015. e-Pub 2015.
187. Falchook GS, Kurzrock R, Amin HM, Fu S, Piha-Paul SA, Janku F, Zheng H, Sarholz B, Johne A, Hong DS. Efficacy, safety, biomarkers, and phase II dose modeling in a phase I trial of the oral selective c-Met inhibitor tepotinib (MSC2156119J). J Clin Oncol, 2015 ASCO Annual Meeting 33(15s), 2015. e-Pub 2015.
188. Hong DS, Morris VK, El Osta BE, Fu S, Overman MJ, Piha-Paul SA, Subbiah V, Kee BK, Tsimberidou AM, Zinner R, Fogelman DR, Bellido J, Shureiqi I, Meric-Bernstam F, Kopetz S. Phase Ib study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated metastatic colorectal cancer and advanced cancers. J Clin Oncol, 2015 ASCO Annual Meeting 33(15s), 2015. e-Pub 2015.
189. Park H, Garrido-Laguna I, Naing A, Fu S, Falchook GS, Piha-Paul SA, Wheler JJ, Hong DS, Subbiah V, Tsimberidou AM, Kaseb AO, Oki Y, Zinner R, Patel S, Velez-Bravo VM, Fanale MA, Meric-Bernstam F, Kurzrock R, Janku F. Phase I study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancies. J Clin Oncol, 2015 ASCO Annual Meeting 33(15s), 2015. e-Pub 2015.
190. Naing A, Fu S, Habra MA, Chugh R, Kebebew E, Russell J, Welshans D, Fassnacht M, Kroiss M, M-E G, Ijzerman M, Plaunt MR, Mohideen P, Phillips M, Smith DC. ATR-101 phase 1 clinical study for adrenocortical carcinoma. J Clin Oncol, 2015 ASCO Annual Meeting 33(15s), 2015. e-Pub 2015.
191. Kato S, Fontes Jardim DL, Johnson FM, Subbiah V, Piha-Paul SA, Tsimberdiou AM, Falchook GS, Karp DD, Wheler JJ, Zinner R, Janku F, Fu S, Dandu L, Browne E, Meric-Bernstam F, Hong DS. Phase I study of combination of crizotinib (C) and dasatinib (D) in patients (pts) with advanced cancer. J Clin Oncol, 2015 ASCO Annual Meeting 33(15s), 2015. e-Pub 2015.
192. Wheler JJ, Yelensky R, Stephen B, Hong DS, Zinner R, Subbiah V, Fu S, Karp DD, Falchook GS, Naing A, Tsimberidou AM, Piha-Paul SA, Janku F, Li Y, Lee JJ, Miller VA, Meric-Bernstam F, Kurzrock R. Prospective study comparing outcomes in patients with advanced malignancies on molecular alteration-matched versus non-matched therapy. J Clin Oncol, 2015 ASCO Annual Meeting 33(15s), 2015. e-Pub 2015.
193. Wagner M, Hess KR, Hong DS, Tang C, Naing A, Fu S, Janku F, Piha-Paul SA, Zinner R, Wheler JJ, Tsimberidou AM, Patel S, Somaiah N, Ravi V, Benjamin RS, Meric-Bernstam F, Subbiah V. Validation of the Royal Marsden Hospital (RMH) prognostic score in 100 patients with advanced sarcoma enrolled in early phase clinical trials at a major cancer center. J Clin Oncol, 2015 ASCO Annual Meeting 33(15s), 2015. e-Pub 2015.
194. Rodrigues HV, Lim JA, Stephen B, Janku F, Tsimberidou AM, Piha-Paul SA, Fu S, Subbiah V, Falchook GS, Kurzrock R, Wheler JJ. Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy. J Clin Oncol, 2015 ASCo Annual Meeting 33(15s), 2015. e-Pub 2015.
195. Wheler J, Janku F, Moulder SL, Naing A, Piha-Paul SA, Falchook GS, Zinner R, Tsimberidou AM, Fu S, Hong DS, Atkins JT, Yelensky R, Miller V, Stephens PJ, Valero V, Meric-Bernstam F, Kurzrock R. Anastrozole and everolimus in hormone receptor-positive metastatic breast cancer: Activity and Associations with Molecular Alterations in the PI3K/AKT/mTOR Pathway. Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) 75(9 Suppl), 2015. e-Pub 2015.
196. Goldstein JB, Tang C, Hong DS, Subbiah V, Janku F, Hess KR, Fu S, Karp DD, Naing A, Tsimberidou AM, Wheler JJ, Zinner R, Javle MM, Varadhachary GR, Wolff RA, Fogelman DR, Meric-Bernstam F, Piha-Paul SA. Evolution of phase 1 trials for patients with advanced pancreatic cancer: An update on the experience from MD Anderson Cancer Center. J Clin Oncol, 2015 Gastrointestinal Cancers Symposium 33(3s), 2015. e-Pub 2015.
197. Janku F, Huang HJ, Claes B, Falchook GS, Naing A, Piha-Paul S, Tsimberidou AM, Zinner RG, Karp DD, Fu S, Subbiah V, Hong DS, Wheler JJ, Luthra RG, Patel SP, Kopetz ES, Sablon E, Maertens G, Kurzrock R, Meric-Bernstam F. BRAF mutation testing in cell-free DNA from plasma of patients with advanced cancers using a novel, rapid, automated molecular diagnostics prototype platform (Idylia™). 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 50(Suppl 6):56-57, 2014. e-Pub 2014.
198. Liu X, Hou M, Wheler J, Naing A, Hong D, Tsimberidou AM, Piha-Paul SA, Zinner R, Falchook G, Janku F, Ramondetta L, Schmeler K, Lu K, Kurzrock R, Fu S. Differential effect of PIK3CA mutations and PTEN loss in patients with advanced endometrial cancers on matched therapy. Cancer Res 74(19S), 2014. e-Pub 2014.
199. Falchook GS, Hong DS, Amin HM, Fu S, Piha-Paul SA, Janku F, Granada JG, Zheng H, Klevesath MB, Kohler K, Bladt F, Johne A, Kurzrock R. MSC2156119J (EMD 1214063), an oral selective c-Met inhibitor, in patients with advanced solid tumors: results of the first-in-human phase I trial. Cancer Res 74(19S), 2014. e-Pub 2014.
200. Tang C, Jardim DF, De Melo Galgiato D, Falchook GS, Hess K, Fu S, Wheler JJ, Zinner RG, Naing A, Tsimberidou AM, Meric-Bernstam F, Hong DS. Analysis of 1115 patients tested for MET amplification and therapy response in the MD Anderson phase I clinic. Cancer res 74(19S), 2014. e-Pub 2014.
201. Tsimberidou AM, Culotta K, Wistuba I, Fu S, Naing A, Falchook GS, Piha-Paul S, Zinner RG, Siddik ZH, He G, Said R, Hess K, Stewart D, Kurzrock R, J-P I. Phase I study of 5-azacytidine and oxaliplatin in patients with advanced cancers relapsed or refractory to platinum compounds. Cancer Res 74(19S), 2014. e-Pub 2014.
202. Janku F, Falchook GS, Piha-Paul SA, Naing A, Holley VR, Hong DS, Subbiah V, Karp DD, Zinner RG, Fu S, Wheler JJ, Meric-Bernstam F, Stepanek VM, Luthra R, l L, Hassaine L, Kosco K, Erlander MG. Digital droplet PCR detection and monitoring of BRAF mutations in cell-free urinary DNA of patients with metastatic cancers or Erdheim-Chester disease. Cancer Res 74(19S), 2014. e-Pub 2014.
203. Janku F, Legendre B, Richardson K, Falchook GS, Naing A, Holley VR, Fu S, Hong DS, Piha-Paul SA, Wheler JJ, Zinner RG, Subbiah V, Tsimberidou AM, Karp DD, Stepanek VM, Cabrilo G, Luthra R, Meric-Bernstam F, Bedikian AY, Kee BK, Eng C, Overman MJ, Kim KB, Kruempel A, Pope J, Cubrich C, Wu G, Shi Y, Lewis M, Kurzrock R. BRAF and KRAS mutation testing in plasma cell-free DNA with ICE-COLD PCR in patients with advanced cancers. Cancer Res 74(19S), 2014. e-Pub 2014.
204. Janku F, Falchook GS, Piha-Paul SA, Naing A, Holley VR, Hong DS, Subbiah V, Karp DD, Zinner RG, Fu S, Wheler JJ, Meric-Bernstam F, Stepanek VM, Luthra R, Leppin L, Hassaine L, Kosco K, Poole JC, Vibat CRT, Erlander MG. Droplet digital PCR detection and longitudinal monitoring of BRAF mutations in cell-free urinary DNA of patients with metastatic cancers or Erdheim-Chester disease. AACR Annual Meeting 2014 74(19_Suppl), 2014. e-Pub 2014.
205. Falchook GS, Hong DS, Amin HM, Fu S, Piha-Paul SA, Janku F, Zheng H, Bladt F, Johne A, Kurzrock R. First-in-human phase I trial assessing the highly selective c-Met inhibitor MSC2156119J (EMD 1214063) in patients with advanced solid tumors. ESMO Congress 2014 25(suppl_4), 2014. e-Pub 2014.
206. Naing A, Habra MA, Fu S, Piha-Paul SA, Lizerman M, Hein JP, Phillips M, Smith DC. Phase 1 study of ATR-101 in adrenocortical carcinoma (ACC): ATR-101-001. J Clin Oncol, 2014 ASCO Annual meeting Abstracts 32(15s), 2014. e-Pub 2014.
207. Wheler JJ, Janku F, Atkins JT, Moulder SL, Zinner R, Lee JJ, Falchook GS, Tsimberidou AM, Piha-Paul SA, Karp DD, Naing A, Fu S, Hong DS, Subbiah V, Stephens PJ, Yelensky R, Miller VA, Valero V, Kurzrock R, Meric-Bernstam F. PI3K/AKT/mTOR genomic alterations in 94 patients with metastatic breast cancer in the phase I clinic at MD Anderson: Prevalence and association with response. J Clin Oncol, 2014 ASCO Annual Meeting Abstracts 32(15s), 2014. e-Pub 2014.
208. Liu X, George GC, Tsimberidou AM, Naing A, Wheler JJ, Kopetz S, Fu S, Piha-Paul SA, Eng C, Falchook GS, Janku F, Garrett CR, Karp DD, Kurzrock R, Zinner R, Singh Raghav KP, Subbiah V, Meric-Bernstam F, Hong DS, Overman MJ. Rechallenge with anti-EGFR–based therapy in metastatic colorectal cancer: Impact of intervening time interval and prior anti-EGFR response. J Clin Oncol, 2014 ASCO Annual Meeting Abstracts 32(15s), 2014. e-Pub 2014.
209. Huang M, Parkhurst KL, Jiang Y, Moulder SL, Naing A, Wheler JJ, Hong DS, Piha-Paul SA, Fu S, Tsimberidou AM, Zinner R, Janku F, Kurzrock R, Falchook GS. HER2 extracellular domain (ECD) and HER2 single nucleotide polymorphisms (SNPs) in patients treated with combination trastuzumab, lapatinib, and bevacizumab. J Clin Oncol, 2014 ASCO Annual meeting Abstracts 32(15s), 2014. e-Pub 2014.
210. Hong DS, Morris VK, Fu S, Overman MJ, Piha-Paul SA, Kee BK, Zinner R, Fogelman DR, Mistry R, Shureiqi I, Meric-Bernstam F, Kopetz S. Phase 1B study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated advanced cancers and metastatic colorectal cancer. J Clin Oncol, 2014 ASCO Annual Meeting Abstracts 32(15s), 2014. e-Pub 2014.
211. Legendre BL, Richardson K Falchook GS, Naing A, Holley VR, Fu S, Hong DS, Piha-Paul SA, Wheler JJ, Zinner R Subbiah V, Tsimberidou AM, Luthra R, Meric-Bernstam F, Bedikian AY, Eng C, Melnikova V, Lewis M, Kurzrock R, Janku F. BRAF and KRAS mutation testing in plasma cell-free DNA with ICE COLD-PCR in patients with advanced cancers. J Clin Oncol, 2014 ASCO Annual Meeting Abstracts 32(15s), 2014. e-Pub 2014.
212. Fu S, Nguyen E, Janku F, Subbiah V, Patel SP, Falchook GS, Zinner R Tsimberidou AM, Hong DS, Piha-Paul SA, Wheler JJ, Shi N, Bomalaski JS, Hwu P, Meric-Bernstam. Targeting argininosuccinate synthetase-deficient advanced solid tumors in a phase I trial of ADI-PEG20 plus cisplatin. J Clin Oncol, 2014 ASCO Annual Meeting Abstracts 32(15s), 2014. e-Pub 2014.
213. Bupathi M, Falchook GS, Hong DS, Subbiah IM, Piha-Paul SA, Karp DD, Saigal B, Zinner R, Wheler JJ, Tsimberidou AM, Fu S, Sherman S, Meric-Bernstam F, Subbiah V. A phase I trial of vandetanib (multikinase inhibitor of EGFR, VEGFR, and RET) in combination with everolimus (mTOR inhibitor) in patients with advanced malignancies. J Clin Oncol, 2014 ASCO Annual Meeting Abstracts 32(15s), 2014. e-Pub 2014.
214. Hou M, Bellido J, Naing A, Falchook GS, Hess KR, Zinner R, Wheler JJ, Subbiah V, Hong DS, Piha-Paul SA, Tsimberidou AM, Karp DD, Kurzrock R, Meric-Bernstam F, Fu S. A phase I trial of pazopanib and vorinostat: The role of TP53 mutations. J Clin Oncol, 2014 ASCO Annual Meeting Abstracts 32(15s), 2014. e-Pub 2014.
215. Huang HJ, Claes B, Falchook GS, Naing A, Piha-Paul SA, Tsimberidou AM, Zinner R, Karp DD, Fu S, Subbiah V, Hong DS, Wheler JJ, Luthra R, Kee BK, Overman MJ, Kim K, Maertens GG, Kurzrock R, Meric-Bernstam F, Janku F. BRAF mutation testing in cell-free DNA from plasma of patients with advanced cancers using a novel, rapid, automated molecular diagnostics platform (Idylla). J Clin Oncol, 2014 ASCO Annual Meeting Abstracts 32(15s), 2014. e-Pub 2014.
216. Boland GM, Piha-Paul SA, Brusco L, Herbich SM, Baggerly KA, Routbort M, Patel K, Luthra R, Naing A, Fu S, Falchook GS, Hong DS, Wheler JJ, Janku F, Shaw RK, Aldape KD, Mendelsohn J, Mills GB, Meric-Bernstam F. Clinical next-generation sequencing to identify actionable alterations in a phase I program. J Clin Oncol, 2014 ASCO Annual Meeting Abstracts 32(15s), 2014. e-Pub 2014.
217. Tsimberidou AM, Ye Y, Wheler JJ, Falchook GS, Hong DS, Naing A, Fu S, Kurzrock R, Piha-Paul SA, Janku F, Zinner R, Moulder SL, Subbiah V, Karp DD, Meric-Bernstam F, Hwu, P, Kies MS, Miller VA, Broaddus R, Hess KR. Genomic profiling and precision medicine in 3,745 patients with advanced cancer. J Clin Oncol, 2014 ASCO Annual Meeting Abstracts 32(15s), 2014. e-Pub 2014.
218. Falchook GS, Hong DS, Amin HM, Fu S, Piha-Paul SA, Janku F, Granda G, Zheng H, Klevesath MB, Köhler K, Bladt F, Johne A, Kurzrock R. Results of the first-in-human phase I trial assessing MSC2156119J (EMD 1214063), an oral selective c-Met inhibitor, in patients (pts) with advanced solid tumors. J Clin Oncol, 2014 ASCO Annual Meeting Abstracts 32(15s), 2014. e-Pub 2014.
219. Livingston JA, Hess KR, Fernandez JG, Naing A, Hong DS, Patel S, Anderson PM, Benjamin RS, Ludwig JA, Herzog CE, Fu S, Wheler JJ, Falchook GS, Tsimberidou AM, Piha-Paul SA, Janku F, Rohren E, Meric-Bernstam F, Kurzrock R, Subbiah V. Eliciting early-response signals from first-in-human clinical trials and validation of prognostic scores in aggressive biology bone cancers: The MD Anderson experience. 2014 ASCO Annual Meeting 32(15 suppl), 2014. e-Pub 2014.
220. Fontes Jardim DL, de Melo Gagliato D, Falchook GS, Wheler JJ, Zinner R, Janku F, Subbiah V, Piha-Paul SA, Fu S, Tannier NM, Gettys Corn P, Tang C, Hess KR, Roy-Chowdhuri S, Kurzrock R, Meric-Bernstam F, Hong DS. c-Met abnormalities in patients with genitourinary (GU) malignancies and outcomes with c-MET inhibitors. J Clin Oncol, 2014 Genitourinary Cancers Symposium 32(4s), 2014. e-Pub 2014.
221. Hou M-M, Liu X, Piha-Paul SA, Janku F, Wheler JJ, Naing A, Bodurka D, Schmeler K, Lu K, Zinner R, Hong DS, Meric-Bernstam F, Kurzrock R, Fu S. Target-matched therapies in patients with advanced cervical cancers harboring PIK3CA mutations and/or PTEN loss. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics 12(11_Suppl), 2013. e-Pub 2013.
222. Wheler JJ, Parker BA, Lee J, Yelensky R, Moulder S, Tsimberidou AM, Janku F, Atkins JT, Zinner R, Schwab RQ, Schwaederle M, Subbiah V, Fu S, Stephens PJ, Kurzrock R. Next generation sequencing (NGS) in 57 patients with advanced or metastatic breast cancer: Identification of unique genomic profiles and correlation with response. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics 12(11_Suppl), 2013. e-Pub 2013.
223. Abdelrahim M, Naing A, Dalal S, Wheler JJ, Hess K, Fu S, Hong DS, Janku F, Falchook GS, Ilustre A, Ouyang F, Kurzrock R. Olanzapine for cachexia in patients with advanced cancer. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics 12(11_Suppl), 2013. e-Pub 2013.
224. Janku F, Falchook GS, Piha-Paul SA, Naing A, Tsimberidou AM, Holley VR, Karp DD, Zinner RG, Fu S, Wheler JJ, Hong DS, Meric-Bernstam F, Stepanek VM, Luthra R, Leppin L, Hassaine L, Kosco K, Poole JC, Erlander MG. Detection and monitoring of BRAF and KRAS mutations in cell-free urinary DNA of metastatic cancer patients by droplet digital PCR. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics 12(11 Suppl), 2013. e-Pub 2013.
225. Janku F, Agenendt P, Naing A, Falchook GS, Tsimberidou AM, Holley VR, Fu S, Hong DS, Wheler JJ, Piha-Paul SA, Ra Z, Karp DD, Subbiah V, Kim KB, Meric-Bernstam F, Diehl F, Kurzrock R. Actionable mutations in cell-free DNA in plasma of patients with advanced cancers referred for experimental targeted therapies. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics 12(11_Suppl), 2013. e-Pub 2013.
226. Huang HJ, Claes B, Falchook GS, Tsimberidou AM, Holley VR, Subbiah V, Zinner RG, Naing A, Karp DD, Piha-Paul SA, Wheler JJ, Fu S, Hong DS, Stepanek VM, Luthra R, Meric-Bernstam F, Ivens T, Sablon E, Maertens G, Kee BK, Kurzrock R, Scherer S, Janku F. BRAF mutation testing in cell-free DNA from plasma of patients with advanced cancers using a novel, rapid, automated molecular diagnostics prototype platform. AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics 12(11_Suppl), 2013. e-Pub 2013.
227. Hou M, Liu X, Wheler JJ, Naing A, Hong DS, Bodurka DC, Schmeler KM, Tsimberidou AM, Janku F, Zinner R, Piha-Paul SA, Lu KH, Wolff, RA, Kurzrock R, Fu S. Outcome analyses of patients with metastatic cervical cancers in a phase I clinic. J Clin Oncol, 2013 ASCO Annual Meeting Abstracts 31(15s):Abst: e13534, 2013. e-Pub 2013.
228. Falchook GS, Hong DS, Amin HM, Fu S, Piha-Paul SA, Janku F, Subbiah V, Naing A, Wheler JJ, Klevesath MB, Kohler K, Johne A, Bladt F, Kurzrock F. Phase I study of oral selective c-Met inhibitor EMD 1214063 in pts with advanced solid tumors. J Clin Oncol, 2013 ASCO Annual Meeting Abstracts 31(15s), 2013. e-Pub 2013.
229. Subbiah IM, Wheler JJ, Hess KR, Hong DS, Fu S, Wolff RA, Kurzrock R, Tsimberidou AM. Outcomes of patients ≥ 65 yrs with advanced cancer treated on phase I clinical trials. J Clin Oncol, 2013 ASCO Annual Meeting Abstracts 31(15s), 2013. e-Pub 2013.
230. Falchook GS, Desai J, Leitch IM, Goldman JW, Wheler JJ, Fu S, Kurzrock R, Baldwin M, Rosen LS. Phase I study of VGX-100, an anti-VEGF-C monoclonal antibody, with or without bevacizumab, in patients (pts) with advanced solid tumors. J Clin Oncol, 2013 ASCO Annual Meeting Abstracts 31(15s), 2013. e-Pub 2013.
231. Liu X, Liu X, Hong DS, Hong DS, Fu S, Fu S, Piha-Paul SA, Piha-Paul SA, McQuinn L, McQuinn L, Falchook GS, Falchook GS, Williams J, Williams J, Karp DD, Karp DD, Subbiah V, Subbiah V, Tsimberidou AM, Tsimberidou AM, Janku F, Janku F, Zinner R, Zinner R, Wheler JJ, Wheler JJ, Rolf A, Rolf A, Kurzrock R, Kurzrock R. Incidence of mucositis in patients treated with mTOR inhibitor-based regimens and correlation to treatment response. J Clin Oncol 31(15s):Abst: e13575, 2013. e-Pub 2013.
232. Tsimberidou AM, Said R, Falchook GS, Janku F, Naing A, Zinner R, Blumenschein GR, Fu S, Hong DS, Piha-Paul SA, Wheler JJ, Ye Y, Hess KR, Palmer GA, Wolff RA, Kurzrock R. Outcomes of patients with advanced cancer and KRAS mutation in phase I clinical trials. J Clin Oncol, 2013 ASCO Annual Meeting Abstracts 31(15s), 2013. e-Pub 2013.
233. Said R, Ye Y, Hong DS, Janku F, Fu S, Naing A, Wheler JJ, Kurzrock R, Thomas C, Palmer GA, Hess KR, Wolff RA, Tsimberidou AM. Characteristics and survival of patients with advanced cancer and TP53 mutations in phase I clinical trials. J Clin Oncol, 2013 ASCO Annual meeting Abstracts 31(15s), 2013. e-Pub 2013.
234. Westin SN, Smart ML, Pal N, Urbauer DL, Janku F, Wheler JJ, Piha-Paul SA, Naing A, Tsimberidou AM, Fu S, Falchook GS, Hong DS, Zinner R, Subbiah V, Culotta KS, Lu KH, Coleman RL, Kurzrock R. Phase I trial of sorafenib, bevacizumab, and temsirolimus in advanced solid tumors. J Clin Oncol, 2013 ASCO Annual Meeting Abstracts 31(15s), 2013. e-Pub 2013.
235. Huang HJ, Devogelaere B, Falchook GS, Fu S, Angelo LS, Hong DS, Piha-Paul SA, Naing A, Holley VR, Tsimberidou AM, Stepanek VM, Kim K, Subbiah V, Wheler JJ, Zinner R, Wolff RA, Sablon E, Maertens G, Kurzrock R, Janku F. BRAF mutation testing with a novel, rapid, fully automated molecular diagnostics prototype platform. AACR 104th Annual Meeting 2013 31(15s), 2013. e-Pub 2013.
236. Wheler JJ, Moulder SL, Naing A, Janku F, Piha-Paul SA, Falchook GS, Zinner R, Tsimberidou AM, Fu S, Hong DS, Atkins JT, Cronin M, Yelensky R, Stephens P. A dose-escalation study of anastrozole and everolimus in patients with advanced gynecologic and breast malignancies: tolerance, biological activity, and molecular alterations in the PI3K/AKT/mTOR pathway. AACR 104th Annual Meeting 2013 73(8_Suppl), 2013. e-Pub 2013.
237. Janku F, Angelo LS, Devogelaere B, Falchook GS, Fu S, Huang HJ, Tsimberidou AM, Hong DS, Stepanek VM, Holley VR, Routbort MJ, Sablon E, Maertens G, Kurzrock R. BRAF mutation testing with a novel, rapid, fully-automated molecular diagnostics prototype platform. AACR 104th Annual Meeting 2013 73(8_Suppl), 2013. e-Pub 2013.
238. Subbiah IM, Janku F, Naing A, Fu S, Hong DS, Kaseb AO, Herzog C, Kurzrock R, Wolff RA, Subbiah V. Theranostic profiling of adolescents and young adults (AYA) with advanced fibrolamellar hepatocellular carcinoma identifies aberrant activation of the PI3K/AKT/MTOR signaling cascade. AACR 104th Annual Meeting 2013 73(8_Suppl), 2013. e-Pub 2013.
239. Agarwal R, Naing A, Falchook GS, Wheler JJ, Fu S, Kurzrock R. Retreatment after secondary resistance: A pilot study. AACR 104th Annual Meeting 2013 73(8_Suppl), 2013. e-Pub 2013.
240. Wheler JJ, Moulder SL, Naing A, Janku F, Piha-Paul SA, Falchook GS, Zinner R, Tsimberidou AM, Fu S, Hong DS, Atkins JT, Cronin M, Yelensky R, Stephens P. A dose-escalation study of anastrozole and everolimus in patients with advanced gynecologic and breast malignancies: tolerance, biological activity, and molecular alterations in the PI3K/AKT/mTOR pathway. AACR 104th Annual Meeting 2013 73(8_Suppl), 2013. e-Pub 2013.
241. Chae YK, Kim K, Hong DS, Falchook GS, Piha-Paul SA, Wheler JJ, Naing A, Fu S, Tsimberidou AM, Zinner RG, Subbiah V, Stepanek VM, Wolff RA, Kurzrock R, Janku F. PIK3CA mutation, aspirin use and mortality in patients with metastatic colorectal cancer participating in early-phase clinical trials. AACR 104th Annual Meeting 2013 73(8 Suppl), 2013. e-Pub 2013.
242. Ganesan P, Piha-Paul SA, Naing A, Falchook G, Wheler JJ, Fu S, Hong DS, Kurzrock R, Janku F, Laday S, Bedikian AY, Kies M, Wolff R, Tsimberidou AM. Phase I clinical trial of Lenalidomide in combination with Sorafenib in patients with advanced cancer. AACR 104th Annual Meeting 2013 73(8_Suppl), 2013. e-Pub 2013.
243. Subbiah IM, Subbiah V, Naing A, Fu S, Kaseb AO, Falchook GS, Tan D, Herzog CE, Janku F, Kurzrock R. Targeted therapies in early-phase trials for the treatment of advanced fibrolamellar hepatocellular carcinoma. J Clin Oncol, 2013 Gastrointestinal Cancers Symposium 31(4s), 2013. e-Pub 2013.
244. Janku F, Hong DS, Fu S, Piha-Paul SA, Naing A, Falchook GS, Tsimberidou AM, Stepanek VM, Wheler JJ, Kurzrock R. Aberrations in PIK3CA, PTEN, and MAPK (KRAS, NRAS, BRAF) in 1,656 patients and experience with early-phase protocols with PI3K/AKT/mTOR Inhibitors. 24 EORTC–NCI–AACR Symposium on Molecular Targets and Cancer Therapeutics 48(Suppl_6):76, 2012. e-Pub 2012.
245. Falchook GS, Hong DS, Amin HM, Fu S, Piha-Paul SA, Klevesath MB, Jego V, Johne A, Stinchi S, Kurzrock R. Phase I dose-escalation study of oral selective c-Met inhibitor EMD 1214063 in patients with advanced solid tumors. Ann Oncol 23(Suppl 9):IX154, 2012. e-Pub 2012.
246. Fu S, Nemunaitis JJ, Bessudo A, Bauman JE, Hamid O, Witta SE, Dy GK, Lai C, Laliberte R, Voi M. A phase Ib study of CUDC-101, a multitargeted inhibitor of EGFR, HER2, and HDAC, in patients with advanced head and neck, gastric, breast, liver, and non-small cell lung cancer. J Clin Oncol 30(15s):Abst: e13101, 2012. e-Pub 2012.
247. Bilen MA, Naing A, Hong DS, Falchook GS, Fu S, Wen J, Wheler JJ, Durand J, Ewer M, Kurzrock R. Association between elevated blood pressure and clinical response in patients treated with anti-vascular endothelial growth factor (anti-VEGF) therapy in phase I clinical trials. J Clin Oncol 30(15s):Abst: e13506, 2012. e-Pub 2012.
248. Subbiah IM, Tsimberidou AM, Naing A, Subbiah V, Kaseb AO, S <, Hong DS, Piha-Paul SA, Wheler JJ, Janku F, Hess KR, Falchook GS, Kurzrock R. Early-phase trials compared to first-and second-line FDA-approved treatments in patients with advanced gallbladder cancer and cholangiocarcinoma. J Clin Oncol 30(15s), 2012. e-Pub 2012.
249. Said R, Hong D, Wheler JJ, Naing A, Falchook GS, Sb F, Janku F, Zinner F, Piha-Paul SA, Warneke CL, Tsimberidou AM, Kurzrock R. p53 mutations in advanced cancers: Clinical characteristics and outcomes in a phase I setting. J Clin Oncol, 2012 ASCO Annual Meeting Abstracts 30(15s), 2012. e-Pub 2012.
250. Naing A, LoRusso P, Fu S, Hong DS, Chen H, Doyle LA, Phan A, Habra MA, Kurzrock R. Activity of insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic refractory adrenocortical carcinoma. J Clin Oncol, 2012 ASCO Annual Meeting 30(15s), 2012. e-Pub 2012.
251. Janku F, Broaddus R, Bakkar R, Hong DS, Stepanek VMT, Naing A, Falchook GS, Fu S, Wheler JJ, Piha-Paul SA, Moulder SL, Luthra R, Tsimberidou AM, Kurzrock R. PTEN assessment and PI3K/mTOR inhibitors: Importance of simultaneous assessment of MAPK pathway aberrations. ASCO 2012 Annual Meeting 30(15s), 2012. e-Pub 2012.
252. Madhusudanannair V, Janku F, Falchook GS, Hong DS, Wheler JJ, Naing A, Fu S Piha-Paul SA, El-Osta HE, Luthra R, Tsimberidou AM, Kurzrock R. NRAS mutations in patients with advanced cancers treated with target-based therapies in early-phase clinical trials. J Clin Oncol, 2012 ASCO Annual Meeting 30(15s), 2012. e-Pub 2012.
253. Henary HA, Hong DS, Falchook GS, Tsimberidou AM, George G, Wheler JJ, Fu S, Naing. Targeted agents matched with tumor molecular abberations: Review of 160 patients with advanced melanoma treated in a phase I clinic. J Clin Oncol, 2012 ASCO Annual Meeting Abstracts 30(15s), 2012. e-Pub 2012.
254. Amin HM, Falchook GS, Fu S, Hong DS, Tsimberidou AM, Naing A, Wheler JJ, Piha-Paul SA, Janku F, Klevesath MB, Jego V, Johne A, Kurzrock R. First-in-human phase I dose-escalation study of the oral selective C-met inhibitor EMD 1204831 in patients with advanced solid tumors. J Clin Oncol, 2012 ASCO Annual Meeting Abstracts 30(15s), 2012. e-Pub 2012.
255. Janku F, Wheler JJ, Piha-Paul SA, Stepanek VM, Fu S, Hong DS, Naing A, Falchook GS, Moulder SL, Luthra R, Tsimberidou AM, Kurzrock R. Target-based therapeutic matching in patients with PIK3CA mutations and PTEN aberrations. AACR 103rd Annual Meeting 2012 72(8_Suppl), 2012. e-Pub 2012.
256. Subbiah IM, Kurzrock R, Naing A, Piha-Paul SA, Falchook GS, Hong DS, Wheler JJ, Fu S, Laday S, Tsimberidou AM. A phase I study of lenalidomide in combination with bevacizumab, sorafenib, temsirolimus, or 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX) in patients with advanced cancers. AACR 103rd Annual Meeting 2012 72(8_Suppl), 2012. e-Pub 2012.
257. Subbiah IM, Tsimberidou AM, Naing A, Subbiah V, Kaseb AO, Falchook GS, Fu S, Hong DS, Piha-Paul SA, Wheler JJ, Janku F, Kurzrock R. Early-phase trials in patients with advanced gallbladder cancer and cholangiocarcinoma: The MD Anderson Clinical Center for Targeted Therapy experience. AACR 103rd Annual Meeting 2012 72(8_Suppl), 2012. e-Pub 2012.
258. Wheler JJ, Moulder S, Falchook GS, Janku F, Naing A, Fu S, Piha-Paul S, Tsimberidou AM, Kurzrock R. Treatment with hormonal blockade in estrogen receptor-positive tumors and correlation with molecular markers: a phase I pilot study of anastrozole in combination with everolimus, bevacizumab, sorafenib or erlotinib. AACR 103rd Annual Meeting 2012 72(8_Suppl), 2012. e-Pub 2012.
259. Naing A, LoRusso P, Subbiah V, Fu S, Hong DS, Anderson P, Benjamin R, Ludwig J, Chen HX, Doyle A, Kurzrock R. Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors. AACR 103rd Annual Meeting 2012 72(8_Suppl), 2012. e-Pub 2012.
260. Janku F, Naing A, Falchook GS, Tsimberidou AM, Stepanek VM, Fu S, Piha-Paul SA, Luthra R, Hong DS, Kurzrock R. Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations. J Clin Oncol, 2012 Gastrointestinal Cancers Symposium 30(4s), 2012. e-Pub 2012.
261. Subbiah IM, Subbiah V, Kaseb AO, Janku F, Wheler JJ, Naing A, bFu S, Piha-Paul SA, Hong DS, Falchook GS, Tsimberidou AM, Kurzrock R. Characteristics and outcomes of patients with gallbladder cancer and cholangiocarcinoma referred to a phase I clinic. J Clin Oncol, 2012 Gastrointestinal Cancers Symposium 30(4s), 2012. e-Pub 2012.
262. Falchook GS, Sarantopoulos J, Kurzrock R, Mita AC, Fu S, Mita MM, Zhou X, Milch C, Jung J, Venkatakrishnan K, Rosen LS. Phase 1 relative bioavailability study of a prototype oral solution (OS) formulation of the investigational Aurora A kinase (AAK) inhibitor alisertib (MLN8237) in reference to a powder-in-capsule (PIC) formulation in patients with advanced solid tumors. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics 10(11_Suppl), 2011. e-Pub 2011.
263. Hong DS, Naing A, Falchook GS, Piha-Paul SA, Wheler JJ, Fu S, Tsimberidou AM, Hui D, Scott R, Khan R, Mistry R, Talley J, Chauhan S, Bermudez D, Stecher M, Simard J, Kurzrock R. A phase I study of MABp1, a first-in-human, first-true human monoclonal antibody against the IL-1 in patients with advanced cancers. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics 10(11_Suppl), 2011. e-Pub 2011.
264. Janku F, Naing A, Stepanek VT, Falchook GS, Hong DS, Tsimberidou AM, Fu S, Lee JJ, Luthra R, Wheler JJ, Kurzrock R. PIK3CA mutations H1047R are associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics 10(11_Suppl), 2011. e-Pub 2011.
265. Sun M, Falchook GS, Wheler JJ, Hong DS, Piha-Paul SA, Tsimberidou AM, Naing A, Fu S, Moulder SL, Wen S, Mueller P, Kurzrock R. Association of VEGF single nucleotide polymorphisms (SNPs) with response and toxicity in patients treated with bevacizumab. J Clin Oncol, 2011 ASCO Annual Meeting Abstracts Part 1 29(15s):Abst: e13560, 2011. e-Pub 2011.
266. Fu S, Hong DS, Naing A, Wheler JJ, Falchook GS, Wen S, Howard A, Barber D, Nates JL, Price KJ, Kurzrock R. Outcome analyses after the first admission to an intensive care unit in patients with cancer enrolled into a phase I clinical trials program: When is the optimal time to trigger code status discussion?. J Clin Oncol, 2011 ASCO Annual Meeting Abstracts Part 1 29(15s):Abst: e13020, 2011. e-Pub 2011.
267. Kurzrock R, Patnaik A, Rosenstein L, Fu S, Papadopoulous KP, Smith DA, Falchook GS, Chambers G, Gauvin JL, Naing A, Smith LS, Gonzalez T, Tsimberidou AM, Mays TA, Cox DS, Hong DS, DeMarini DJ, Le NT, Morris SR, Tolcher AW. Phase I dose-escalation of the oral MEK1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral AKT inhibitor GSK2141795 (GSK795). J Clin Oncol, 2011 ASCO Annual Meeting Abstracts Part 1 29(15s), 2011. e-Pub 2011.
268. Munster PN, van der Noll R, Voest EE, Dees EC, Tan AR, Specht JM, Falchook GS, Daud A, Lolkema MP, Grilley-Olson JE, Yu EY, Fu S, Bergsland EK, Kleha J, Peng S, Smith DA, Lampkin TA, Schellens JHM, Morris SR, Kurzrock R. Phase I first-in-human study of the PI3 kinase inhibitor GSK2126458 (GSK458) in patients with advanced solid tumors (study P3K112826). J Clin Oncol, 2011 ASCO Annual Meeting Abstracts Part 1 29(15s), 2011. e-Pub 2011.
269. Westin JR, Fu S, Hong DS, Helgason T, Ouyang F, Angelo LS, Culotta KS, Westin SN, Kurzrock R. Validation of the phase 0 concept. J Clin Oncol, 2011 ASCo Annual Meeting Abstracts Part 1 29(15s), 2011. e-Pub 2011.
270. Veasey Rodrigues H, Naing A, Hong DS, Falchook GS, Fu S, Wheler JJ, Tsimberidou AM, Moulder SL, Janku F, Wen S, Fessahaye SN, Golden EC, Westerhold DI, Ewer M, Kurzrock R. The role of the electrocardiogram (ECG) in phase I drug development in patients with cancer: The University of Texas M. D. Anderson Cancer Center experience with 8,966 ECGs. J Clin Oncol, 2011 ASCO Annual Meeting Abstracts Part 1 29(15s), 2011. e-Pub 2011.
271. Naing A, LoRusso S, Fu S, Hong DS, Anderson PM, Benjamin RS, Ludwig JA, Chen HX, Doyle LA, Kurzrock R. Cixutumumab combined with temsirolimus in patients with refractory Ewing’s sarcoma. J Clin Oncol, 2011 ASCO Annual Meeting Abstracts Part 1 29(15s), 2011. e-Pub 2011.
272. Wheler JJ, Janku F, Jackson T, Fu S, Sun M, Yang H, Naing A, Moulder SL, Tsimberidou AM, Hong DS, Falchook GS, Piha-Paul SA, Garcia-Manero G, Kurzrock R. Phase I study of anti-VEGF monoclonal antibody bevacizumab and HDAC inhibitor valproic acid in patients with advanced cancers. J Clin Oncol, 2011 ASCO Annual Meeting Abstracts Part 1 29(15s), 2011. e-Pub 2011.
273. Garrido-Laguna I, Kurzrock R, Wheler JJ, Falchook GS, Piha-Paul SA, Fu S, Naing A, Hinojosa C, Mistry R, Scamardo A, Culotta KS, Ekmekcioglu S, Wen S, Camacho LH, Ivy SP, Hong DS. Dual inhibition of VEGF pathway: phase I trial of bevacizumab and cediranib in advanced solid tumors. J Clin Oncol, 2011 ASCO Annual Meeting Abstracts Part 1 29(15s), 2011. e-Pub 2011.
274. Janku F, Garrido-Laguna I, Wheler JJ, Hong DS, Naing A, Falchook GS, Fu S, Moulder SL, Luthra R, Lee JJ, Tsimberidou AM, Kurzrock R. Screening for PIK3CA mutations, PTEN loss, and RAS/RAF mutations in early-phase protocols with PI3K/mTOR pathway inhibitors. J Clin Oncol, 2011 ASCO Annual Meeting Abstracts Part 1 29(15s), 2011. e-Pub 2011.
275. Fok J, Kurzrock R, Tsimberidou AM, Wen S, Naing A, Hong DS, Janku F, Falchook GS, Piha-Paul SA, Katz R, Fu S, Moulder SL, Wheler JJ. An umbrella protocol for histology-independent, phase I modular study based on EGFR mutation status: Using erlotinib alone or in combination with cetuximab, bortezomib, or dasatinib to overcome resistance. J Clin Oncol, 2011 ASCO Annual Meeting Abstracts Part 1 29(15s), 2011. e-Pub 2011.
276. Stephen B, Wheler JJ, Tsimberidou AM, Wen S, Naing A, Hong DS, Falchook GS, Piha-Paul SA, Fu S, Janku F, Moulder SL, Kurzrock R. Survival of 1,181 patients in a phase I clinic: The University of Texas M. D. Anderson Cancer Center experience. J Clin Oncol, 2011 ASCO Annual Meeting Abstracts Part 1 29(15s), 2011. e-Pub 2011.
277. Tsimberidou AM, Iskander NG, Hong DS, Wheler JJ, Fu S, Piha-Paul SA, Naing A, Falchook GS, Janku F, Luthra R, Wen S, Kurzrock R. Personalized medicine in a phase I clinical trials program: The MD Anderson Cancer Center initiative. J Clin Oncol, 2011 ASCO Annual Meeting Abstracts Part 1 29(15s), 2011. e-Pub 2011.
278. Tsimiberidou AM, Hong DS, Wheler JJ, Fu S, Piha-Paul S, Naing A, Falchook GS, Luthra R, Iskander NG, Wen S, Kurzrock R. Initiative for Molecular Profile and Advanced Cancer Therapy (IMPACT): A personalized medicine Phase I clinical trials program at MD Anderson Cancer Center. AACR 102nd Annual Meeting 2011 71(8_Suppl), 2011. e-Pub 2011.
279. Garrido-Laguna I, Janku F, Falchook GS, Fu S, Naing A, Wheler JJ, Tsimberidou AM, Hong DS, Kurzrock R. K-ras mutations in colorectal cancer may predict a pattern of organ-specific metastasis. AACR 102nd Annual Meeting 2011 71(8_Suppl), 2011. e-Pub 2011.
280. Tsimberidou AM, Hong DS, Wheler JJ, Fu S, Piha-Paul SA, Naing A, Falchook GS, Luthra R, Iskander NG, Wen S, Kurzrock R. Profile-related evidence to determine individualized cancer therapy (PREDICT): Preliminary results of the Personalized Phase I Clinical Trials program at MD Anderson Cancer Center. AACR 102nd Annual Meeting 2011 71(8_Suppl), 2011. e-Pub 2011.
281. Janku F, Garrido-Laguna I, Tsimberidou AM, Naing A, Fu S, Falchook GS, Abraham SC, Hong DS, Kurzrock R. Loss of PTEN expression in patients treated with PI3K/AKT/mTOR signaling pathway inhibitors. AACR 102nd Annual Meeting 2011 71(8_Suppl), 2011. e-Pub 2011.
282. Garrido-Laguna I, Janku F, Falchook GS, Naing A, Fu S, Wheler JJ, Tsimberidou AM, Hong DS, Kurzrock R. Retrospective study to elucidate a K-ras phenotype in patients with colorectal cancer. J Clin Oncol, 2011 Gastrointestinal Cancers Symposium 29(4s), 2011. e-Pub 2011.
283. Janku F, Tsimberidou AM, Garrido-Laguna I, Hong DS, Naing AM, Falchook GS, Fu S, LUthra R, Wang X, Kurzrock R. Screening for PIK3CA, RAS, and RAF mutations in trials with PI3K/AKT/mTOR signaling pathway inhibitors. Eur J Cancer 8(7):83, 2010. e-Pub 2010.
284. Garrido-Laguna I, Janku F, Tsimberidou A, Wheler J, Falchook GS, Fu S, Hong DS, Naing A, Piha-Paul S, Kurzrock R. Phosphatase and tensin homologue (PTEN) loss and response to phase I trials targeting PI3K/AKT/mTOR pathway in patients with advanced cancer. J Clin Oncol, 2010 ASCO Annual Meeting 28(15s), 2010. e-Pub 2010.
285. Fu S, Naing A, Moulder S, Falchook G, Culotta K, Zhang Y, Madoff D, Ng C, Lim J, Kurzrock R. A phase I study of hepatic arterial infusion of nab-paclitaxel in patients with predominant hepatic metastases. J Clin Oncol 28(15S):Abst: e13044, 2010. e-Pub 2010.
286. Vaklavas C, Tsimberidou AM, Wen S, Fu S, Hong DS, Wheler J, Naing A, Uehara C, Wolff RA, Kurzrock R. Clinical outcomes and prognostic factors of hepatic arterial infusion (HAI) chemotherapy combination regimens in 202 patients with advanced cancer metastatic to the liver: The phase I program M. D. Anderson Cancer Center experience. J Clin Oncol, 2010 ASCO Annual Meeting 28(15 suppl):Abst: e13101, 2010. e-Pub 2010.
287. Janku F, Tsimberidou A, Garrido-Laguna I, Hong D, Naing A, Falchook G, Wheler J, Fu S, Piha-Paul S, Kurzrock R. PIK3CA, KRAS and BRAF mutations in patients with advanced cancers treated with PI3K/AKT/mTor axis inhibitors. J Clin Oncol, 2010 ASCO Annual Meeting 28(15S):224s, 2010. e-Pub 2010.
288. Bustinza-Linares E, Falchook GS, Fu S Naing A, Hong DS, Hu W, Moulder SL, Wheler JJ, Sood A, Kurzrock R. Phase I trial of sequential azacitidine and valproic acid plus carboplatin in the treatment of patients with advanced malignancies. J Clin Oncol, 2010 ASCO Annual Meeting 28(15S):227s, 2010. e-Pub 2010.
289. Wheler JJ, Tsimberidou AM, Wen S, Naing A, Hong DS, Falchook GS, Piha-Paul SA, Fu S, Moulder SL, Kurzrock R. Toxicity in 1,181 patients with advanced solid tumors treated in phase I clinical trials of predominantly targeted agents: The M. D. Anderson Cancer Center experience. J Clin Oncol, 2010 ASCO Annual Meeting 28(15S):230s, 2010. e-Pub 2010.
290. Stephen S, Naing A, Hong D, Fu S, Wheler J, Moulder S, Falchook G, Tsimberidou A, Piha-Paul S, Kurzrock R. The use of complementary and alternative medicine in patients seen in phase I clinical trials program. J Clin Oncol, 2010 ASCO Annual Meeting 28(15S):658s, 2010. e-Pub 2010.
291. Fu S, Li Y, Shen DY, Zheng H, Kavanagh JJ, Bast RC, Sood AK, Hu W. Aurora kinase inhibitor VE 465 synergistically enhances cytotoxicity of carboplatin in ovarian cancer cells through induction of apoptosis and downregulation of histone 3. AACR 101st Annual Meeting 2010 70(8_Suppl), 2010. e-Pub 2010.
292. Hong DS, Davis D, Naing A, Fu S, Falchook GS, Ricks LW, Bekele N, Mittleman D, Liu W, Ivy P, Herbst R, Kurzrock R. Phase I clinical trial evaluating the safety, pharmacokinetics and biological effect of intravenous bevacizumab (avastin) in combination with escalating doses of AZD2171 (cediranib) administered orally for 21 consecutive days to patients with advanced malignancies (NCI protocol #7534). AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics 8(12_Suppl), 2009. e-Pub 2009.
293. Janku F, Garrido-Laguna I, Hong DS, Tsimberidou AM, Naing A, Falchook GS, Wheler JJ, Moulder SL, Fu S, Piha-Paul SA, Kurzrock R. PIK3CA mutations in patients with advanced cancers treated in phase I clinical trials. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics 8(12_Suppl), 2009. e-Pub 2009.
294. Kurzrock R, Hamlin P, Gordon M, Hong DS, Fu S, Younes A, Hannah A, Palladino MA. NPI-0052 (a 2nd generation proteasome inhibitor) phase I study in patients with lymphoma and solid tumors. Eur J Cancer Supplements 6(12):73-74, 2008. e-Pub 2008.
295. Takimoto CH, Fu S, Dhillon N, Mita MM, Mita AC, Cheung W, Xu Y, Ali A, Johri A, Kurzrock R. Evaluation of pharmacokinetics (PK) and pharmacodynamics (PD) of patupilone and warfarin in patients (pts) with advanced solid tumors: An open-label, phase I study. 2008 ASCO Annual Meeting 26(15_suppl), 2008. e-Pub 2008.
296. Camacho LH, Moulder SL, LoRusso PM, Blumenschein GR, Bristow PJ, Kurzrock R, Fu S, Schlienger K, Bergstrom DA. First in human phase I study of MK-2461, a small molecule inhibitor of c-Met, for patients with advanced solid tumors. 2008 ASCO Annual Meeting 26(15_suppl), 2008. e-Pub 2008.
297. Fu S, Chintala L, Madoff D, Hong DS, Naing A, Moulder SL, Wheler JJ, Ng CS, Lim J, Patterson M, Kurzrock R. A phase I study of hepatic arterial infusion of oxaliplatin plus intravenous fluoracil, leucovorin, and bevacizumab in patients with predominant hepatic metastases. 2008 ASCO Annual Meeting 26(15_suppl), 2008. e-Pub 2008.
298. Naing A, Reuben JM, Verschraegen CF, Camacho LH, Stephen S, Hong DS, Wheler JJ, Fu S, Martinez M Akinsanmi L, Kurzrock R. Phase I dose-escalation study of sodium stibogluconate (SSG), a protein tyrosine phosphatase inhibitor, combined with interferon-alfa for patients with solid tumors. 2008 ASCO Annual Meeting 26(15_suppl), 2008. e-Pub 2008.
299. Chintala L, Kurzrock R, Fu S, Naing A, Wheler JJ, Moulder SL, Newman R, Gagel R, Sebti S, Wright JJ, Hong DS. Phase I study of tipifarnib and sorafenib in patients with biosiable advanced cancer (NCI protocol 7156). 2008 ASCO Annual Meeting 26(15 suppl), 2008. e-Pub 2008.
300. Bast RC, Iyer B, Hu W, Kavanagh J, Coleman RL, Levenback C, Sood AK, Wolf J, Gershenson DM, Markman M, Fu S. A phase IIa study of a sequential regimen using azacitidine to reverse platinum resistant or refractory epithelial ovarian cancer. 2008 ASCO Annual Meeting 26(15_suppl), 2008. e-Pub 2008.
301. Kavanagh JJ, Hu W, Fu S, Deavers M, Moore C, Coleman RL, Levenback CF, Shen D, Mueller P, Gershenson DM, Zheng H, Li YF. Anti-tumor activity of letrozole in patients with recurrent advanced low malignant potential or low-grade serous ovarian tumors. 2007 ASCO Annual Meeting 25(18 suppl), 2007. e-Pub 2007.
302. Zheng H, Hu W, Deavers M, Shen DY, Fu S, Li Y, Moore C, Kavanagh J. Cyclin G1 expression in borderline or low grade and high grade ovarian cancer. AACR Annual Meeting 67(9_Suppl), 2007. e-Pub 2007.
303. Fu S. A phase I study of a hypomethylating agent azacitidine in combination with carboplatin in patients with platinum resistant epithelial ovarian cancer. 2006 ASCO Annual Meeting 24(18_Suppl), 2006. e-Pub 2006.

Book Chapters

1. Fu S, Holman LI, Westin SN. Uterine (Endometrial) Cancer. In: Handbook of Targeted Cancer Therapy and Immunotherapy. 3rd Edition. Wolters Kluwer, 47-54, 2022.
2. Fu S, Holman LI, Westin SN. Ovarian Cancer. In: Handbook of Targeted Cancer Therapy and Immunotherapy. 3rd Edition. Wolters Kluwer, 111-122, 2022.
3. Fu S, Holman LI, Westin SN. Cervical Cancer. In: Handbook of Targeted Cancer Therapy and Immunotherapy. 3rd Edition. Wolters Kluwer, 31-33, 2022.
4. Deisseroth AB, Fu S, Hanania EG, Talpaz M, Kantarjian H, Champlin R. Gene Therapy Using Stem Cell Modification. In: Biologic Therapy of Cancer. J.B. Lippincott Company, 738-746, 1995.
5. Fu S. Transposable Elements. In: Molecular Genetics. SMU, 1987.

Letters to the Editor

1. Liu X, Lorusso P, Mita M, Piha-Paul S, Hong DS, Fu S, McQuinn L, Asatiani E, Doyle LA, Chen HX, Hess KR, Kurzrock R, Naing A. Incidence of mucositis in patients treated with temsirolimus-based regimens and correlation to treatment response. Oncologist 19: 426-8, 2014.
2. Fu S, Barber D. Reply to M. Rouanne et al. J Clin Oncol 31: 818, 2013.